instruction,input,output,task_type,source,text
"Provide a comprehensive drug development assessment for:
Molecular Structure: O=C(O)CCn1c2c(c3ccccc31)C[C@H](NS(=O)(=O)c1ccc(F)cc1)CC2
Candidate Name: RAMATROBAN",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 416.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.09 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 88.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: O=C(O)CCn1c2c(c3ccccc31)C[C@H](NS(=O)(=O)c1ccc(F)cc1)CC2
Candidate Name: RAMATROBAN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 416.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.09 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 88.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CCCOC(=O)Cn1cc(I)c(=O)c(I)c1
Name: PROPYLIODONE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 447.0 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.01 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 48.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CCCOC(=O)Cn1cc(I)c(=O)c(I)c1
Name: PROPYLIODONE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 447.0 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.01 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 48.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
[Ca]
Name: CALCIUM",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 40.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
[Ca]
Name: CALCIUM
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 40.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: Cc1ccc(S(=O)(=O)NC(=O)NC2CCCCCCC2)cc1
Candidate Name: GLYOCTAMIDE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 324.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.10 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 75.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: Cc1ccc(S(=O)(=O)NC(=O)NC2CCCCCCC2)cc1
Candidate Name: GLYOCTAMIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 324.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.10 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 75.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Describe the molecular properties and drug-likeness of:
C[C@]12N[C@H](Cc3ccccc31)c1ccccc12",,"## Molecular Property Analysis: DIZOCILPINE

### Structure
```
C[C@]12N[C@H](Cc3ccccc31)c1ccccc12
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 221.3 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 3.15 | 0-5 | ‚úì |
| H-Bond Acceptors | 1.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 12.0 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.720
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Describe the molecular properties and drug-likeness of:
C[C@]12N[C@H](Cc3ccccc31)c1ccccc12
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: DIZOCILPINE

### Structure
```
C[C@]12N[C@H](Cc3ccccc31)c1ccccc12
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 221.3 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 3.15 | 0-5 | ‚úì |
| H-Bond Acceptors | 1.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 12.0 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.720
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1
ALVOCIDIB",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 401.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.30 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 94.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1
ALVOCIDIB
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 401.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.30 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 94.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CCCCC1(CN2CCN(C)CC2)C(=O)N(c2ccccc2)N(c2ccccc2)C1=O
Drug Name: PIPEBUZONE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 420.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.41 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 47.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CCCCC1(CN2CCN(C)CC2)C(=O)N(c2ccccc2)N(c2ccccc2)C1=O
Drug Name: PIPEBUZONE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 420.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.41 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 47.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
CCCCNC(=O)NC1CCN(c2ncnc3cc(OC)c(OC)cc23)CC1",,"## Molecular Property Analysis: BUQUINERAN

### Structure
```
CCCCNC(=O)NC1CCN(c2ncnc3cc(OC)c(OC)cc23)CC1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 387.5 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 2.72 | 0-5 | ‚úì |
| H-Bond Acceptors | 6.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |
| PSA | 88.6 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 7.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.710
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- CYP450 substrate likely
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
CCCCNC(=O)NC1CCN(c2ncnc3cc(OC)c(OC)cc23)CC1
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: BUQUINERAN

### Structure
```
CCCCNC(=O)NC1CCN(c2ncnc3cc(OC)c(OC)cc23)CC1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 387.5 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 2.72 | 0-5 | ‚úì |
| H-Bond Acceptors | 6.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |
| PSA | 88.6 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 7.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.710
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- CYP450 substrate likely
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
Cc1ccccc1C(OCCN(C)C)c1ccccc1.Cl
ORPHENADRINE HYDROCHLORIDE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 305.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.66 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 12.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
Cc1ccccc1C(OCCN(C)C)c1ccccc1.Cl
ORPHENADRINE HYDROCHLORIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 305.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.66 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 12.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CCCNCC(O)COc1ccc2c(=O)cc(-c3ccccc3)oc2c1
Name: FLAVODILOL",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 353.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.20 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 71.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CCCNCC(O)COc1ccc2c(=O)cc(-c3ccccc3)oc2c1
Name: FLAVODILOL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 353.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.20 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 71.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze the ADMET properties of this compound:
O=C1CN2Cc3c(ccc(Cl)c3Cl)N=C2N1",,"## Molecular Property Analysis: ANAGRELIDE

### Structure
```
O=C1CN2Cc3c(ccc(Cl)c3Cl)N=C2N1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 256.1 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 1.93 | 0-5 | ‚úì |
| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 44.7 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.770
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze the ADMET properties of this compound:
O=C1CN2Cc3c(ccc(Cl)c3Cl)N=C2N1
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: ANAGRELIDE

### Structure
```
O=C1CN2Cc3c(ccc(Cl)c3Cl)N=C2N1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 256.1 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 1.93 | 0-5 | ‚úì |
| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 44.7 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.770
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CC[C@]12C=CCN3CC[C@@]4(c5cc([C@@]6(C(=O)OC)C[C@@H]7C[C@@H](C(C)(F)F)CN(Cc8c6[nH]c6ccccc86)C7)c(OC)cc5N(C)[C@H]4[C@@](O)(C(=O)OC)[C@@H]1OC(C)=O)[C@@H]32",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 816.9 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 5.08 | ‚ö† High (>5) |
| H-Bond Acceptors | 11.0 | ‚ö† High (>10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 133.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 3.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CC[C@]12C=CCN3CC[C@@]4(c5cc([C@@]6(C(=O)OC)C[C@@H]7C[C@@H](C(C)(F)F)CN(Cc8c6[nH]c6ccccc86)C7)c(OC)cc5N(C)[C@H]4[C@@](O)(C(=O)OC)[C@@H]1OC(C)=O)[C@@H]32
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 816.9 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 5.08 | ‚ö† High (>5) |
| H-Bond Acceptors | 11.0 | ‚ö† High (>10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 133.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 3.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: C[C@@H](Nc1ncnc2[nH]c(-c3ccc(O)cc3)cc12)c1ccccc1
Candidate Name: PKI-166",,"## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 330.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.50 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 73.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: C[C@@H](Nc1ncnc2[nH]c(-c3ccc(O)cc3)cc12)c1ccccc1
Candidate Name: PKI-166
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 330.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.50 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 73.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: Cl.c1ccc(CN(CC2=NCCN2)c2ccccc2)cc1
Drug Name: ANTAZOLINE HYDROCHLORIDE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 301.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.69 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 27.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: Cl.c1ccc(CN(CC2=NCCN2)c2ccccc2)cc1
Drug Name: ANTAZOLINE HYDROCHLORIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 301.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.69 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 27.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1cccc(Cl)c1Cl
Name: FELODIPINE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 384.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.96 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 64.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1cccc(Cl)c1Cl
Name: FELODIPINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 384.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.96 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 64.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Describe the molecular properties and drug-likeness of:
CN1C(=O)NC(=O)C(C)(C2=CCCCC2)C1=O",,"## Molecular Property Analysis: HEXOBARBITAL

### Structure
```
CN1C(=O)NC(=O)C(C)(C2=CCCCC2)C1=O
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 236.3 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 1.20 | 0-5 | ‚úì |
| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 66.5 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 1.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.550
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Describe the molecular properties and drug-likeness of:
CN1C(=O)NC(=O)C(C)(C2=CCCCC2)C1=O
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: HEXOBARBITAL

### Structure
```
CN1C(=O)NC(=O)C(C)(C2=CCCCC2)C1=O
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 236.3 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 1.20 | 0-5 | ‚úì |
| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 66.5 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 1.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.550
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
Cl.Cn1c(=O)c(Oc2ccc(F)cc2F)cc2cnc(NC3CCOCC3)nc21
Name: R-1487 HYDROCHLORIDE",,"## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 424.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.99 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 78.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
Cl.Cn1c(=O)c(Oc2ccc(F)cc2F)cc2cnc(NC3CCOCC3)nc21
Name: R-1487 HYDROCHLORIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 424.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.99 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 78.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
NS(=O)(=O)c1cc2c(cc1C(F)(F)F)NCNS2(=O)=O
HYDROFLUMETHIAZIDE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 331.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.01 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 118.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
NS(=O)(=O)c1cc2c(cc1C(F)(F)F)NCNS2(=O)=O
HYDROFLUMETHIAZIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 331.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.01 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 118.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3C(=O)C[C@@]21C",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 402.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.56 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 97.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3C(=O)C[C@@]21C
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 402.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.56 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 97.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
Cc1cc(N2CCCCC2)nn2cnnc12",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 217.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.42 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 46.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
Cc1cc(N2CCCCC2)nn2cnnc12
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 217.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.42 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 46.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CN1C(=O)c2ccccc2C1Nc1ccc(OCCN2CCCCC2)cc1",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 365.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.75 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 44.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CN1C(=O)c2ccccc2C1Nc1ccc(OCCN2CCCCC2)cc1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 365.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.75 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 44.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: C[C@@H]1C[C@H](C)CN(S(=O)(=O)c2ccc3c(c2)C(=NO)c2cc(S(=O)(=O)N4C[C@H](C)C[C@H](C)C4)ccc2C3=NO)C1
Drug Name: TEGAVIVINT",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 588.8 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 3.79 | ‚úì Good (<5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 139.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: C[C@@H]1C[C@H](C)CN(S(=O)(=O)c2ccc3c(c2)C(=NO)c2cc(S(=O)(=O)N4C[C@H](C)C[C@H](C)C4)ccc2C3=NO)C1
Drug Name: TEGAVIVINT
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 588.8 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 3.79 | ‚úì Good (<5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 139.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
O=C1C[C@@]2(C(=O)N1)C(=O)N(Cc1ccc(Br)cc1F)C(=O)c1cccn12
Name: RANIRESTAT",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 420.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.31 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 88.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
O=C1C[C@@]2(C(=O)N1)C(=O)N(Cc1ccc(Br)cc1F)C(=O)c1cccn12
Name: RANIRESTAT
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 420.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.31 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 88.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CCCc1cc(C(N)=S)ccn1
PROTIONAMIDE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 180.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.67 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 38.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CCCc1cc(C(N)=S)ccn1
PROTIONAMIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 180.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.67 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 38.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: O=C(CCCCCCCCCCCCC1CCCC1)Nc1ccc(S(=O)(=O)c2ccc(NC(=O)CCCCCCCCCCCCC3CCCC3)cc2)cc1
Candidate Name: CHAULMOSULFONE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 777.2 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 14.14 | ‚ö† High (>5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 92.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: O=C(CCCCCCCCCCCCC1CCCC1)Nc1ccc(S(=O)(=O)c2ccc(NC(=O)CCCCCCCCCCCCC3CCCC3)cc2)cc1
Candidate Name: CHAULMOSULFONE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 777.2 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 14.14 | ‚ö† High (>5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 92.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
Cc1cc(C(C)(C)C)cc(C)c1CC1=NCCN1",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 244.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.15 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 24.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
Cc1cc(C(C)(C)C)cc(C)c1CC1=NCCN1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 244.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.15 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 24.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CC(=O)Nc1c(I)c(C(=O)O)c(I)c(N(C)C(C)=O)c1I.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 823.2 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 3.14 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 86.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CC(=O)Nc1c(I)c(C(=O)O)c(I)c(N(C)C(C)=O)c1I.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 823.2 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 3.14 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 86.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: Brc1c(NC2=NCCN2)ccc2nccnc12
Candidate Name: BRIMONIDINE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 292.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.76 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 62.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: Brc1c(NC2=NCCN2)ccc2nccnc12
Candidate Name: BRIMONIDINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 292.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.76 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 62.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: O=c1[nH]c(=O)n([C@H]2C[C@H](O)[C@@H](CO)O2)cc1Br
Candidate Name: BROXURIDINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 307.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -1.06 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 104.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: O=c1[nH]c(=O)n([C@H]2C[C@H](O)[C@@H](CO)O2)cc1Br
Candidate Name: BROXURIDINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 307.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -1.06 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 104.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CN1CCC(OC(c2ccccc2)c2ccccc2)CC1
Candidate Name: DIPHENYLPYRALINE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 281.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.89 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 12.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CN1CCC(OC(c2ccccc2)c2ccccc2)CC1
Candidate Name: DIPHENYLPYRALINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 281.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.89 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 12.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CCOc1ccccc1O[C@@H](c1ccccc1)[C@@H]1CNCCO1
ESREBOXETINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 313.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.19 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 39.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CCOc1ccccc1O[C@@H](c1ccccc1)[C@@H]1CNCCO1
ESREBOXETINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 313.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.19 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 39.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
N=C(Nc1c([N+](=O)[O-])cnc2ccccc12)N1CCOCC1
TROQUIDAZOLE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 301.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.82 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 104.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
N=C(Nc1c([N+](=O)[O-])cnc2ccccc12)N1CCOCC1
TROQUIDAZOLE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 301.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.82 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 104.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
Cc1ccc(CCn2c3c(c4cc(Cl)ccc42)CN(C)CC3)cn1
DORASTINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 339.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.23 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 21.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
Cc1ccc(CCn2c3c(c4cc(Cl)ccc42)CN(C)CC3)cn1
DORASTINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 339.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.23 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 21.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CC(C)=CCOC(=O)c1ccccc1Nc1cccc(C(F)(F)F)c1
PREFENAMATE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 349.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.57 | ‚ö† High (>5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 38.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CC(C)=CCOC(=O)c1ccccc1Nc1cccc(C(F)(F)F)c1
PREFENAMATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 349.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.57 | ‚ö† High (>5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 38.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
C#C[C@]1(O)CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@@]21C
Name: ETHINYL ESTRADIOL",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 296.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.61 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 40.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
C#C[C@]1(O)CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@@]21C
Name: ETHINYL ESTRADIOL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 296.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.61 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 40.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: COc1ccc([N-]S(=O)(=O)c2c(F)c(F)c(F)c(F)c2F)cc1F.[Na+]
Candidate Name: BATABULIN SODIUM",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 393.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.33 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 55.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: COc1ccc([N-]S(=O)(=O)c2c(F)c(F)c(F)c(F)c2F)cc1F.[Na+]
Candidate Name: BATABULIN SODIUM
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 393.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.33 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 55.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CC(C)(Oc1ccc(Cl)cc1)C(=O)OCCSCCCCCCCCCCSCCOC(=O)C(C)(C)Oc1ccc(Cl)cc1",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 687.8 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 9.68 | ‚ö† High (>5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 71.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CC(C)(Oc1ccc(Cl)cc1)C(=O)OCCSCCCCCCCCCCSCCOC(=O)C(C)(C)Oc1ccc(Cl)cc1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 687.8 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 9.68 | ‚ö† High (>5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 71.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: COC(=O)[C@@H]1[C@H]2C[C@H]3c4[nH]c5ccccc5c4CCN3C[C@@H]2CC[C@@H]1O
Drug Name: YOHIMBINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 354.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.65 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 65.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: COC(=O)[C@@H]1[C@H]2C[C@H]3c4[nH]c5ccccc5c4CCN3C[C@@H]2CC[C@@H]1O
Drug Name: YOHIMBINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 354.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.65 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 65.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: COc1ccccc1[C@H](Cn1c(=O)n(C(C)(C)C(=O)O)c(=O)c2c(C)c(-c3ncco3)sc21)OC1CCOCC1
Candidate Name: FIRSOCOSTAT",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 569.6 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 3.95 | ‚úì Good (<5) |
| H-Bond Acceptors | 11.0 | ‚ö† High (>10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 135.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: COc1ccccc1[C@H](Cn1c(=O)n(C(C)(C)C(=O)O)c(=O)c2c(C)c(-c3ncco3)sc21)OC1CCOCC1
Candidate Name: FIRSOCOSTAT
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 569.6 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 3.95 | ‚úì Good (<5) |
| H-Bond Acceptors | 11.0 | ‚ö† High (>10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 135.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CC(NNC(=O)c1ccccc1)c1ccccc1",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 240.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.68 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 41.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CC(NNC(=O)c1ccccc1)c1ccccc1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 240.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.68 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 41.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CC1(C)[C@@H](OC(=O)[C@H]2CCCC[C@H]2C(=O)O)CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@@](C)(C(=O)O)CC[C@]5(C)CC[C@@]4(C)[C@]3(C)CC[C@@H]12
CICLOXOLONE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 624.9 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 7.85 | ‚ö† High (>5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 118.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CC1(C)[C@@H](OC(=O)[C@H]2CCCC[C@H]2C(=O)O)CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@@](C)(C(=O)O)CC[C@]5(C)CC[C@@]4(C)[C@]3(C)CC[C@@H]12
CICLOXOLONE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 624.9 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 7.85 | ‚ö† High (>5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 118.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
COc1cc(CCN)cc(OC)c1OC
Name: MESCALINE",,"## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 211.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.21 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 53.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
COc1cc(CCN)cc(OC)c1OC
Name: MESCALINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 211.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.21 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 53.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
O=C(CCBr)N1CCN(C(=O)CCBr)CC1
Name: PIPOBROMAN",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 356.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.23 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 40.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
O=C(CCBr)N1CCN(C(=O)CCBr)CC1
Name: PIPOBROMAN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 356.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.23 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 40.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CC[N+](C)(C)CCN(C)CC[N+](C)(C)CC
AZAMETHONIUM",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 231.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.11 | ‚úì Good (<5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 3.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CC[N+](C)(C)CCN(C)CC[N+](C)(C)CC
AZAMETHONIUM
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 231.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.11 | ‚úì Good (<5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 3.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CN(C)CCCOC1(Cc2ccccc2)CCCCCC1
BENCYCLANE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 289.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.29 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 12.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CN(C)CCCOC1(Cc2ccccc2)CCCCCC1
BENCYCLANE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 289.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.29 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 12.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
OCCC1CCN(CC/C=C2/c3ccc(F)cc3Sc3ccc(C(F)(F)F)cc32)CC1",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 451.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 6.23 | ‚ö† High (>5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 23.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
OCCC1CCN(CC/C=C2/c3ccc(F)cc3Sc3ccc(C(F)(F)F)cc32)CC1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 451.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 6.23 | ‚ö† High (>5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 23.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CCN1CCN(c2cc3c(cc2F)c(=O)c(C(=O)O)cn3C2CC2)CC1
Candidate Name: ENROFLOXACIN",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 359.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.32 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 65.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CCN1CCN(c2cc3c(cc2F)c(=O)c(C(=O)O)cn3C2CC2)CC1
Candidate Name: ENROFLOXACIN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 359.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.32 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 65.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CN(C)C(=O)CCn1nc(Nc2ccc3c(c2)OC(F)(F)O3)nc1-c1ccncc1
Drug Name: JNJ-39393406",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 416.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.88 | ‚úì Good (<5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 94.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CN(C)C(=O)CCn1nc(Nc2ccc3c(c2)OC(F)(F)O3)nc1-c1ccncc1
Drug Name: JNJ-39393406
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 416.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.88 | ‚úì Good (<5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 94.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
COc1cc(N)c(Br)cc1C(=O)NC1CCN(Cc2ccc(Cl)cc2)CC1
BROCLEPRIDE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 452.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.09 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 67.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
COc1cc(N)c(Br)cc1C(=O)NC1CCN(Cc2ccc(Cl)cc2)CC1
BROCLEPRIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 452.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.09 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 67.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: O=S(=O)(O)CI
Candidate Name: METHIODAL",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 222.0 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.27 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 54.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: O=S(=O)(O)CI
Candidate Name: METHIODAL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 222.0 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.27 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 54.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CCN(CC)CCNc1ccc2ncn3c4ccc(O)cc4c(=O)c1c23
C-1311",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 350.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.90 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 69.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CCN(CC)CCNc1ccc2ncn3c4ccc(O)cc4c(=O)c1c23
C-1311
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 350.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.90 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 69.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: Nc1c(Cl)cc([C@@H](O)CNCCCCCCOCCc2ccccn2)cc1Cl
Drug Name: PICUMETEROL",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 426.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.41 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 80.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: Nc1c(Cl)cc([C@@H](O)CNCCCCCCOCCc2ccccn2)cc1Cl
Drug Name: PICUMETEROL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 426.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.41 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 80.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
CC(C)Cc1ccc(C(C)C(=O)O)cc1",,"## Molecular Property Analysis: IBUPROFEN

### Structure
```
CC(C)Cc1ccc(C(C)C(=O)O)cc1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 206.3 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 3.07 | 0-5 | ‚úì |
| H-Bond Acceptors | 1.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 37.3 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 4.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.820
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
CC(C)Cc1ccc(C(C)C(=O)O)cc1
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: IBUPROFEN

### Structure
```
CC(C)Cc1ccc(C(C)C(=O)O)cc1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 206.3 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 3.07 | 0-5 | ‚úì |
| H-Bond Acceptors | 1.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 37.3 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 4.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.820
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
C[N+]1(C)CCCC(OC(=O)C(O)(c2ccccc2)c2ccccc2)C1",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 340.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.70 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 46.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
C[N+]1(C)CCCC(OC(=O)C(O)(c2ccccc2)c2ccccc2)C1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 340.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.70 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 46.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: NC(=O)C1c2ccccc2CCc2ccccc21
Drug Name: CYHEPTAMIDE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 237.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.40 | ‚úì Good (<5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 43.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: NC(=O)C1c2ccccc2CCc2ccccc21
Drug Name: CYHEPTAMIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 237.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.40 | ‚úì Good (<5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 43.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CN(C)CCOC(C)(c1ccccc1)c1ccccn1.O=C(O)CCC(=O)O
Candidate Name: DOXYLAMINE SUCCINATE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 388.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.92 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 25.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CN(C)CCOC(C)(c1ccccc1)c1ccccn1.O=C(O)CCC(=O)O
Candidate Name: DOXYLAMINE SUCCINATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 388.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.92 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 25.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze the ADMET properties of this compound:
CCCN(CC)C(CC)C(=O)Nc1c(C)cccc1C",,"## Molecular Property Analysis: ETIDOCAINE

### Structure
```
CCCN(CC)C(CC)C(=O)Nc1c(C)cccc1C
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 276.4 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 3.75 | 0-5 | ‚úì |
| H-Bond Acceptors | 2.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 32.3 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 7.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.820
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze the ADMET properties of this compound:
CCCN(CC)C(CC)C(=O)Nc1c(C)cccc1C
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: ETIDOCAINE

### Structure
```
CCCN(CC)C(CC)C(=O)Nc1c(C)cccc1C
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 276.4 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 3.75 | 0-5 | ‚úì |
| H-Bond Acceptors | 2.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 32.3 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 7.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.820
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CCCCCCCCCC(=O)OCCN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1
FLUPHENAZINE DECANOATE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 591.8 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 8.00 | ‚ö† High (>5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 36.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CCCCCCCCCC(=O)OCCN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1
FLUPHENAZINE DECANOATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 591.8 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 8.00 | ‚ö† High (>5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 36.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CCCCNc1c2c(nc3ccccc13)CCCC2
Name: BUCRICAINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 254.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.33 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 24.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CCCCNc1c2c(nc3ccccc13)CCCC2
Name: BUCRICAINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 254.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.33 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 24.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CCC1(c2ccncc2)CCC(=O)NC1=O
Candidate Name: ROGLETIMIDE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 218.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.17 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 59.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CCC1(c2ccncc2)CCC(=O)NC1=O
Candidate Name: ROGLETIMIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 218.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.17 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 59.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CCC/N=C1\S/C(=C\c2ccc(OC[C@H](O)CO)c(Cl)c2)C(=O)N1c1ccccc1C
PONESIMOD",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 461.0 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.27 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 82.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CCC/N=C1\S/C(=C\c2ccc(OC[C@H](O)CO)c(Cl)c2)C(=O)N1c1ccccc1C
PONESIMOD
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 461.0 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.27 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 82.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
C[N+]1(CC2COC(c3ccccc3)(C3CCCCC3)O2)CCCCC1",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 344.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.47 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 18.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
C[N+]1(CC2COC(c3ccccc3)(C3CCCCC3)O2)CCCCC1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 344.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.47 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 18.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CC(=O)OCC(=O)Nc1cc(C#N)cc(NC(=O)COC(C)=O)c1Cl",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 367.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.21 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 134.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CC(=O)OCC(=O)Nc1cc(C#N)cc(NC(=O)COC(C)=O)c1Cl
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 367.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.21 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 134.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CC(OC(=O)NCC1(CC(=O)O)CCCCC1)OC(=O)C(C)C
Drug Name: GABAPENTIN ENACARBIL",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 329.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.68 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 101.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CC(OC(=O)NCC1(CC(=O)O)CCCCC1)OC(=O)C(C)C
Drug Name: GABAPENTIN ENACARBIL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 329.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.68 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 101.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: C#CCOC(C(=O)OCCN(C)C)(c1ccccc1)c1ccccc1
Drug Name: PARGEVERINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 337.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.68 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 38.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: C#CCOC(C(=O)OCCN(C)C)(c1ccccc1)c1ccccc1
Drug Name: PARGEVERINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 337.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.68 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 38.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO
Candidate Name: DEXAMETHASONE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 392.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.90 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 94.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO
Candidate Name: DEXAMETHASONE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 392.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.90 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 94.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CC(=O)Oc1cc(C(F)(F)F)ccc1C(=O)O
TRIFLUSAL",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 248.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.33 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 63.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CC(=O)Oc1cc(C(F)(F)F)ccc1C(=O)O
TRIFLUSAL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 248.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.33 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 63.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
C[N+]1(CC2CC2)CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 356.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.67 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 66.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
C[N+]1(CC2CC2)CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 356.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.67 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 66.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: Cc1cc(Cl)cc2c1N(Cc1cccc(C(F)(F)F)c1)C(=O)C21NC(=O)NC1=O
Candidate Name: AZD1386",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 423.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.25 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 78.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: Cc1cc(Cl)cc2c1N(Cc1cccc(C(F)(F)F)c1)C(=O)C21NC(=O)NC1=O
Candidate Name: AZD1386
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 423.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.25 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 78.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CC(C)(OCc1ccc(-c2ccc(Cl)cc2)cc1)C(=O)O
Name: CLOBUZARIT",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 304.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.39 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 46.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CC(C)(OCc1ccc(-c2ccc(Cl)cc2)cc1)C(=O)O
Name: CLOBUZARIT
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 304.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.39 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 46.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
O=C(O)c1ccccc1O.c1c[nH]cn1
IMIDAZOLE SALICYLATE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 206.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
O=C(O)c1ccccc1O.c1c[nH]cn1
IMIDAZOLE SALICYLATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 206.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
COC(=O)OCOc1c2n(ccc1=O)N([C@@H]1c3ccccc3SCc3c1ccc(F)c3F)[C@@H]1COCCN1C2=O",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | nan Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics

### Success Factors

This drug was successfully approved, demonstrating:
1. **Favorable safety profile** through clinical development
2. **Clear efficacy** in target patient population
3. **Acceptable risk-benefit ratio** for intended indication

### Key Success Indicators
- Completed Phase III trials with positive outcomes
- Manageable side effect profile
- Clear differentiation from existing treatments",drug_analysis,processed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
COC(=O)OCOc1c2n(ccc1=O)N([C@@H]1c3ccccc3SCc3c1ccc(F)c3F)[C@@H]1COCCN1C2=O
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | nan Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics

### Success Factors

This drug was successfully approved, demonstrating:
1. **Favorable safety profile** through clinical development
2. **Clear efficacy** in target patient population
3. **Acceptable risk-benefit ratio** for intended indication

### Key Success Indicators
- Completed Phase III trials with positive outcomes
- Manageable side effect profile
- Clear differentiation from existing treatments
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
O=P([O-])([O-])O.[Na+].[Na+]",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 142.0 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
O=P([O-])([O-])O.[Na+].[Na+]
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 142.0 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
N[C@H](CC(=O)O)C(=O)O
D-ASPARTATE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 133.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -1.13 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 100.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
N[C@H](CC(=O)O)C(=O)O
D-ASPARTATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 133.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -1.13 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 100.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
Cc1nnc(SCC2=C(C(=O)O)N3C(=O)[C@@H](NC(=O)[C@H](N)c4ccc(O)cc4)[C@H]3SC2)s1
CEFAPAROLE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 493.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.08 | ‚úì Good (<5) |
| H-Bond Acceptors | 10.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 158.7 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
Cc1nnc(SCC2=C(C(=O)O)N3C(=O)[C@@H](NC(=O)[C@H](N)c4ccc(O)cc4)[C@H]3SC2)s1
CEFAPAROLE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 493.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.08 | ‚úì Good (<5) |
| H-Bond Acceptors | 10.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 158.7 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CC1CCC2(CC1)N=C(N)N=C(N)N2c1ccc(Cl)cc1
Drug Name: SPIROTRIAZINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 305.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.70 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 80.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CC1CCC2(CC1)N=C(N)N=C(N)N2c1ccc(Cl)cc1
Drug Name: SPIROTRIAZINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 305.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.70 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 80.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: Cc1cc2ncc(C(=O)NCC(C)(C)NCC(=O)N3CCC[C@H]3C#N)cn2n1
Candidate Name: ANAGLIPTIN",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 383.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.65 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 115.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: Cc1cc2ncc(C(=O)NCC(C)(C)NCC(=O)N3CCC[C@H]3C#N)cn2n1
Candidate Name: ANAGLIPTIN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 383.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.65 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 115.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CCCn1c(=O)c2ccccc2n2c(CN3CCCCC3)nnc12
Name: BINIZOLAST",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 325.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.44 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 55.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CCCn1c(=O)c2ccccc2n2c(CN3CCCCC3)nnc12
Name: BINIZOLAST
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 325.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.44 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 55.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CN[C@@H](C)[C@@H]1CCN(c2c(F)cc3c(=O)c(C(=O)O)cn(C4CC4)c3c2OC)C1
Candidate Name: PREMAFLOXACIN",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 403.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.62 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 83.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CN[C@@H](C)[C@@H]1CCN(c2c(F)cc3c(=O)c(C(=O)O)cn(C4CC4)c3c2OC)C1
Candidate Name: PREMAFLOXACIN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 403.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.62 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 83.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CCC(NC(C)C)C(O)c1ccc(O)c(O)c1
Candidate Name: ISOETHARINE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 239.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.91 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 72.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CCC(NC(C)C)C(O)c1ccc(O)c(O)c1
Candidate Name: ISOETHARINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 239.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.91 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 72.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
COC(=O)[C@H]1[C@H]2C[C@@H]3c4[nH]c5cc(OC)ccc5c4CCN3C[C@H]2C[C@@H](OC(=O)COc2ccc(OC)cc2)[C@@H]1OC
MEFESERPINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 578.7 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 3.92 | ‚úì Good (<5) |
| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 108.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
COC(=O)[C@H]1[C@H]2C[C@@H]3c4[nH]c5cc(OC)ccc5c4CCN3C[C@H]2C[C@@H](OC(=O)COc2ccc(OC)cc2)[C@@H]1OC
MEFESERPINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 578.7 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 3.92 | ‚úì Good (<5) |
| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 108.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
Cc1cccc(OC2CCNCC2O)c1C",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 221.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.41 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 41.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
Cc1cccc(OC2CCNCC2O)c1C
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 221.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.41 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 41.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: COC(=O)N[C@H](C(=O)N1CCC[C@H]1c1nc(-c2ccc3cc(-c4ccc5[nH]c([C@@H]6CCCN6C(=O)[C@@H](NC(=O)OC)C(C)C)nc5c4)ccc3c2)c[nH]1)C(C)C.Cl.Cl
Drug Name: RAVIDASVIR HYDROCHLORIDE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 835.8 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 6.86 | ‚ö† High (>5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 174.6 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: COC(=O)N[C@H](C(=O)N1CCC[C@H]1c1nc(-c2ccc3cc(-c4ccc5[nH]c([C@@H]6CCCN6C(=O)[C@@H](NC(=O)OC)C(C)C)nc5c4)ccc3c2)c[nH]1)C(C)C.Cl.Cl
Drug Name: RAVIDASVIR HYDROCHLORIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 835.8 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 6.86 | ‚ö† High (>5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 174.6 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: Cc1cc(/C=C/C#N)cc(C)c1Nc1ccnc(Nc2ccc(C#N)cc2)n1
Candidate Name: RILPIVIRINE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 366.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.99 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 97.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: Cc1cc(/C=C/C#N)cc(C)c1Nc1ccnc(Nc2ccc(C#N)cc2)n1
Candidate Name: RILPIVIRINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 366.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.99 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 97.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CCNC1=NC(=O)C(c2ccccc2)O1
Candidate Name: FENOZOLONE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 204.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.25 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 50.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CCNC1=NC(=O)C(c2ccccc2)O1
Candidate Name: FENOZOLONE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 204.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.25 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 50.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CC(C)Cn1nc(-c2ccccc2)c(-c2ccccc2)c1CC(=O)O
Candidate Name: BUFEZOLAC",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 334.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.50 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 55.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CC(C)Cn1nc(-c2ccccc2)c(-c2ccccc2)c1CC(=O)O
Candidate Name: BUFEZOLAC
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 334.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.50 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 55.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
c1ccc2c(Cc3c[nH]c4ccccc34)c[nH]c2c1
Name: ARUNDINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 246.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.24 | ‚úì Good (<5) |
| H-Bond Acceptors | 0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 31.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
c1ccc2c(Cc3c[nH]c4ccccc34)c[nH]c2c1
Name: ARUNDINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 246.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.24 | ‚úì Good (<5) |
| H-Bond Acceptors | 0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 31.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CCc1c(-c2ccccc2)[nH]n(C2CCN(C)CC2)c1=O
PIPERYLONE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 285.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.67 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 41.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CCc1c(-c2ccccc2)[nH]n(C2CCN(C)CC2)c1=O
PIPERYLONE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 285.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.67 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 41.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CC(C)(C)c1cc(NC(=O)NCc2ccccc2Sc2ccc3nnc(-c4ccccc4SCCO)n3c2)n(-c2ccc(O)c(Cl)c2)n1
Drug Name: PF-03715455",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 700.3 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 7.80 | ‚ö† High (>5) |
| H-Bond Acceptors | 10.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 129.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CC(C)(C)c1cc(NC(=O)NCc2ccccc2Sc2ccc3nnc(-c4ccccc4SCCO)n3c2)n(-c2ccc(O)c(Cl)c2)n1
Drug Name: PF-03715455
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 700.3 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 7.80 | ‚ö† High (>5) |
| H-Bond Acceptors | 10.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 129.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CC(C)CC(C=O)NC(=O)C(CC(C)C)NC(=O)C(Cc1ccccc1)NC(=O)C(C)NC(=O)OC(C)(C)C
Drug Name: Semagacestat",,"## Drug Analysis Report

### Prediction: ‚ùå FAILED/WITHDRAWN
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | nan Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics

### Failure Analysis

**Reason for Failure:** nan

This compound was withdrawn/failed likely due to:
1. **Safety signals** detected in clinical trials or post-market surveillance
2. **Mechanism-related toxicity** affecting non-target tissues
3. **Drug-drug interaction** potential from metabolic vulnerabilities

### Lessons Learned
To avoid similar failures, future candidates should:
- Undergo comprehensive safety profiling early in development
- Include diversity in clinical trial populations
- Monitor for class-related adverse effects",drug_analysis,processed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CC(C)CC(C=O)NC(=O)C(CC(C)C)NC(=O)C(Cc1ccccc1)NC(=O)C(C)NC(=O)OC(C)(C)C
Drug Name: Semagacestat
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚ùå FAILED/WITHDRAWN
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | nan Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics

### Failure Analysis

**Reason for Failure:** nan

This compound was withdrawn/failed likely due to:
1. **Safety signals** detected in clinical trials or post-market surveillance
2. **Mechanism-related toxicity** affecting non-target tissues
3. **Drug-drug interaction** potential from metabolic vulnerabilities

### Lessons Learned
To avoid similar failures, future candidates should:
- Undergo comprehensive safety profiling early in development
- Include diversity in clinical trial populations
- Monitor for class-related adverse effects
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CN(C)CCOC(c1ccccc1)c1ccc(Br)cc1.Cl
BROMODIPHENHYDRAMINE HYDROCHLORIDE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 370.7 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.12 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 12.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CN(C)CCOC(c1ccccc1)c1ccc(Br)cc1.Cl
BROMODIPHENHYDRAMINE HYDROCHLORIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 370.7 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.12 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 12.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CC(C)(/C=C(\C#N)C(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3F)c3c(N)ncnc32)C1)N1CCN(C2COC2)CC1",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 665.8 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 4.42 | ‚úì Good (<5) |
| H-Bond Acceptors | 11.0 | ‚ö† High (>10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 138.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CC(C)(/C=C(\C#N)C(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3F)c3c(N)ncnc32)C1)N1CCN(C2COC2)CC1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 665.8 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 4.42 | ‚úì Good (<5) |
| H-Bond Acceptors | 11.0 | ‚ö† High (>10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 138.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CCNCC(O)c1cccc(OC(=O)C(C)(C)C)c1
Name: ETILEFRINE PIVALATE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 265.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.28 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 58.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CCNCC(O)c1cccc(OC(=O)C(C)(C)C)c1
Name: ETILEFRINE PIVALATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 265.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.28 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 58.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
Cc1cc(C(=O)Nc2cc(Nc3ccc4c(/C=C/c5ccccn5)n[nH]c4c3)ccc2F)n(C)n1",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 467.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.31 | ‚ö† High (>5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 100.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
Cc1cc(C(=O)Nc2cc(Nc3ccc4c(/C=C/c5ccccn5)n[nH]c4c3)ccc2F)n(C)n1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 467.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.31 | ‚ö† High (>5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 100.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
C#CCC1(OC(N)=O)CCCCC1",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 181.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.81 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 52.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
C#CCC1(OC(N)=O)CCCCC1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 181.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.81 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 52.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
NC(=O)C(c1ccccc1)(c1ccccc1)[C@@H]1CCN(CCc2ccc3c(c2)CCO3)C1
Name: DARIFENACIN",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 426.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.96 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 55.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
NC(=O)C(c1ccccc1)(c1ccccc1)[C@@H]1CCN(CCc2ccc3c(c2)CCO3)C1
Name: DARIFENACIN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 426.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.96 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 55.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
N=C(N)NCCC[C@H](N)C(=O)O.N[C@@H](CCC(=O)O)C(=O)O
Name: ARGININE GLUTAMATE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 321.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
N=C(N)NCCC[C@H](N)C(=O)O.N[C@@H](CCC(=O)O)C(=O)O
Name: ARGININE GLUTAMATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 321.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Analyze the ADMET properties of this compound:
N=C(N)N/N=C/c1c(Cl)cccc1Cl",,"## Molecular Property Analysis: GUANABENZ

### Structure
```
N=C(N)N/N=C/c1c(Cl)cccc1Cl
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 231.1 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 1.81 | 0-5 | ‚úì |
| H-Bond Acceptors | 2.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 3.0 | ‚â§5 | ‚úì |
| PSA | 74.3 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 2.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.410
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze the ADMET properties of this compound:
N=C(N)N/N=C/c1c(Cl)cccc1Cl
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: GUANABENZ

### Structure
```
N=C(N)N/N=C/c1c(Cl)cccc1Cl
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 231.1 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 1.81 | 0-5 | ‚úì |
| H-Bond Acceptors | 2.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 3.0 | ‚â§5 | ‚úì |
| PSA | 74.3 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 2.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.410
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CCCC(=O)C1c2cccc(O)c2C(=O)c2c(O)cccc21
Name: BUTANTRONE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 296.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.14 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 74.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CCCC(=O)C1c2cccc(O)c2C(=O)c2c(O)cccc21
Name: BUTANTRONE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 296.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.14 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 74.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
Cc1c(S(=O)(=O)[O-])oc2c1C(=O)C(=O)c1c-2ccc2c1CCCC2(C)C.[Na+]
Name: SODIUM TANSHINONE IIA SULFONATE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 396.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.49 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 101.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
Cc1c(S(=O)(=O)[O-])oc2c1C(=O)C(=O)c1c-2ccc2c1CCCC2(C)C.[Na+]
Name: SODIUM TANSHINONE IIA SULFONATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 396.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.49 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 101.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Describe the molecular properties and drug-likeness of:
S=P(N1CC1)(N1CC1)N1CC1",,"## Molecular Property Analysis: THIOTEPA

### Structure
```
S=P(N1CC1)(N1CC1)N1CC1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 189.2 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 0.16 | 0-5 | ‚úì |
| H-Bond Acceptors | 1.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 0 | ‚â§5 | ‚úì |
| PSA | 9.0 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.460
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Limited CNS penetration expected

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Low (hydrophilic)

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- May undergo renal clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Describe the molecular properties and drug-likeness of:
S=P(N1CC1)(N1CC1)N1CC1
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: THIOTEPA

### Structure
```
S=P(N1CC1)(N1CC1)N1CC1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 189.2 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 0.16 | 0-5 | ‚úì |
| H-Bond Acceptors | 1.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 0 | ‚â§5 | ‚úì |
| PSA | 9.0 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.460
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Limited CNS penetration expected

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Low (hydrophilic)

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- May undergo renal clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
N[C@@]1(C(=O)O)CS(=O)(=O)[C@H]2[C@H](C(=O)O)[C@H]21",,"## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 235.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -2.10 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 134.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
N[C@@]1(C(=O)O)CS(=O)(=O)[C@H]2[C@H](C(=O)O)[C@H]21
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 235.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -2.10 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 134.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CC(=O)Nc1cnn2c(C)nc3ccccc3c12",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 240.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.15 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 59.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CC(=O)Nc1cnn2c(C)nc3ccccc3c12
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 240.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.15 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 59.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: COC1=C(OC)C(=O)C(C/C=C(\C)CC/C=C(\C)CC/C=C(\C)CC/C=C(\C)CC/C=C(\C)CC/C=C(\C)CC/C=C(\C)CC/C=C(\C)CC/C=C(\C)CCC=C(C)C)=C(C)C1=O
Candidate Name: UBIDECARENONE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 863.4 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 17.85 | ‚ö† High (>5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 52.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: COC1=C(OC)C(=O)C(C/C=C(\C)CC/C=C(\C)CC/C=C(\C)CC/C=C(\C)CC/C=C(\C)CC/C=C(\C)CC/C=C(\C)CC/C=C(\C)CC/C=C(\C)CCC=C(C)C)=C(C)C1=O
Candidate Name: UBIDECARENONE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 863.4 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 17.85 | ‚ö† High (>5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 52.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: O=C(CCCN1CCCCC1)c1ccc(F)cc1
Drug Name: PRIMAPERONE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 249.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.27 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 20.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: O=C(CCCN1CCCCC1)c1ccc(F)cc1
Drug Name: PRIMAPERONE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 249.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.27 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 20.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CN(C)CC[C@@H](c1ccc(Br)cc1)c1ccccn1.O=C(O)/C=C\C(=O)O
DEXBROMPHENIRAMINE MALEATE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 435.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.93 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 16.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CN(C)CC[C@@H](c1ccc(Br)cc1)c1ccccn1.O=C(O)/C=C\C(=O)O
DEXBROMPHENIRAMINE MALEATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 435.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.93 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 16.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CCCC[C@@H](O)/C=C(C)/C=C/C=C/C(=O)N1CCCC1=O
Name: PECILOCIN",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 291.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.75 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 57.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CCCC[C@@H](O)/C=C(C)/C=C/C=C/C(=O)N1CCCC1=O
Name: PECILOCIN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 291.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.75 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 57.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
COc1cc(NCCCCCCN2CCN(CCC(C)O)CC2)c2ncccc2c1
Name: MOXIPRAQUINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 414.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.60 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 60.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
COc1cc(NCCCCCCN2CCN(CCC(C)O)CC2)c2ncccc2c1
Name: MOXIPRAQUINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 414.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.60 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 60.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CC2(C[C@H]1C(=O)O)SCCS2",,"## Molecular Property Analysis: SPIRAPRIL

### Structure
```
CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CC2(C[C@H]1C(=O)O)SCCS2
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 466.6 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 2.39 | 0-5 | ‚úì |
| H-Bond Acceptors | 7.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |
| PSA | 95.9 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 9.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.540
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Limited CNS penetration expected

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- CYP450 substrate likely
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CC2(C[C@H]1C(=O)O)SCCS2
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: SPIRAPRIL

### Structure
```
CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CC2(C[C@H]1C(=O)O)SCCS2
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 466.6 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 2.39 | 0-5 | ‚úì |
| H-Bond Acceptors | 7.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |
| PSA | 95.9 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 9.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.540
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Limited CNS penetration expected

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- CYP450 substrate likely
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
C[N+]1(C)CCC(OC(=O)C(O)(c2ccccc2)C2CCCCC2)C1.[Br-]",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 412.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.85 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 46.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
C[N+]1(C)CCC(OC(=O)C(O)(c2ccccc2)C2CCCCC2)C1.[Br-]
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 412.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.85 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 46.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CN1CCC23CCCCC2C1Cc1ccc(O)cc13
Name: RACEMORPHAN",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 257.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.08 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 23.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CN1CCC23CCCCC2C1Cc1ccc(O)cc13
Name: RACEMORPHAN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 257.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.08 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 23.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CC(=O)NS(=O)(=O)c1cc(N)ccc1S(=O)(=O)c1ccc(N)cc1",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 369.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.51 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 149.4 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CC(=O)NS(=O)(=O)c1cc(N)ccc1S(=O)(=O)c1ccc(N)cc1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 369.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.51 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 149.4 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1.O=P(O)(O)O
Drug Name: OSELTAMIVIR PHOSPHATE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 410.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.29 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 90.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1.O=P(O)(O)O
Drug Name: OSELTAMIVIR PHOSPHATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 410.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.29 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 90.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CC(C)(C)NCC(O)COc1cccc2c1CC(O)C(O)C2
NADOLOL",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 309.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.63 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 82.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CC(C)(C)NCC(O)COc1cccc2c1CC(O)C(O)C2
NADOLOL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 309.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.63 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 82.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CCC1(O)CCN2CCc3ccc(C)cc3C2C1
Candidate Name: TOLQUINZOLE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 245.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.83 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 23.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CCC1(O)CCN2CCc3ccc(C)cc3C2C1
Candidate Name: TOLQUINZOLE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 245.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.83 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 23.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2
Name: VINORELBINE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 779.0 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 4.75 | ‚úì Good (<5) |
| H-Bond Acceptors | 11.0 | ‚ö† High (>10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 133.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2
Name: VINORELBINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 779.0 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 4.75 | ‚úì Good (<5) |
| H-Bond Acceptors | 11.0 | ‚ö† High (>10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 133.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CC(C)(Sc1cc(C(C)(C)C)c(O)c(C(C)(C)C)c1)Sc1cc(C(C)(C)C)c(O)c(C(C)(C)C)c1
Name: PROBUCOL",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 516.9 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 9.91 | ‚ö† High (>5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 40.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CC(C)(Sc1cc(C(C)(C)C)c(O)c(C(C)(C)C)c1)Sc1cc(C(C)(C)C)c(O)c(C(C)(C)C)c1
Name: PROBUCOL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 516.9 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 9.91 | ‚ö† High (>5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 40.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CN(C)CCCOc1nn(Cc2ccccc2)c2ccccc12.Cl
Name: BENZYDAMINE HYDROCHLORIDE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 345.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.42 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 30.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CN(C)CCCOc1nn(Cc2ccccc2)c2ccccc12.Cl
Name: BENZYDAMINE HYDROCHLORIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 345.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.42 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 30.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CCOCCOC(=O)c1nc2cc(Cl)ccc2o1
Candidate Name: ECLAZOLAST",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 269.7 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.67 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 61.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CCOCCOC(=O)c1nc2cc(Cl)ccc2o1
Candidate Name: ECLAZOLAST
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 269.7 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.67 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 61.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 356.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.16 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 68.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 356.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.16 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 68.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: O=C(Cn1ccnc1)c1ccc2ccccc2c1
Drug Name: NAFIMIDONE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 236.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.92 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 34.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: O=C(Cn1ccnc1)c1ccc2ccccc2c1
Drug Name: NAFIMIDONE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 236.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.92 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 34.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: Oc1noc2c1CCNC2
Candidate Name: GABOXADOL",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 140.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.03 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 58.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: Oc1noc2c1CCNC2
Candidate Name: GABOXADOL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 140.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.03 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 58.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CCCCCC(O)/C=C/C1C(O)CC2N=C(SCCCC(=O)OC)CC21
TILSUPROST",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 383.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.34 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 79.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CCCCCC(O)/C=C/C1C(O)CC2N=C(SCCCC(=O)OC)CC21
TILSUPROST
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 383.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.34 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 79.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
NC(=O)c1csc([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)n1",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 260.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -1.60 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 125.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
NC(=O)c1csc([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)n1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 260.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -1.60 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 125.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze the ADMET properties of this compound:
Cc1ccccc1OCC(O)CNCCOc1ccc(C(N)=O)cc1",,"## Molecular Property Analysis: TOLAMOLOL

### Structure
```
Cc1ccccc1OCC(O)CNCCOc1ccc(C(N)=O)cc1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 344.4 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 1.50 | 0-5 | ‚úì |
| H-Bond Acceptors | 5.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 3.0 | ‚â§5 | ‚úì |
| PSA | 93.8 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 10.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.570
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Limited CNS penetration expected

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- CYP450 substrate likely
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze the ADMET properties of this compound:
Cc1ccccc1OCC(O)CNCCOc1ccc(C(N)=O)cc1
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: TOLAMOLOL

### Structure
```
Cc1ccccc1OCC(O)CNCCOc1ccc(C(N)=O)cc1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 344.4 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 1.50 | 0-5 | ‚úì |
| H-Bond Acceptors | 5.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 3.0 | ‚â§5 | ‚úì |
| PSA | 93.8 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 10.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.570
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Limited CNS penetration expected

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- CYP450 substrate likely
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: Nc1ccn([C@H]2CC[C@@H](CO)O2)c(=O)n1
Drug Name: ZALCITABINE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 211.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -0.50 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 90.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: Nc1ccn([C@H]2CC[C@@H](CO)O2)c(=O)n1
Drug Name: ZALCITABINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 211.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -0.50 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 90.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CC(=O)Nc1nc2c(Oc3cc(-c4ccc(C(F)(F)F)cc4)ncn3)cccc2s1
Drug Name: AMG-517",,"## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 430.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.52 | ‚ö† High (>5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 77.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CC(=O)Nc1nc2c(Oc3cc(-c4ccc(C(F)(F)F)cc4)ncn3)cccc2s1
Drug Name: AMG-517
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 430.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.52 | ‚ö† High (>5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 77.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CN1CCN(c2ccc(C(=O)Nc3n[nH]c4ccc(Cc5cc(F)cc(F)c5)cc34)c(NC3CCOCC3)c2)CC1
ENTRECTINIB",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 560.6 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 5.03 | ‚ö† High (>5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 85.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CN1CCN(c2ccc(C(=O)Nc3n[nH]c4ccc(Cc5cc(F)cc(F)c5)cc34)c(NC3CCOCC3)c2)CC1
ENTRECTINIB
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 560.6 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 5.03 | ‚ö† High (>5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 85.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: C[N+](C)(CCOc1ccccc1)Cc1cccs1.O=S(=O)([O-])c1ccc(Cl)cc1
Candidate Name: THENIUM CLOSYLATE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 454.0 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.40 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 9.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: C[N+](C)(CCOc1ccccc1)Cc1cccs1.O=S(=O)([O-])c1ccc(Cl)cc1
Candidate Name: THENIUM CLOSYLATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 454.0 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.40 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 9.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CC[N+](CC)(CCOc1ccc(CC(C)(C)CC(C)C)cc1)Cc1ccccc1
OCTAFONIUM",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 396.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 6.74 | ‚ö† High (>5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 9.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CC[N+](CC)(CCOc1ccc(CC(C)(C)CC(C)C)cc1)Cc1ccccc1
OCTAFONIUM
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 396.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 6.74 | ‚ö† High (>5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 9.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Describe the molecular properties and drug-likeness of:
O=C1c2ccccc2C(=O)C1c1ccccc1",,"## Molecular Property Analysis: PHENINDIONE

### Structure
```
O=C1c2ccccc2C(=O)C1c1ccccc1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 222.2 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 2.85 | 0-5 | ‚úì |
| H-Bond Acceptors | 2.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 0 | ‚â§5 | ‚úì |
| PSA | 34.1 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 1.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.700
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Describe the molecular properties and drug-likeness of:
O=C1c2ccccc2C(=O)C1c1ccccc1
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: PHENINDIONE

### Structure
```
O=C1c2ccccc2C(=O)C1c1ccccc1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 222.2 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 2.85 | 0-5 | ‚úì |
| H-Bond Acceptors | 2.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 0 | ‚â§5 | ‚úì |
| PSA | 34.1 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 1.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.700
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CC(C)=CCC1C(=O)N(c2ccccc2)N(c2ccccc2)C1=O",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 320.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.95 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 40.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CC(C)=CCC1C(=O)N(c2ccccc2)N(c2ccccc2)C1=O
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 320.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.95 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 40.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: O=C(O)/C=C/c1ccc(O)c(O)c1
Candidate Name: CAFFEIC ACID",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 180.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.20 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 77.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: O=C(O)/C=C/c1ccc(O)c(O)c1
Candidate Name: CAFFEIC ACID
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 180.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.20 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 77.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CN1CCC(C(=O)N2c3ccccc3NC(=O)c3cccnc32)CC1
Candidate Name: NUVENZEPINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 336.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.65 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 65.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CN1CCC(C(=O)N2c3ccccc3NC(=O)c3cccnc32)CC1
Candidate Name: NUVENZEPINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 336.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.65 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 65.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
Cc1cc(-c2ccccc2)n[n+](CCCC(=O)O)c1N.[Cl-]
FAMIRAPRINIUM CHLORIDE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 307.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.79 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 80.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
Cc1cc(-c2ccccc2)n[n+](CCCC(=O)O)c1N.[Cl-]
FAMIRAPRINIUM CHLORIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 307.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.79 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 80.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
CCNc1cccnc1N1CCN(C(=O)c2cc3cc(OC)ccc3[nH]2)CC1",,"## Molecular Property Analysis: ATEVIRDINE MESYLATE

### Structure
```
CCNc1cccnc1N1CCN(C(=O)c2cc3cc(OC)ccc3[nH]2)CC1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 379.5 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 2.97 | 0-5 | ‚úì |
| H-Bond Acceptors | 5.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |
| PSA | 73.5 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 5.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.710
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- CYP450 substrate likely
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
CCNc1cccnc1N1CCN(C(=O)c2cc3cc(OC)ccc3[nH]2)CC1
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: ATEVIRDINE MESYLATE

### Structure
```
CCNc1cccnc1N1CCN(C(=O)c2cc3cc(OC)ccc3[nH]2)CC1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 379.5 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 2.97 | 0-5 | ‚úì |
| H-Bond Acceptors | 5.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |
| PSA | 73.5 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 5.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.710
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- CYP450 substrate likely
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity
<|im_end|>"
"Analyze the ADMET properties of this compound:
C[S+]([O-])c1ccc2oc3ccc(C(=O)O)cc3c(=O)c2c1",,"## Molecular Property Analysis: TIXANOX

### Structure
```
C[S+]([O-])c1ccc2oc3ccc(C(=O)O)cc3c(=O)c2c1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 302.3 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 2.38 | 0-5 | ‚úì |
| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 90.6 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 2.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.580
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Limited CNS penetration expected

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- CYP450 substrate likely
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze the ADMET properties of this compound:
C[S+]([O-])c1ccc2oc3ccc(C(=O)O)cc3c(=O)c2c1
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: TIXANOX

### Structure
```
C[S+]([O-])c1ccc2oc3ccc(C(=O)O)cc3c(=O)c2c1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 302.3 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 2.38 | 0-5 | ‚úì |
| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 90.6 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 2.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.580
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Limited CNS penetration expected

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- CYP450 substrate likely
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CC[C@@]1(CC(=O)O)OC[C@H](Cc2ccccc2)c2c1[nH]c1ccccc21",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 349.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.60 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 62.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CC[C@@]1(CC(=O)O)OC[C@H](Cc2ccccc2)c2c1[nH]c1ccccc21
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 349.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.60 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 62.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1.Cl
Candidate Name: EPIRUBICIN HYDROCHLORIDE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 580.0 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 0.00 | ‚úì Good (<5) |
| H-Bond Acceptors | 12.0 | ‚ö† High (>10) |
| H-Bond Donors | 6.0 | ‚ö† High (>5) |
| Polar Surface Area | 206.1 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 3.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1.Cl
Candidate Name: EPIRUBICIN HYDROCHLORIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 580.0 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 0.00 | ‚úì Good (<5) |
| H-Bond Acceptors | 12.0 | ‚ö† High (>10) |
| H-Bond Donors | 6.0 | ‚ö† High (>5) |
| Polar Surface Area | 206.1 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 3.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
O=[N+]([O-])OC[C@@H](O[N+](=O)[O-])[C@@H](O[N+](=O)[O-])[C@H](O[N+](=O)[O-])[C@@H](CO[N+](=O)[O-])O[N+](=O)[O-]
MANNITOL HEXANITRATE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 452.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -2.29 | ‚úì Good (<5) |
| H-Bond Acceptors | 18.0 | ‚ö† High (>10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 314.2 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
O=[N+]([O-])OC[C@@H](O[N+](=O)[O-])[C@@H](O[N+](=O)[O-])[C@H](O[N+](=O)[O-])[C@@H](CO[N+](=O)[O-])O[N+](=O)[O-]
MANNITOL HEXANITRATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 452.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -2.29 | ‚úì Good (<5) |
| H-Bond Acceptors | 18.0 | ‚ö† High (>10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 314.2 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
Cc1cc(C)[n+]([N-]C(=O)c2ccc(Cl)c(S(N)(=O)=O)c2)c(C)c1
Name: BESULPAMIDE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 353.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.18 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 95.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
Cc1cc(C)[n+]([N-]C(=O)c2ccc(Cl)c(S(N)(=O)=O)c2)c(C)c1
Name: BESULPAMIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 353.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.18 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 95.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
COC(=O)CCCCC(CCSS/C(CCO)=C(/C)N(C=O)Cc1cnc(C)nc1N)SC(C)=O
OCTOTIAMINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 544.8 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 4.09 | ‚úì Good (<5) |
| H-Bond Acceptors | 11.0 | ‚ö† High (>10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 135.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
COC(=O)CCCCC(CCSS/C(CCO)=C(/C)N(C=O)Cc1cnc(C)nc1N)SC(C)=O
OCTOTIAMINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 544.8 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 4.09 | ‚úì Good (<5) |
| H-Bond Acceptors | 11.0 | ‚ö† High (>10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 135.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
O=C(CN1CC[C@]23CCCC[C@H]2[C@H]1Cc1ccc(O)cc13)c1ccccc1",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 361.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.33 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 40.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
O=C(CN1CC[C@]23CCCC[C@H]2[C@H]1Cc1ccc(O)cc13)c1ccccc1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 361.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.33 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 40.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CCCCCCCCCCCCCCCCCCCCCCO
Drug Name: DOCOSANOL",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 326.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 7.80 | ‚ö† High (>5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 20.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CCCCCCCCCCCCCCCCCCCCCCO
Drug Name: DOCOSANOL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 326.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 7.80 | ‚ö† High (>5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 20.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: C=C[C@@H]1CNCC[C@H]1CCCc1ccnc2ccc(OC)cc12
Candidate Name: IVOQUALINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 310.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.98 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 34.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: C=C[C@@H]1CNCC[C@H]1CCCc1ccnc2ccc(OC)cc12
Candidate Name: IVOQUALINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 310.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.98 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 34.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CC1(C)C(=O)N(C(=O)NCC2CCN(CC3(O)CCOCC3)CC2)c2cc(F)ccc21
Name: PF-03382792",,"## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 433.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.41 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 82.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CC1(C)C(=O)N(C(=O)NCC2CCN(CC3(O)CCOCC3)CC2)c2cc(F)ccc21
Name: PF-03382792
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 433.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.41 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 82.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CC(C)S(=O)(=O)n1c(N)nc2ccc(/C(=N/O)c3ccccc3)cc21
ENVIROXIME",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 358.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.43 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 110.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CC(C)S(=O)(=O)n1c(N)nc2ccc(/C(=N/O)c3ccccc3)cc21
ENVIROXIME
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 358.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.43 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 110.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
Nc1nc2c(c(=O)[nH]1)N1CN(c3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)C[C@H]1CN2
ARFOLITIXORIN",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 457.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -0.52 | ‚úì Good (<5) |
| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 6.0 | ‚ö† High (>5) |
| Polar Surface Area | 194.0 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
Nc1nc2c(c(=O)[nH]1)N1CN(c3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)C[C@H]1CN2
ARFOLITIXORIN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 457.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -0.52 | ‚úì Good (<5) |
| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 6.0 | ‚ö† High (>5) |
| Polar Surface Area | 194.0 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
Cn1c(=O)c(F)c(Nc2ccc(I)cc2F)c2c(=O)n(C[C@@H](O)CO)cnc21
TAK-733",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 504.2 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 1.07 | ‚úì Good (<5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 109.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
Cn1c(=O)c(F)c(Nc2ccc(I)cc2F)c2c(=O)n(C[C@@H](O)CO)cnc21
TAK-733
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 504.2 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 1.07 | ‚úì Good (<5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 109.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
O=C(CN1CCN(Cc2ccc3c(c2)OCO3)CC1)N1c2ccccc2Sc2ccccc21
Name: FENOVERINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 459.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.36 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 45.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
O=C(CN1CCN(Cc2ccc3c(c2)OCO3)CC1)N1c2ccccc2Sc2ccccc21
Name: FENOVERINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 459.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.36 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 45.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CCn1cc(C(=O)O)c(=O)c2ccc(C)nc21",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 232.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.42 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 72.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CCn1cc(C(=O)O)c(=O)c2ccc(C)nc21
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 232.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.42 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 72.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CCN(CC)C(=O)C1(c2ccccc2)CC1CN
Drug Name: MILNACIPRAN",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 246.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.77 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 46.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CCN(CC)C(=O)C1(c2ccccc2)CC1CN
Drug Name: MILNACIPRAN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 246.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.77 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 46.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
O=C(Nc1ccccc1)c1cc(Br)cc(Br)c1O",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 371.0 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.17 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 49.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
O=C(Nc1ccccc1)c1cc(Br)cc(Br)c1O
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 371.0 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.17 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 49.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CN(C(=O)/C=C/c1ccoc1)[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
Candidate Name: NALFURAFINE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 476.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.09 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 86.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CN(C(=O)/C=C/c1ccoc1)[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
Candidate Name: NALFURAFINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 476.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.09 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 86.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
Nc1cc[nH]c(=O)n1",,"## Molecular Property Analysis: CYTOSINE

### Structure
```
Nc1cc[nH]c(=O)n1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 111.1 Da | 150-500 Da | ‚ö† |
| LogP (cLogP) | -0.65 | 0-5 | ‚ö† |
| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |
| PSA | 71.8 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.470
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Limited CNS penetration expected

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Low (hydrophilic)

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- May undergo renal clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
Nc1cc[nH]c(=O)n1
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: CYTOSINE

### Structure
```
Nc1cc[nH]c(=O)n1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 111.1 Da | 150-500 Da | ‚ö† |
| LogP (cLogP) | -0.65 | 0-5 | ‚ö† |
| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |
| PSA | 71.8 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.470
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Limited CNS penetration expected

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Low (hydrophilic)

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- May undergo renal clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CC(C)N1CCN(c2ccc(N3CCN(c4ccc(OC[C@H]5OC[C@](Cn6cncn6)(c6ccc(F)cc6F)O5)cc4)CC3)cc2)C1=O
Name: PRAMICONAZOLE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 659.7 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 4.88 | ‚úì Good (<5) |
| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 88.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CC(C)N1CCN(c2ccc(N3CCN(c4ccc(OC[C@H]5OC[C@](Cn6cncn6)(c6ccc(F)cc6F)O5)cc4)CC3)cc2)C1=O
Name: PRAMICONAZOLE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 659.7 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 4.88 | ‚úì Good (<5) |
| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 88.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CO[C@@H]1[C@H](OP(=O)(S)OC[C@H]2O[C@@H](n3cnc4c(N)ncnc43)C[C@@H]2O)[C@@H](CO)O[C@H]1n1ccc(=O)[nH]c1=O
Name: INARIGIVIR",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 587.5 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | -1.05 | ‚úì Good (<5) |
| H-Bond Acceptors | 16.0 | ‚ö† High (>10) |
| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 228.2 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CO[C@@H]1[C@H](OP(=O)(S)OC[C@H]2O[C@@H](n3cnc4c(N)ncnc43)C[C@@H]2O)[C@@H](CO)O[C@H]1n1ccc(=O)[nH]c1=O
Name: INARIGIVIR
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 587.5 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | -1.05 | ‚úì Good (<5) |
| H-Bond Acceptors | 16.0 | ‚ö† High (>10) |
| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 228.2 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: COc1c(NC(=O)C(=O)c2ccc(OCCN3CCOCC3)c3ccccc23)cc(C(C)(C)C)cc1NS(C)(=O)=O
Candidate Name: ITX-5061 FREE BASE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 583.7 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 4.05 | ‚úì Good (<5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 123.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: COc1c(NC(=O)C(=O)c2ccc(OCCN3CCOCC3)c3ccccc23)cc(C(C)(C)C)cc1NS(C)(=O)=O
Candidate Name: ITX-5061 FREE BASE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 583.7 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 4.05 | ‚úì Good (<5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 123.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CC(C)n1cc(C#N)c2cc(-n3cc(C(=O)O)cn3)ccc21
TIGULIXOSTAT",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 294.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.98 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 83.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CC(C)n1cc(C#N)c2cc(-n3cc(C(=O)O)cn3)ccc21
TIGULIXOSTAT
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 294.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.98 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 83.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CC(C)[C@@]1(C(=O)N[C@H]2CC(=O)O[C@]2(O)CF)CC(c2nccc3ccccc23)=NO1
Name: NIVOCASAN",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 415.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.84 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 110.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CC(C)[C@@]1(C(=O)N[C@H]2CC(=O)O[C@]2(O)CF)CC(c2nccc3ccccc23)=NO1
Name: NIVOCASAN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 415.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.84 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 110.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
Oc1ccc2c(c1)C(Cc1c[nH]cn1)CC2",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 214.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.39 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 48.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
Oc1ccc2c(c1)C(Cc1c[nH]cn1)CC2
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 214.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.39 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 48.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
C[C@@H]1Cc2cc(O)ccc2[C@H]2CC[C@]3(C)C(=O)CC[C@H]3[C@H]12
Name: ALMESTRONE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 284.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.06 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 37.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
C[C@@H]1Cc2cc(O)ccc2[C@H]2CC[C@]3(C)C(=O)CC[C@H]3[C@H]12
Name: ALMESTRONE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 284.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.06 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 37.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
N[C@@H](Cc1ccc(N(CCCl)CCCl)cc1)C(=O)O",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 305.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.93 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 66.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
N[C@@H](Cc1ccc(N(CCCl)CCCl)cc1)C(=O)O
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 305.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.93 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 66.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CCN(CC)CCCNc1nccc2c(C)c3[nH]c4ccc(OC)cc4c3c(C)c12
Drug Name: RETELLIPTINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 404.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.64 | ‚ö† High (>5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 53.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CCN(CC)CCCNc1nccc2c(C)c3[nH]c4ccc(OC)cc4c3c(C)c12
Drug Name: RETELLIPTINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 404.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.64 | ‚ö† High (>5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 53.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
NC(=O)Oc1ccc(Cc2ccccc2)cc1",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 227.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.73 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 52.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
NC(=O)Oc1ccc(Cc2ccccc2)cc1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 227.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.73 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 52.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
O=P([O-])([O-])O.[K+].[K+]
Name: POTASSIUM PHOSPHATE, DIBASIC",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 174.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
O=P([O-])([O-])O.[K+].[K+]
Name: POTASSIUM PHOSPHATE, DIBASIC
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 174.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
NS(=O)(=O)c1ccc(-n2nc(C(F)(F)F)cc2-c2ccc(F)cc2)cc1",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 385.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.34 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 78.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
NS(=O)(=O)c1ccc(-n2nc(C(F)(F)F)cc2-c2ccc(F)cc2)cc1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 385.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.34 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 78.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CS(=O)(=O)c1ccc(Oc2cc(F)cc(C#N)c2)c2c1[C@H](O)[C@H](F)[C@@H]2F
Candidate Name: BELZUTIFAN",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | nan Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics

### Success Factors

This drug was successfully approved, demonstrating:
1. **Favorable safety profile** through clinical development
2. **Clear efficacy** in target patient population
3. **Acceptable risk-benefit ratio** for intended indication

### Key Success Indicators
- Completed Phase III trials with positive outcomes
- Manageable side effect profile
- Clear differentiation from existing treatments",drug_analysis,processed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CS(=O)(=O)c1ccc(Oc2cc(F)cc(C#N)c2)c2c1[C@H](O)[C@H](F)[C@@H]2F
Candidate Name: BELZUTIFAN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | nan Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics

### Success Factors

This drug was successfully approved, demonstrating:
1. **Favorable safety profile** through clinical development
2. **Clear efficacy** in target patient population
3. **Acceptable risk-benefit ratio** for intended indication

### Key Success Indicators
- Completed Phase III trials with positive outcomes
- Manageable side effect profile
- Clear differentiation from existing treatments
<|im_end|>"
"Analyze the ADMET properties of this compound:
NCCNCCNCCN",,"## Molecular Property Analysis: TRIENTINE

### Structure
```
NCCNCCNCCN
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 146.2 Da | 150-500 Da | ‚ö† |
| LogP (cLogP) | -1.92 | 0-5 | ‚ö† |
| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 4.0 | ‚â§5 | ‚úì |
| PSA | 76.1 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 7.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.320
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Limited CNS penetration expected

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Low (hydrophilic)

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- May undergo renal clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze the ADMET properties of this compound:
NCCNCCNCCN
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: TRIENTINE

### Structure
```
NCCNCCNCCN
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 146.2 Da | 150-500 Da | ‚ö† |
| LogP (cLogP) | -1.92 | 0-5 | ‚ö† |
| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 4.0 | ‚â§5 | ‚úì |
| PSA | 76.1 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 7.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.320
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Limited CNS penetration expected

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Low (hydrophilic)

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- May undergo renal clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CC(C)OC(=O)CCC/C=C\C[C@@H]1[C@@H](/C=C/C(F)(F)COc2ccccc2)[C@H](O)C[C@@H]1O
Drug Name: TAFLUPROST",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 452.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.68 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 76.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CC(C)OC(=O)CCC/C=C\C[C@@H]1[C@@H](/C=C/C(F)(F)COc2ccccc2)[C@H](O)C[C@@H]1O
Drug Name: TAFLUPROST
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 452.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.68 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 76.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CC(=O)Nc1c(I)c(C(=O)[O-])c(I)c(N(C)C(C)=O)c1I.CC(=O)Nc1c(I)c(C(=O)[O-])c(I)c(N(C)C(C)=O)c1I.[Mg+2]
Drug Name: METRIZOATE MAGNESIUM",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 1278.2 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 3.14 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 86.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CC(=O)Nc1c(I)c(C(=O)[O-])c(I)c(N(C)C(C)=O)c1I.CC(=O)Nc1c(I)c(C(=O)[O-])c(I)c(N(C)C(C)=O)c1I.[Mg+2]
Drug Name: METRIZOATE MAGNESIUM
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 1278.2 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 3.14 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 86.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
O=C(O)c1ccccc1-c1ccc(C(F)(F)F)cc1",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 266.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.07 | ‚úì Good (<5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 37.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
O=C(O)c1ccccc1-c1ccc(C(F)(F)F)cc1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 266.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.07 | ‚úì Good (<5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 37.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CC(C)c1cccc(C(C)C)c1OCOP(=O)([O-])[O-].[Na+].[Na+]
Drug Name: FOSPROPOFOL DISODIUM",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 332.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.38 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 76.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CC(C)c1cccc(C(C)C)c1OCOP(=O)([O-])[O-].[Na+].[Na+]
Drug Name: FOSPROPOFOL DISODIUM
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 332.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.38 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 76.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CCOc1nc(N)nc2c1ncn2[C@@H]1O[C@@H]2COP(=O)(OC(C)C)O[C@H]2[C@@]1(C)F",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 431.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.38 | ‚úì Good (<5) |
| H-Bond Acceptors | 11.0 | ‚ö† High (>10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 132.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CCOc1nc(N)nc2c1ncn2[C@@H]1O[C@@H]2COP(=O)(OC(C)C)O[C@H]2[C@@]1(C)F
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 431.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.38 | ‚úì Good (<5) |
| H-Bond Acceptors | 11.0 | ‚ö† High (>10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 132.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
COc1cc(/C=C2\CCC/C(=C\c3ccc(O)c(OC)c3)C2=O)ccc1O",,"## Molecular Property Analysis: CYCLOVALONE

### Structure
```
COc1cc(/C=C2\CCC/C(=C\c3ccc(O)c(OC)c3)C2=O)ccc1O
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 366.4 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 4.34 | 0-5 | ‚úì |
| H-Bond Acceptors | 5.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |
| PSA | 76.0 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 4.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.790
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- CYP450 substrate likely
- Potential CYP inhibition risk

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
COc1cc(/C=C2\CCC/C(=C\c3ccc(O)c(OC)c3)C2=O)ccc1O
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: CYCLOVALONE

### Structure
```
COc1cc(/C=C2\CCC/C(=C\c3ccc(O)c(OC)c3)C2=O)ccc1O
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 366.4 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 4.34 | 0-5 | ‚úì |
| H-Bond Acceptors | 5.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |
| PSA | 76.0 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 4.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.790
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- CYP450 substrate likely
- Potential CYP inhibition risk

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CN(C)/C=N/c1c(I)cc(I)c(CCC(=O)[O-])c1I.[Na+]
Name: IPODATE SODIUM",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 619.9 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 3.74 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 52.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CN(C)/C=N/c1c(I)cc(I)c(CCC(=O)[O-])c1I.[Na+]
Name: IPODATE SODIUM
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 619.9 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 3.74 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 52.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CCCCCCNC(=N)NC(=N)N
POLIHEXANIDE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 185.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.57 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 97.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CCCCCCNC(=N)NC(=N)N
POLIHEXANIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 185.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.57 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 97.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
O=C(O)COc1ccccc1NC(=O)c1ccc(Cl)c(Cl)c1
Name: CLAMIDOXIC ACID",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 340.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.71 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 75.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
O=C(O)COc1ccccc1NC(=O)c1ccc(Cl)c(Cl)c1
Name: CLAMIDOXIC ACID
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 340.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.71 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 75.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: Cc1ccc(/C=C/C(=O)NCCCCN2CCN(C(c3ccccc3)c3ccccc3)CC2)cn1
Candidate Name: TAGORIZINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 468.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.71 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 48.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: Cc1ccc(/C=C/C(=O)NCCCCN2CCN(C(c3ccccc3)c3ccccc3)CC2)cn1
Candidate Name: TAGORIZINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 468.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.71 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 48.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CNCC(O)CC12CCC(c3ccccc31)c1ccccc12
OXAPROTILINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 293.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.18 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 32.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CNCC(O)CC12CCC(c3ccccc31)c1ccccc12
OXAPROTILINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 293.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.18 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 32.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
Cc1cc(O)c(C(C)C)cc1/N=N/c1ccc(S(=O)(=O)c2ccc(/N=N/c3cc(C(C)C)c(O)cc3C)cc2)cc1
DIATHYMOSULFONE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 570.7 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 9.63 | ‚ö† High (>5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 124.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
Cc1cc(O)c(C(C)C)cc1/N=N/c1ccc(S(=O)(=O)c2ccc(/N=N/c3cc(C(C)C)c(O)cc3C)cc2)cc1
DIATHYMOSULFONE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 570.7 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 9.63 | ‚ö† High (>5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 124.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: O=C(O)Cn1c(C(=O)Nc2nc(-c3ccccc3Cl)cs2)cc2ccccc21
Candidate Name: LINTITRIPT",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 411.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.76 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 84.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: O=C(O)Cn1c(C(=O)Nc2nc(-c3ccccc3Cl)cs2)cc2ccccc21
Candidate Name: LINTITRIPT
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 411.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.76 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 84.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
O=C(NCCN1CCN(c2cccc3c2OC[C@H](CO)O3)CC1)c1ccc(F)cc1
Name: FLESINOXAN",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 415.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.51 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 74.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
O=C(NCCN1CCN(c2cccc3c2OC[C@H](CO)O3)CC1)c1ccc(F)cc1
Name: FLESINOXAN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 415.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.51 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 74.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CCC(Cc1c(I)cc(I)c(N2CCCC2=O)c1I)C(=O)O
Drug Name: IOLIDONIC ACID",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 639.0 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 4.28 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 57.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CCC(Cc1c(I)cc(I)c(N2CCCC2=O)c1I)C(=O)O
Drug Name: IOLIDONIC ACID
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 639.0 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 4.28 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 57.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CS[C@H](c2cccs2)CN(CC(=O)O)C1=O",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 476.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.97 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 95.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CS[C@H](c2cccs2)CN(CC(=O)O)C1=O
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 476.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.97 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 95.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Describe the molecular properties and drug-likeness of:
O=C(O)Cn1c(=O)n(Cc2ccc(Br)cc2F)c(=O)c2ccc(Cl)cc21",,"## Molecular Property Analysis: ZENARESTAT

### Structure
```
O=C(O)Cn1c(=O)n(Cc2ccc(Br)cc2F)c(=O)c2ccc(Cl)cc21
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 441.6 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 2.85 | 0-5 | ‚úì |
| H-Bond Acceptors | 5.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 81.3 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 4.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.680
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- CYP450 substrate likely
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Describe the molecular properties and drug-likeness of:
O=C(O)Cn1c(=O)n(Cc2ccc(Br)cc2F)c(=O)c2ccc(Cl)cc21
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: ZENARESTAT

### Structure
```
O=C(O)Cn1c(=O)n(Cc2ccc(Br)cc2F)c(=O)c2ccc(Cl)cc21
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 441.6 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 2.85 | 0-5 | ‚úì |
| H-Bond Acceptors | 5.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 81.3 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 4.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.680
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- CYP450 substrate likely
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
COc1ccc(Cc2nccc3cc(OC)c(OC)cc23)cc1OC.Cl
Name: PAPAVERINE HYDROCHLORIDE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 375.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.86 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 49.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
COc1ccc(Cc2nccc3cc(OC)c(OC)cc23)cc1OC.Cl
Name: PAPAVERINE HYDROCHLORIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 375.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.86 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 49.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CN(C)[C@@H]1C(O)=C(C(N)=O)C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)cccc4C[C@H]3C[C@@H]12",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 414.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.12 | ‚úì Good (<5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 161.4 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CN(C)[C@@H]1C(O)=C(C(N)=O)C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)cccc4C[C@H]3C[C@@H]12
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 414.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.12 | ‚úì Good (<5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 161.4 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
Cc1cc(C)cc(NC(=O)Cc2ccc(OC(C)(C)C(=O)O)cc2)c1",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 341.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.73 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 75.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
Cc1cc(C)cc(NC(=O)Cc2ccc(OC(C)(C)C(=O)O)cc2)c1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 341.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.73 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 75.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)CO",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 362.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.78 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 94.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)CO
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 362.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.78 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 94.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CCCCCCCCCCCCS[C@H](C(=O)Nc1cc(C)c(O)c(C)c1C)c1ccccc1
EFLUCIMIBE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 469.7 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 8.65 | ‚ö† High (>5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 49.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CCCCCCCCCCCCS[C@H](C(=O)Nc1cc(C)c(O)c(C)c1C)c1ccccc1
EFLUCIMIBE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 469.7 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 8.65 | ‚ö† High (>5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 49.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CC(C)OC(=O)c1cc2c(OCC(O)CNC(C)(C)C)cccc2[nH]1",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 348.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.86 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 83.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CC(C)OC(=O)c1cc2c(OCC(O)CNC(C)(C)C)cccc2[nH]1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 348.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.86 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 83.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: C#C[C@]1(OC(C)=O)CC[C@H]2[C@@H]3CC=C4C=C(OC5CCCC5)CC[C@@H]4[C@H]3CC[C@@]21C
Drug Name: QUINGESTANOL ACETATE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 408.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.95 | ‚ö† High (>5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 35.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: C#C[C@]1(OC(C)=O)CC[C@H]2[C@@H]3CC=C4C=C(OC5CCCC5)CC[C@@H]4[C@H]3CC[C@@]21C
Drug Name: QUINGESTANOL ACETATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 408.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.95 | ‚ö† High (>5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 35.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: COCC(O)COC(C)(C)C
Drug Name: TERBUPROL",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 162.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.81 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 38.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: COCC(O)COC(C)(C)C
Drug Name: TERBUPROL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 162.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.81 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 38.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CC(I)C1OCC(CO)O1
GLYCEROL, IODINATED",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 258.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.54 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 38.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CC(I)C1OCC(CO)O1
GLYCEROL, IODINATED
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 258.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.54 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 38.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
Oc1ccc(C(O)CNC2CCC2)cc1O
NORBUDRINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 223.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.27 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 72.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
Oc1ccc(C(O)CNC2CCC2)cc1O
NORBUDRINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 223.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.27 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 72.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CN1CCN=C(c2ccccc2)c2cc(Cl)ccc21
Drug Name: MEDAZEPAM",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 270.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.63 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 15.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CN1CCN=C(c2ccccc2)c2cc(Cl)ccc21
Drug Name: MEDAZEPAM
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 270.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.63 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 15.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CC(N)C12CC3CC(CC(C3)C1)C2
Candidate Name: RIMANTADINE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 179.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.55 | ‚úì Good (<5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 26.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CC(N)C12CC3CC(CC(C3)C1)C2
Candidate Name: RIMANTADINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 179.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.55 | ‚úì Good (<5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 26.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Describe the molecular properties and drug-likeness of:
C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C=O)[C@@H](C(=O)CO)CC[C@@H]12",,"## Molecular Property Analysis: ALDOSTERONE

### Structure
```
C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C=O)[C@@H](C(=O)CO)CC[C@@H]12
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 360.4 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 1.85 | 0-5 | ‚úì |
| H-Bond Acceptors | 5.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |
| PSA | 91.7 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.750
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Limited CNS penetration expected

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- CYP450 substrate likely
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Describe the molecular properties and drug-likeness of:
C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C=O)[C@@H](C(=O)CO)CC[C@@H]12
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: ALDOSTERONE

### Structure
```
C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C=O)[C@@H](C(=O)CO)CC[C@@H]12
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 360.4 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 1.85 | 0-5 | ‚úì |
| H-Bond Acceptors | 5.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |
| PSA | 91.7 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.750
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Limited CNS penetration expected

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- CYP450 substrate likely
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1
Drug Name: HALOPERIDOL",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 375.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.43 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 40.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1
Drug Name: HALOPERIDOL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 375.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.43 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 40.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CC1NC(=O)COC1c1ccccc1
Candidate Name: FENMETRAMIDE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 191.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.26 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 38.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CC1NC(=O)COC1c1ccccc1
Candidate Name: FENMETRAMIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 191.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.26 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 38.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CC[C@H](OC(C)=O)C(C[C@H](C)N(C)C)(c1ccccc1)c1ccccc1
Drug Name: LEVOMETHADYL ACETATE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 353.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.65 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 29.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CC[C@H](OC(C)=O)C(C[C@H](C)N(C)C)(c1ccccc1)c1ccccc1
Drug Name: LEVOMETHADYL ACETATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 353.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.65 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 29.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CC(C)C[C@H](CN)CC(=O)O",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 159.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.08 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 63.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CC(C)C[C@H](CN)CC(=O)O
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 159.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.08 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 63.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: O=c1oc(CCN2CCN(c3ccccc3)CC2)c(-c2ccc(Cl)cc2)o1
Candidate Name: CLODOXOPONE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 384.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.92 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 49.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: O=c1oc(CCN2CCN(c3ccccc3)CC2)c(-c2ccc(Cl)cc2)o1
Candidate Name: CLODOXOPONE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 384.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.92 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 49.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CCCC(CCC)C(=O)O.CCCC(CCC)C(=O)[O-].[Na+]
Name: DIVALPROEX SODIUM",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 310.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.29 | ‚úì Good (<5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 37.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CCCC(CCC)C(=O)O.CCCC(CCC)C(=O)[O-].[Na+]
Name: DIVALPROEX SODIUM
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 310.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.29 | ‚úì Good (<5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 37.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
NC(=O)c1ccc(N(C(N)=O)c2c(F)cccc2F)nc1-c1ccc(F)cc1F
VX-702",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 404.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.62 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 102.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
NC(=O)c1ccc(N(C(N)=O)c2c(F)cccc2F)nc1-c1ccc(F)cc1F
VX-702
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 404.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.62 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 102.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: C[C@H](NC(=O)C(C)(C)Oc1ccc(C(F)(F)F)cn1)[C@@H](Cc1ccc(Cl)cc1)c1cccc(C#N)c1
Drug Name: TARANABANT",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 516.0 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 6.31 | ‚ö† High (>5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 75.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: C[C@H](NC(=O)C(C)(C)Oc1ccc(C(F)(F)F)cn1)[C@@H](Cc1ccc(Cl)cc1)c1cccc(C#N)c1
Drug Name: TARANABANT
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 516.0 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 6.31 | ‚ö† High (>5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 75.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(OCCN3CCOCC3)c3ccccc23)cc1",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 527.7 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 5.99 | ‚ö† High (>5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 80.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(OCCN3CCOCC3)c3ccccc23)cc1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 527.7 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 5.99 | ‚ö† High (>5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 80.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
C=C1C[C@@H]2CC[C@@]34C[C@H]5O[C@H]6[C@@H](O3)[C@H]3O[C@H](CC[C@@H]3O[C@H]6[C@H]5O4)CC(=O)C[C@@H]3[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]3C[C@H]3O[C@@H](CC[C@@H]1O2)C[C@@H](C)C3=C.CS(=O)(=O)O
ERIBULIN MESYLATE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 826.0 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 3.44 | ‚úì Good (<5) |
| H-Bond Acceptors | 12.0 | ‚ö† High (>10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 146.4 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
C=C1C[C@@H]2CC[C@@]34C[C@H]5O[C@H]6[C@@H](O3)[C@H]3O[C@H](CC[C@@H]3O[C@H]6[C@H]5O4)CC(=O)C[C@@H]3[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]3C[C@H]3O[C@@H](CC[C@@H]1O2)C[C@@H](C)C3=C.CS(=O)(=O)O
ERIBULIN MESYLATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 826.0 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 3.44 | ‚úì Good (<5) |
| H-Bond Acceptors | 12.0 | ‚ö† High (>10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 146.4 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: Cc1cc2c(cc1CC(=O)c1sccc1S(=O)(=O)Nc1onc(C)c1Cl)OCO2
Drug Name: SITAXENTAN",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 454.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.96 | ‚úì Good (<5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 107.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: Cc1cc2c(cc1CC(=O)c1sccc1S(=O)(=O)Nc1onc(C)c1Cl)OCO2
Drug Name: SITAXENTAN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 454.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.96 | ‚úì Good (<5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 107.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CCCCOCCOC(=O)C(c1ccccc1)N1CCCCC1
Drug Name: BUTOPIPRINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 319.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.57 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 38.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CCCCOCCOC(=O)C(c1ccccc1)N1CCCCC1
Drug Name: BUTOPIPRINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 319.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.57 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 38.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CC(=O)Oc1ccc(C2(c3ccc(OC(C)=O)cc3)C(=O)N(C(C)=O)c3ccccc32)cc1
Candidate Name: TRIACETYLDIPHENOLISATIN",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 443.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.76 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 90.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CC(=O)Oc1ccc(C2(c3ccc(OC(C)=O)cc3)C(=O)N(C(C)=O)c3ccccc32)cc1
Candidate Name: TRIACETYLDIPHENOLISATIN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 443.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.76 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 90.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: O=C1OCCN1/N=C/c1ccc([N+](=O)[O-])o1
Drug Name: FURAZOLIDONE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 225.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.97 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 98.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: O=C1OCCN1/N=C/c1ccc([N+](=O)[O-])o1
Drug Name: FURAZOLIDONE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 225.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.97 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 98.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: COc1ccc(CC(=O)Nc2ccccc2)cc1
Drug Name: Compound_EXP005",,"## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | nan Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,processed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: COc1ccc(CC(=O)Nc2ccccc2)cc1
Drug Name: Compound_EXP005
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | nan Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CCCC(=O)O[C@]1(C(=O)CC)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C
RESOCORTOL BUTYRATE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 430.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.55 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 80.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CCCC(=O)O[C@]1(C(=O)CC)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C
RESOCORTOL BUTYRATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 430.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.55 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 80.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CC(C)(F)C[C@H](N[C@@H](c1ccc(-c2ccc(S(C)(=O)=O)cc2)cc1)C(F)(F)F)C(=O)NC1(C#N)CC1
Candidate Name: ODANACATIB",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 525.6 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 4.63 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 99.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CC(C)(F)C[C@H](N[C@@H](c1ccc(-c2ccc(S(C)(=O)=O)cc2)cc1)C(F)(F)F)C(=O)NC1(C#N)CC1
Candidate Name: ODANACATIB
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 525.6 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 4.63 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 99.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CCCCCCCCCCCCCCCCOCCCOP(=O)(O)CO[C@H](C)Cn1cnc2c(N)ncnc21
Candidate Name: TENOFOVIR EXALIDEX",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 569.7 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 6.86 | ‚ö† High (>5) |
| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 134.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CCCCCCCCCCCCCCCCOCCCOP(=O)(O)CO[C@H](C)Cn1cnc2c(N)ncnc21
Candidate Name: TENOFOVIR EXALIDEX
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 569.7 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 6.86 | ‚ö† High (>5) |
| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 134.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
COc1ccc2nc3cc(Cl)ccc3c(Nc3cc(CN4CCCC4)c(O)c(CN4CCCC4)c3)c2n1",,"## Molecular Property Analysis: PYRONARIDINE

### Structure
```
COc1ccc2nc3cc(Cl)ccc3c(Nc3cc(CN4CCCC4)c(O)c(CN4CCCC4)c3)c2n1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 518.1 Da | 150-500 Da | ‚ö† |
| LogP (cLogP) | 6.09 | 0-5 | ‚ö† |
| H-Bond Acceptors | 7.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |
| PSA | 73.8 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 7.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.230
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- May have oral absorption challenges
- Limited CNS penetration expected

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- CYP450 substrate likely
- Potential CYP inhibition risk

**Excretion:**
- Likely hepatic clearance
- Long half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚ö† FAIL
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
COc1ccc2nc3cc(Cl)ccc3c(Nc3cc(CN4CCCC4)c(O)c(CN4CCCC4)c3)c2n1
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: PYRONARIDINE

### Structure
```
COc1ccc2nc3cc(Cl)ccc3c(Nc3cc(CN4CCCC4)c(O)c(CN4CCCC4)c3)c2n1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 518.1 Da | 150-500 Da | ‚ö† |
| LogP (cLogP) | 6.09 | 0-5 | ‚ö† |
| H-Bond Acceptors | 7.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |
| PSA | 73.8 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 7.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.230
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- May have oral absorption challenges
- Limited CNS penetration expected

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- CYP450 substrate likely
- Potential CYP inhibition risk

**Excretion:**
- Likely hepatic clearance
- Long half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚ö† FAIL
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
O=C([O-])C1N=C(c2ccccc2)c2cc(Cl)ccc2NC1=O.[K+].[K+].[OH-]
CLORAZEPATE DIPOTASSIUM",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 408.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.58 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 78.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
O=C([O-])C1N=C(c2ccccc2)c2cc(Cl)ccc2NC1=O.[K+].[K+].[OH-]
CLORAZEPATE DIPOTASSIUM
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 408.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.58 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 78.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CC(C)(C)c1ccc2c(c1)CC[C@H]2NC(=O)Nc1cccc2[nH]ncc12
Name: ABT-102",,"## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 348.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.67 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 69.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CC(C)(C)c1ccc2c(c1)CC[C@H]2NC(=O)Nc1cccc2[nH]ncc12
Name: ABT-102
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 348.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.67 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 69.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
NCCCC[C@H](OP(=O)(O)CCCCc1ccccc1)C(=O)N1CCC[C@H]1C(=O)O
CERONAPRIL",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 440.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.78 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 130.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
NCCCC[C@H](OP(=O)(O)CCCCc1ccccc1)C(=O)N1CCC[C@H]1C(=O)O
CERONAPRIL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 440.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.78 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 130.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
C=C(C)[C@@H]1CC[C@]2(C(=O)O)CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](OC(=O)CC(C)(C)C(=O)O)C(C)(C)[C@@H]5CC[C@]43C)[C@@H]12",,"## Molecular Property Analysis: BEVIRIMAT

### Structure
```
C=C(C)[C@@H]1CC[C@]2(C(=O)O)CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](OC(=O)CC(C)(C)C(=O)O)C(C)(C)[C@@H]5CC[C@]43C)[C@@H]12
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 584.8 Da | 150-500 Da | ‚ö† |
| LogP (cLogP) | 8.14 | 0-5 | ‚ö† |
| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |
| PSA | 100.9 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 6.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.240
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- May have oral absorption challenges
- Limited CNS penetration expected

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- CYP450 substrate likely
- Potential CYP inhibition risk

**Excretion:**
- Likely hepatic clearance
- Long half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚ö† FAIL
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
C=C(C)[C@@H]1CC[C@]2(C(=O)O)CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](OC(=O)CC(C)(C)C(=O)O)C(C)(C)[C@@H]5CC[C@]43C)[C@@H]12
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: BEVIRIMAT

### Structure
```
C=C(C)[C@@H]1CC[C@]2(C(=O)O)CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](OC(=O)CC(C)(C)C(=O)O)C(C)(C)[C@@H]5CC[C@]43C)[C@@H]12
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 584.8 Da | 150-500 Da | ‚ö† |
| LogP (cLogP) | 8.14 | 0-5 | ‚ö† |
| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |
| PSA | 100.9 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 6.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.240
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- May have oral absorption challenges
- Limited CNS penetration expected

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- CYP450 substrate likely
- Potential CYP inhibition risk

**Excretion:**
- Likely hepatic clearance
- Long half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚ö† FAIL
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CC(C)NCC(O)c1ccc(NS(C)(=O)=O)cc1
SOTALOL",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 272.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.09 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 78.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CC(C)NCC(O)c1ccc(NS(C)(=O)=O)cc1
SOTALOL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 272.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.09 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 78.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CN(C)[C@]1(c2ccccc2)CC[C@]2(CC1)OCCc1c3cc(F)ccc3[nH]c12
Candidate Name: CEBRANOPADOL",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 378.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.11 | ‚ö† High (>5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 28.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CN(C)[C@]1(c2ccccc2)CC[C@]2(CC1)OCCc1c3cc(F)ccc3[nH]c12
Candidate Name: CEBRANOPADOL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 378.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.11 | ‚ö† High (>5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 28.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
Cc1sc2ccccc2c1CC1=NCCN1",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 230.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.75 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 24.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
Cc1sc2ccccc2c1CC1=NCCN1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 230.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.75 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 24.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
C[S+]([O-])c1ccc2oc3ccc(C(=O)O)cc3c(=O)c2c1
TIXANOX",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 302.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.38 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 90.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
C[S+]([O-])c1ccc2oc3ccc(C(=O)O)cc3c(=O)c2c1
TIXANOX
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 302.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.38 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 90.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Describe the molecular properties and drug-likeness of:
CNC(=O)[C@@H](Cc1ccccc1)N(C)C(=O)[C@@H](Cc1ccc2ccccc2c1)N(C)C(=O)/C=C/CC(C)(C)N",,"## Molecular Property Analysis: TABIMORELIN

### Structure
```
CNC(=O)[C@@H](Cc1ccccc1)N(C)C(=O)[C@@H](Cc1ccc2ccccc2c1)N(C)C(=O)/C=C/CC(C)(C)N
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 528.7 Da | 150-500 Da | ‚ö† |
| LogP (cLogP) | 3.71 | 0-5 | ‚úì |
| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |
| PSA | 95.7 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 11.0 | ‚â§10 | ‚ö† |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.370
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Limited CNS penetration expected

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- CYP450 substrate likely
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Long half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚ö† FAIL
**Veber Rules (Oral Bioavailability):** ‚ö† FAIL",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Describe the molecular properties and drug-likeness of:
CNC(=O)[C@@H](Cc1ccccc1)N(C)C(=O)[C@@H](Cc1ccc2ccccc2c1)N(C)C(=O)/C=C/CC(C)(C)N
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: TABIMORELIN

### Structure
```
CNC(=O)[C@@H](Cc1ccccc1)N(C)C(=O)[C@@H](Cc1ccc2ccccc2c1)N(C)C(=O)/C=C/CC(C)(C)N
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 528.7 Da | 150-500 Da | ‚ö† |
| LogP (cLogP) | 3.71 | 0-5 | ‚úì |
| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |
| PSA | 95.7 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 11.0 | ‚â§10 | ‚ö† |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.370
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Limited CNS penetration expected

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- CYP450 substrate likely
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Long half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚ö† FAIL
**Veber Rules (Oral Bioavailability):** ‚ö† FAIL
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
O=C(Nc1cccc2c(=O)cc(-c3nnn[nH]3)oc12)c1ccc(OCCCCc2ccccc2)cc1
Name: PRANLUKAST",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 481.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.63 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 123.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
O=C(Nc1cccc2c(=O)cc(-c3nnn[nH]3)oc12)c1ccc(OCCCCc2ccccc2)cc1
Name: PRANLUKAST
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 481.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.63 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 123.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CC1(C)C=C(n2ccccc2=O)c2cc(C#N)ccc2O1",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 278.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.78 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 55.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CC1(C)C=C(n2ccccc2=O)c2cc(C#N)ccc2O1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 278.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.78 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 55.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
Cc1cc(-c2ccc(/N=N/c3c(S(=O)(=O)[O-])cc4cc(S(=O)(=O)[O-])cc(N)c4c3O)c(C)c2)ccc1/N=N/c1c(S(=O)(=O)[O-])cc2cc(S(=O)(=O)[O-])cc(N)c2c1O.[Na+].[Na+].[Na+].[Na+]
Name: TRYPAN BLUE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 960.8 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 6.67 | ‚ö† High (>5) |
| H-Bond Acceptors | 16.0 | ‚ö† High (>10) |
| H-Bond Donors | 8.0 | ‚ö† High (>5) |
| Polar Surface Area | 359.4 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 4.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
Cc1cc(-c2ccc(/N=N/c3c(S(=O)(=O)[O-])cc4cc(S(=O)(=O)[O-])cc(N)c4c3O)c(C)c2)ccc1/N=N/c1c(S(=O)(=O)[O-])cc2cc(S(=O)(=O)[O-])cc(N)c2c1O.[Na+].[Na+].[Na+].[Na+]
Name: TRYPAN BLUE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 960.8 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 6.67 | ‚ö† High (>5) |
| H-Bond Acceptors | 16.0 | ‚ö† High (>10) |
| H-Bond Donors | 8.0 | ‚ö† High (>5) |
| Polar Surface Area | 359.4 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 4.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Analyze the ADMET properties of this compound:
CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C",,"## Molecular Property Analysis: MEDROXYPROGESTERONE ACETATE

### Structure
```
CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 386.5 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 4.66 | 0-5 | ‚úì |
| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 0 | ‚â§5 | ‚úì |
| PSA | 60.4 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 2.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.650
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- CYP450 substrate likely
- Potential CYP inhibition risk

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze the ADMET properties of this compound:
CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: MEDROXYPROGESTERONE ACETATE

### Structure
```
CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 386.5 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 4.66 | 0-5 | ‚úì |
| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 0 | ‚â§5 | ‚úì |
| PSA | 60.4 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 2.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.650
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- CYP450 substrate likely
- Potential CYP inhibition risk

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: Cc1c(-c2ccc(-c3ccccc3F)cc2)nc2ccc(F)cc2c1C(=O)O
Candidate Name: BREQUINAR",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 375.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.85 | ‚ö† High (>5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 50.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: Cc1c(-c2ccc(-c3ccccc3F)cc2)nc2ccc(F)cc2c1C(=O)O
Candidate Name: BREQUINAR
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 375.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.85 | ‚ö† High (>5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 50.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
CCCN1C[C@H](CSC)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21",,"## Molecular Property Analysis: PERGOLIDE

### Structure
```
CCCN1C[C@H](CSC)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 314.5 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 4.27 | 0-5 | ‚úì |
| H-Bond Acceptors | 2.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 19.0 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 4.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.910
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- CYP450 substrate likely
- Potential CYP inhibition risk

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
CCCN1C[C@H](CSC)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: PERGOLIDE

### Structure
```
CCCN1C[C@H](CSC)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 314.5 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 4.27 | 0-5 | ‚úì |
| H-Bond Acceptors | 2.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 19.0 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 4.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.910
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- CYP450 substrate likely
- Potential CYP inhibition risk

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
COc1cc(NCCCC(C)N)c2ncccc2c1
Name: QUINOCIDE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 259.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.78 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 60.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
COc1cc(NCCCC(C)N)c2ncccc2c1
Name: QUINOCIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 259.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.78 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 60.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CC(CN(C)C)CN1c2ccccc2Sc2ccccc21
Drug Name: METHYLPROMAZINE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 298.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.49 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 6.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CC(CN(C)C)CN1c2ccccc2Sc2ccccc21
Drug Name: METHYLPROMAZINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 298.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.49 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 6.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
Cc1nc2sccn2c(=O)c1CCN1CCC(=C(c2ccc(F)cc2)c2ccc(F)cc2)CC1",,"## Molecular Property Analysis: RITANSERIN

### Structure
```
Cc1nc2sccn2c(=O)c1CCN1CCC(=C(c2ccc(F)cc2)c2ccc(F)cc2)CC1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 477.6 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 5.48 | 0-5 | ‚ö† |
| H-Bond Acceptors | 5.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 0 | ‚â§5 | ‚úì |
| PSA | 37.6 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 5.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.380
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- May have oral absorption challenges
- Limited CNS penetration expected

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- CYP450 substrate likely
- Potential CYP inhibition risk

**Excretion:**
- Likely hepatic clearance
- Long half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚ö† FAIL
**Veber Rules (Oral Bioavailability):** ‚úì PASS",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
Cc1nc2sccn2c(=O)c1CCN1CCC(=C(c2ccc(F)cc2)c2ccc(F)cc2)CC1
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: RITANSERIN

### Structure
```
Cc1nc2sccn2c(=O)c1CCN1CCC(=C(c2ccc(F)cc2)c2ccc(F)cc2)CC1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 477.6 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 5.48 | 0-5 | ‚ö† |
| H-Bond Acceptors | 5.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 0 | ‚â§5 | ‚úì |
| PSA | 37.6 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 5.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.380
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- May have oral absorption challenges
- Limited CNS penetration expected

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- CYP450 substrate likely
- Potential CYP inhibition risk

**Excretion:**
- Likely hepatic clearance
- Long half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚ö† FAIL
**Veber Rules (Oral Bioavailability):** ‚úì PASS
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
Nc1ccc(/N=N/c2ccccc2)c(N)n1
Name: PHENAZOPYRIDINE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 213.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.66 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 89.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
Nc1ccc(/N=N/c2ccccc2)c(N)n1
Name: PHENAZOPYRIDINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 213.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.66 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 89.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H]2CN1C(=O)[C@H](C(C)(C)C)NC(=O)O[C@@H]1C[C@H]1CCCCCc1nc3ccc(OC)cc3nc1O2)C(=O)NS(=O)(=O)C1CC1.O",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 784.9 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 3.30 | ‚úì Good (<5) |
| H-Bond Acceptors | 11.0 | ‚ö† High (>10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 195.2 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H]2CN1C(=O)[C@H](C(C)(C)C)NC(=O)O[C@@H]1C[C@H]1CCCCCc1nc3ccc(OC)cc3nc1O2)C(=O)NS(=O)(=O)C1CC1.O
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 784.9 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 3.30 | ‚úì Good (<5) |
| H-Bond Acceptors | 11.0 | ‚ö† High (>10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 195.2 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)/C2=C\F)c(=O)n1
Candidate Name: TEZACITABINE ANHYDROUS",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 257.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -1.07 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 110.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)/C2=C\F)c(=O)n1
Candidate Name: TEZACITABINE ANHYDROUS
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 257.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -1.07 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 110.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: Oc1ccc2c(c1)[C@@]13CCCC[C@@]1(O)[C@@H](C2)N(CC1CC1)CC3
Drug Name: OXILORPHAN",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 313.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.98 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 43.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: Oc1ccc2c(c1)[C@@]13CCCC[C@@]1(O)[C@@H](C2)N(CC1CC1)CC3
Drug Name: OXILORPHAN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 313.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.98 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 43.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CCC(=O)O[C@]1(C(=O)SCCl)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
Candidate Name: CLOTICASONE PROPIONATE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 517.0 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 4.70 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 80.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CCC(=O)O[C@]1(C(=O)SCCl)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
Candidate Name: CLOTICASONE PROPIONATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 517.0 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 4.70 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 80.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CCN(CC)CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 475.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.67 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 104.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CCN(CC)CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 475.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.67 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 104.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CN(C)CC(O)C(c1ccccc1)c1cccc(Cl)c1
Candidate Name: CLEMEPROL",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 289.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.39 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 23.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CN(C)CC(O)C(c1ccccc1)c1cccc(Cl)c1
Candidate Name: CLEMEPROL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 289.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.39 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 23.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: O=C(O)c1ccc(C(c2ccccc2)(c2ccccc2)c2ccccc2)cn1
Drug Name: PICOTRIN",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 365.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.16 | ‚ö† High (>5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 50.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: O=C(O)c1ccc(C(c2ccccc2)(c2ccccc2)c2ccccc2)cn1
Drug Name: PICOTRIN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 365.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.16 | ‚ö† High (>5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 50.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CC(=O)O.Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 530.7 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 6.33 | ‚ö† High (>5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 57.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CC(=O)O.Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 530.7 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 6.33 | ‚ö† High (>5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 57.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CN(C)Cc1ccc(CSCCNC(=O)c2ccc[n+]([O-])c2)o1
Drug Name: RAMIXOTIDINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 335.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.64 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 72.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CN(C)Cc1ccc(CSCCNC(=O)c2ccc[n+]([O-])c2)o1
Drug Name: RAMIXOTIDINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 335.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.64 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 72.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: Cc1c(O)cc2c(c1C)O[C@](C)(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)CC2
Candidate Name: GAMMA-TOCOPHEROL",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 416.7 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 8.53 | ‚ö† High (>5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 29.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: Cc1c(O)cc2c(c1C)O[C@](C)(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)CC2
Candidate Name: GAMMA-TOCOPHEROL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 416.7 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 8.53 | ‚ö† High (>5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 29.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
COCc1c(C(=O)OC(C)C)ncc2[nH]c3cccc(Oc4ccc(Cl)cc4)c3c12
Name: GEDOCARNIL",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 424.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.87 | ‚ö† High (>5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 73.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
COCc1c(C(=O)OC(C)C)ncc2[nH]c3cccc(Oc4ccc(Cl)cc4)c3c12
Name: GEDOCARNIL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 424.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.87 | ‚ö† High (>5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 73.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)CO
Drug Name: XYLOSE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 150.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -2.74 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 98.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: O=C[C@H](O)[C@@H](O)[C@H](O)CO
Drug Name: XYLOSE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 150.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -2.74 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 98.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CCN(CC)CC(=O)Nc1c(C)cccc1C",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 234.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.58 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 32.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CCN(CC)CC(=O)Nc1c(C)cccc1C
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 234.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.58 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 32.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CC(=O)O[C@H]1C[C@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3[C@@H](O)C[C@H](O[C@H]4CC[C@@]5(C)[C@H](CC[C@@H]6[C@@H]5C[C@@H](O)[C@]5(C)[C@@H](C7=CC(=O)OC7)CC[C@]65O)C4)O[C@@H]3C)O[C@@H]2C)O[C@H](C)[C@H]1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 985.1 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 0.61 | ‚úì Good (<5) |
| H-Bond Acceptors | 20.0 | ‚ö† High (>10) |
| H-Bond Donors | 8.0 | ‚ö† High (>5) |
| Polar Surface Area | 288.3 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 3.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CC(=O)O[C@H]1C[C@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3[C@@H](O)C[C@H](O[C@H]4CC[C@@]5(C)[C@H](CC[C@@H]6[C@@H]5C[C@@H](O)[C@]5(C)[C@@H](C7=CC(=O)OC7)CC[C@]65O)C4)O[C@@H]3C)O[C@@H]2C)O[C@H](C)[C@H]1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 985.1 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 0.61 | ‚úì Good (<5) |
| H-Bond Acceptors | 20.0 | ‚ö† High (>10) |
| H-Bond Donors | 8.0 | ‚ö† High (>5) |
| Polar Surface Area | 288.3 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 3.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
Nc1nc(OCCc2ccc(Cl)cc2)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
SONEDENOSON",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 421.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.29 | ‚úì Good (<5) |
| H-Bond Acceptors | 10.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 148.8 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
Nc1nc(OCCc2ccc(Cl)cc2)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
SONEDENOSON
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 421.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.29 | ‚úì Good (<5) |
| H-Bond Acceptors | 10.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 148.8 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
Cc1ccc(C)n1Nc1ccc(N2CCOCC2)nn1",,"## Molecular Property Analysis: MOPIDRALAZINE

### Structure
```
Cc1ccc(C)n1Nc1ccc(N2CCOCC2)nn1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 273.3 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 1.61 | 0-5 | ‚úì |
| H-Bond Acceptors | 6.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 55.2 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.920
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
Cc1ccc(C)n1Nc1ccc(N2CCOCC2)nn1
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: MOPIDRALAZINE

### Structure
```
Cc1ccc(C)n1Nc1ccc(N2CCOCC2)nn1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 273.3 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 1.61 | 0-5 | ‚úì |
| H-Bond Acceptors | 6.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 55.2 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.920
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CCOC(=O)c1ncn2c1CN(C)C(=O)c1c(I)cccc1-2",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 411.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.24 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 64.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CCOC(=O)c1ncn2c1CN(C)C(=O)c1c(I)cccc1-2
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 411.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.24 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 64.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
COc1ccc2c(OCc3nnc4ccc(-c5ccccc5)nn34)ccnc2c1",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 383.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.93 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 74.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
COc1ccc2c(OCc3nnc4ccc(-c5ccccc5)nn34)ccnc2c1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 383.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.93 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 74.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
COc1cc(/C=C/c2ccc(O)cc2)cc(OC)c1",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 256.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.58 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 38.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
COc1cc(/C=C/c2ccc(O)cc2)cc(OC)c1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 256.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.58 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 38.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
O=C(N[C@@H](Cc1ccccc1)[C@@H](O)C(=O)N1C[C@@H](O)[C@@H](O)C1)c1cc2cc(Cl)ccc2[nH]1",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 457.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.09 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 125.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
O=C(N[C@@H](Cc1ccccc1)[C@@H](O)C(=O)N1C[C@@H](O)[C@@H](O)C1)c1cc2cc(Cl)ccc2[nH]1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 457.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.09 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 125.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: Cc1ccc(S(=O)(=O)NC(=O)NN2CCCCCC2)cc1
Candidate Name: TOLAZAMIDE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 311.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.77 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 78.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: Cc1ccc(S(=O)(=O)NC(=O)NN2CCCCCC2)cc1
Candidate Name: TOLAZAMIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 311.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.77 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 78.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: COc1ccc(C(C)C)cc1CN[C@H]1C2CCN(CC2)[C@H]1C(c1ccccc1)c1ccccc1
Candidate Name: EZLOPITANT",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 454.7 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 6.20 | ‚ö† High (>5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 24.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: COc1ccc(C(C)C)cc1CN[C@H]1C2CCN(CC2)[C@H]1C(c1ccccc1)c1ccccc1
Candidate Name: EZLOPITANT
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 454.7 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 6.20 | ‚ö† High (>5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 24.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: COc1ccc(/C(C)=C\C(=O)O)c(OC)c1
Candidate Name: DIMECROTIC ACID",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 222.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.19 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 55.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: COc1ccc(/C(C)=C\C(=O)O)c(OC)c1
Candidate Name: DIMECROTIC ACID
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 222.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.19 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 55.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
COc1nc(/C=C/c2nc3n(n2)CCC[C@H]3c2ccccc2C(F)(F)F)ccc1-n1cnc(C)c1
E-2212",,"## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 480.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.29 | ‚ö† High (>5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 70.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
COc1nc(/C=C/c2nc3n(n2)CCC[C@H]3c2ccccc2C(F)(F)F)ccc1-n1cnc(C)c1
E-2212
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 480.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.29 | ‚ö† High (>5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 70.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Describe the molecular properties and drug-likeness of:
CC1(C)C(=O)Nc2ccc(C3=NNC(=O)CC3)cc21",,"## Molecular Property Analysis: INDOLIDAN

### Structure
```
CC1(C)C(=O)Nc2ccc(C3=NNC(=O)CC3)cc21
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 257.3 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 1.53 | 0-5 | ‚úì |
| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |
| PSA | 70.6 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 1.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.800
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Describe the molecular properties and drug-likeness of:
CC1(C)C(=O)Nc2ccc(C3=NNC(=O)CC3)cc21
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: INDOLIDAN

### Structure
```
CC1(C)C(=O)Nc2ccc(C3=NNC(=O)CC3)cc21
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 257.3 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 1.53 | 0-5 | ‚úì |
| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |
| PSA | 70.6 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 1.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.800
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS
<|im_end|>"
"Describe the molecular properties and drug-likeness of:
COc1ccc(-c2nc(S(C)(=O)=O)[nH]c2-c2ccc(OC)cc2)cc1",,"## Molecular Property Analysis: nan

### Structure
```
COc1ccc(-c2nc(S(C)(=O)=O)[nH]c2-c2ccc(OC)cc2)cc1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 358.4 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 3.16 | 0-5 | ‚úì |
| H-Bond Acceptors | 5.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 81.3 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 5.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.760
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- CYP450 substrate likely
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Describe the molecular properties and drug-likeness of:
COc1ccc(-c2nc(S(C)(=O)=O)[nH]c2-c2ccc(OC)cc2)cc1
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: nan

### Structure
```
COc1ccc(-c2nc(S(C)(=O)=O)[nH]c2-c2ccc(OC)cc2)cc1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 358.4 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 3.16 | 0-5 | ‚úì |
| H-Bond Acceptors | 5.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 81.3 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 5.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.760
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- CYP450 substrate likely
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: C[N+]1(CC2CC2)CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5.[Br-]
Candidate Name: METHYLNALTREXONE BROMIDE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 436.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.67 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 66.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: C[N+]1(CC2CC2)CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5.[Br-]
Candidate Name: METHYLNALTREXONE BROMIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 436.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.67 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 66.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
Cl.OC(CCN1CCCCC1)(c1ccccc1)C1CC2C=CC1C2",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 347.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.96 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 23.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
Cl.OC(CCN1CCCCC1)(c1ccccc1)C1CC2C=CC1C2
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 347.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.96 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 23.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: NCCCCN
Candidate Name: PUTRESCINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 88.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -0.32 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 52.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: NCCCCN
Candidate Name: PUTRESCINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 88.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -0.32 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 52.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1
Drug Name: DABRAFENIB",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 519.6 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 5.36 | ‚ö† High (>5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 110.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1
Drug Name: DABRAFENIB
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 519.6 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 5.36 | ‚ö† High (>5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 110.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
O=C(O)CC[C@H](NP(=O)(O)OCCC[C@H](NC(=O)CC[C@H](NC(=O)CCCCCNC(=O)c1ccc(F)cc1)C(=O)O)C(=O)O)C(=O)O
CTT-1057",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 706.6 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 0.84 | ‚úì Good (<5) |
| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 9.0 | ‚ö† High (>5) |
| Polar Surface Area | 295.1 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
O=C(O)CC[C@H](NP(=O)(O)OCCC[C@H](NC(=O)CC[C@H](NC(=O)CCCCCNC(=O)c1ccc(F)cc1)C(=O)O)C(=O)O)C(=O)O
CTT-1057
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 706.6 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 0.84 | ‚úì Good (<5) |
| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 9.0 | ‚ö† High (>5) |
| Polar Surface Area | 295.1 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
COc1cc2c(cc1OC)[C@H](c1cc(OC)c(OC)c(OC)c1)[N@@+](C)(CCCOC(=O)/C=C(\Cl)C(=O)OCCC[N@+]1(C)CCc3cc(OC)c(OC)cc3[C@H]1Cc1cc(OC)c(OC)c(OC)c1)CC2",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 993.6 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 7.84 | ‚ö† High (>5) |
| H-Bond Acceptors | 14.0 | ‚ö† High (>10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 144.9 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 3.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
COc1cc2c(cc1OC)[C@H](c1cc(OC)c(OC)c(OC)c1)[N@@+](C)(CCCOC(=O)/C=C(\Cl)C(=O)OCCC[N@+]1(C)CCc3cc(OC)c(OC)cc3[C@H]1Cc1cc(OC)c(OC)c(OC)c1)CC2
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 993.6 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 7.84 | ‚ö† High (>5) |
| H-Bond Acceptors | 14.0 | ‚ö† High (>10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 144.9 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 3.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: C[C@@H]1CN([C@H]2CC[C@](C#N)(c3ccc(F)cc3)CC2)CC[C@]1(C(=O)O)c1ccccc1.Cl
Candidate Name: LEVOCABASTINE HYDROCHLORIDE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 457.0 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.89 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 64.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: C[C@@H]1CN([C@H]2CC[C@](C#N)(c3ccc(F)cc3)CC2)CC[C@]1(C(=O)O)c1ccccc1.Cl
Candidate Name: LEVOCABASTINE HYDROCHLORIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 457.0 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.89 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 64.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
Cc1ccc(S(=O)(=O)O)cc1.Cn1ncnc1[C@H]1c2n[nH]c(=O)c3cc(F)cc(c23)N[C@@H]1c1ccc(F)cc1
TALAZOPARIB TOSYLATE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 552.6 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 2.63 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 88.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
Cc1ccc(S(=O)(=O)O)cc1.Cn1ncnc1[C@H]1c2n[nH]c(=O)c3cc(F)cc(c23)N[C@@H]1c1ccc(F)cc1
TALAZOPARIB TOSYLATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 552.6 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 2.63 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 88.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
C[N+]1(C)CCC(OC(=O)C(O)(c2ccccc2)C2CCCC2)C1.[Br-]
GLYCOPYRRONIUM BROMIDE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 398.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.46 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 46.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
C[N+]1(C)CCC(OC(=O)C(O)(c2ccccc2)C2CCCC2)C1.[Br-]
GLYCOPYRRONIUM BROMIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 398.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.46 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 46.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CC(C)(Sc1cc(C(C)(C)C)c(O)c(C(C)(C)C)c1)Sc1cc(C(C)(C)C)c(OCC(=O)O)c(C(C)(C)C)c1
Name: CAMOBUCOL",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 574.9 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 9.67 | ‚ö† High (>5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 66.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CC(C)(Sc1cc(C(C)(C)C)c(O)c(C(C)(C)C)c1)Sc1cc(C(C)(C)C)c(OCC(=O)O)c(C(C)(C)C)c1
Name: CAMOBUCOL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 574.9 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 9.67 | ‚ö† High (>5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 66.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
Cl.Clc1ccc([C@]23CNC[C@H]2C3)cc1Cl
Name: AMITIFADINE HYDROCHLORIDE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 264.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.85 | ‚úì Good (<5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 12.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
Cl.Clc1ccc([C@]23CNC[C@H]2C3)cc1Cl
Name: AMITIFADINE HYDROCHLORIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 264.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.85 | ‚úì Good (<5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 12.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
COc1cc([N-]S(=O)(=O)c2ccc(N)cc2)nc(OC)n1.[Na+]
SULFADIMETHOXINE SODIUM",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 332.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.88 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 116.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
COc1cc([N-]S(=O)(=O)c2ccc(N)cc2)nc(OC)n1.[Na+]
SULFADIMETHOXINE SODIUM
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 332.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.88 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 116.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)c(O)c1O
Candidate Name: COMBRETASTATIN A-1",,"## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 332.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.30 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 77.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)c(O)c1O
Candidate Name: COMBRETASTATIN A-1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 332.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.30 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 77.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
C[C@@H]1CC[C@@]2(OC1)O[C@H]1C[C@H]3[C@@H]4CC=C5C[C@@H](O[C@@H]6O[C@H](CO)[C@@H](O)[C@H](O)[C@H]6O)CC[C@]5(C)[C@H]4CC[C@]3(C)[C@H]1[C@@H]2C
DISOGLUSIDE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 576.8 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 3.54 | ‚úì Good (<5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 117.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
C[C@@H]1CC[C@@]2(OC1)O[C@H]1C[C@H]3[C@@H]4CC=C5C[C@@H](O[C@@H]6O[C@H](CO)[C@@H](O)[C@H](O)[C@H]6O)CC[C@]5(C)[C@H]4CC[C@]3(C)[C@H]1[C@@H]2C
DISOGLUSIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 576.8 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 3.54 | ‚úì Good (<5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 117.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CCN(CC)CCNC(=O)c1cc(Cl)c(N)cc1OC.Cl.O
Name: METOCLOPRAMIDE HYDROCHLORIDE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 354.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.00 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 67.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CCN(CC)CCNC(=O)c1cc(Cl)c(N)cc1OC.Cl.O
Name: METOCLOPRAMIDE HYDROCHLORIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 354.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.00 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 67.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CNC[C@H](O)c1ccc(O)c(O)c1.O=C(O)C(O)C(O)C(=O)O
EPINEPHRINE BITARTRATE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 333.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.35 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 72.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CNC[C@H](O)c1ccc(O)c(O)c1.O=C(O)C(O)C(O)C(=O)O
EPINEPHRINE BITARTRATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 333.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.35 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 72.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
Clc1ccc(C(OCCN2CCCCC2)c2ccccc2)cc1
Name: CLOPERASTINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 329.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.93 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 12.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
Clc1ccc(C(OCCN2CCCCC2)c2ccccc2)cc1
Name: CLOPERASTINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 329.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.93 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 12.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
O=C(O)CCCCCCCC(=O)O
AZELAIC ACID",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 188.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.89 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 74.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
O=C(O)CCCCCCCC(=O)O
AZELAIC ACID
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 188.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.89 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 74.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C=C2c3cccc4[nH]cc(c34)C[C@H]21
Drug Name: ERGOTAMINE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 581.7 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 1.99 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 118.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C=C2c3cccc4[nH]cc(c34)C[C@H]21
Drug Name: ERGOTAMINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 581.7 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 1.99 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 118.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
C=CCC1(C(C)C#CCC)C(=O)N=C([O-])N(C)C1=O.[Na+]",,"## Molecular Property Analysis: METHOHEXITAL SODIUM

### Structure
```
C=CCC1(C(C)C#CCC)C(=O)N=C([O-])N(C)C1=O.[Na+]
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 284.3 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 1.31 | 0-5 | ‚úì |
| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 66.5 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.470
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
C=CCC1(C(C)C#CCC)C(=O)N=C([O-])N(C)C1=O.[Na+]
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: METHOHEXITAL SODIUM

### Structure
```
C=CCC1(C(C)C#CCC)C(=O)N=C([O-])N(C)C1=O.[Na+]
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 284.3 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 1.31 | 0-5 | ‚úì |
| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 66.5 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.470
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CCCCCCCCCCCCCCSCC(=O)O",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 288.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.51 | ‚ö† High (>5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 37.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CCCCCCCCCCCCCCSCC(=O)O
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 288.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.51 | ‚ö† High (>5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 37.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: O=C1OCCC1C1(O)CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1
Drug Name: FUROMAZINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 459.0 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.72 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 53.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: O=C1OCCC1C1(O)CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1
Drug Name: FUROMAZINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 459.0 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.72 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 53.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
O=P(O)(O)O.c1ccc(CN(CC2=NCCN2)c2ccccc2)cc1",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 363.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.69 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 27.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
O=P(O)(O)O.c1ccc(CN(CC2=NCCN2)c2ccccc2)cc1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 363.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.69 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 27.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CCCN(CCC)C(=O)C1=Cc2ccc(-c3ccc(C(=O)N4CCCC4)cc3)cc2N=C(N)C1",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 458.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.01 | ‚ö† High (>5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 79.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CCCN(CCC)C(=O)C1=Cc2ccc(-c3ccc(C(=O)N4CCCC4)cc3)cc2N=C(N)C1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 458.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.01 | ‚ö† High (>5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 79.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
NC(=O)[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O
GLUCURONAMIDE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 193.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -3.73 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 133.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
NC(=O)[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O
GLUCURONAMIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 193.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -3.73 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 133.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
NCc1ccccc1Sc1ccccc1CO",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 245.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.79 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 46.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
NCc1ccccc1Sc1ccccc1CO
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 245.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.79 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 46.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
UPADACITINIB",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 380.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.91 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 78.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
UPADACITINIB
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 380.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.91 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 78.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: NC(=O)c1ccc(Oc2ccc(CNCCC3CCOCC3)cc2F)nc1
Candidate Name: ONDELOPRAN",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 373.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.02 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 86.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: NC(=O)c1ccc(Oc2ccc(CNCCC3CCOCC3)cc2F)nc1
Candidate Name: ONDELOPRAN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 373.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.02 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 86.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CC(=O)c1ccc2c(c1)N(CC(C)N(C)C)c1ccccc1S2",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 326.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.44 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 23.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CC(=O)c1ccc2c(c1)N(CC(C)N(C)C)c1ccccc1S2
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 326.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.44 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 23.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: NS(=O)(=O)c1cc2c(cc1Cl)N=C(CSCc1ccccc1)NS2(=O)=O
Drug Name: BENZTHIAZIDE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 431.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.24 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 118.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: NS(=O)(=O)c1cc2c(cc1Cl)N=C(CSCc1ccccc1)NS2(=O)=O
Drug Name: BENZTHIAZIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 431.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.24 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 118.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CCC1(c2ccccc2)C(=O)NC(=O)N(C)C1=O
Candidate Name: MEPHOBARBITAL",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 246.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.04 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 66.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CCC1(c2ccccc2)C(=O)NC(=O)N(C)C1=O
Candidate Name: MEPHOBARBITAL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 246.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.04 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 66.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CNCCSC1=Cc2ccccc2Oc2ccc(F)cc21
Candidate Name: FLURADOLINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 301.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.38 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 21.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CNCCSC1=Cc2ccccc2Oc2ccc(F)cc21
Candidate Name: FLURADOLINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 301.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.38 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 21.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
Cc1c(F)cccc1CCCCOc1ccc(C#Cc2ccc(F)c3c(CCCC(=O)O)c(C)n(CCCC(=O)O)c23)cc1",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 601.7 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 7.61 | ‚ö† High (>5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 88.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
Cc1c(F)cccc1CCCCOc1ccc(C#Cc2ccc(F)c3c(CCCC(=O)O)c(C)n(CCCC(=O)O)c23)cc1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 601.7 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 7.61 | ‚ö† High (>5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 88.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
LEVOMENTHOL",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 156.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.44 | ‚úì Good (<5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 20.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
LEVOMENTHOL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 156.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.44 | ‚úì Good (<5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 20.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CC(=O)Nc1c(Br)cc(Br)cc1CN(C)C12CC3CC(CC(C3)C1)C2
Drug Name: ADAMEXINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 470.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.57 | ‚ö† High (>5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 32.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CC(=O)Nc1c(Br)cc(Br)cc1CN(C)C12CC3CC(CC(C3)C1)C2
Drug Name: ADAMEXINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 470.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.57 | ‚ö† High (>5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 32.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
Br.Nc1nc(=O)c2c([nH]1)N[C@@H]1O[C@@H]3COP(=O)(O)O[C@@H]3C(O)(O)[C@@H]1N2.O.O
Name: FOSDENOPTERIN HYDROBROMIDE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | nan Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics

### Success Factors

This drug was successfully approved, demonstrating:
1. **Favorable safety profile** through clinical development
2. **Clear efficacy** in target patient population
3. **Acceptable risk-benefit ratio** for intended indication

### Key Success Indicators
- Completed Phase III trials with positive outcomes
- Manageable side effect profile
- Clear differentiation from existing treatments",drug_analysis,processed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
Br.Nc1nc(=O)c2c([nH]1)N[C@@H]1O[C@@H]3COP(=O)(O)O[C@@H]3C(O)(O)[C@@H]1N2.O.O
Name: FOSDENOPTERIN HYDROBROMIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | nan Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics

### Success Factors

This drug was successfully approved, demonstrating:
1. **Favorable safety profile** through clinical development
2. **Clear efficacy** in target patient population
3. **Acceptable risk-benefit ratio** for intended indication

### Key Success Indicators
- Completed Phase III trials with positive outcomes
- Manageable side effect profile
- Clear differentiation from existing treatments
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CN(C)CCOCCOC(=O)C1(c2ccccc2)CCCC1
Drug Name: MINEPENTATE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 305.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.62 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 38.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CN(C)CCOCCOC(=O)C1(c2ccccc2)CCCC1
Drug Name: MINEPENTATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 305.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.62 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 38.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: O=C(/C=C/c1cccc(S(=O)(=O)Nc2ccccc2)c1)NO
Candidate Name: BELINOSTAT",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 318.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.01 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 95.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: O=C(/C=C/c1cccc(S(=O)(=O)Nc2ccccc2)c1)NO
Candidate Name: BELINOSTAT
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 318.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.01 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 95.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CC1(C)S[C@@H]2[C@H](N3C(=O)[C@@H](c4ccccc4)NC3(C)C)C(=O)N2[C@H]1C(=O)O
Drug Name: HETACILLIN",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 389.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.41 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 90.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CC1(C)S[C@@H]2[C@H](N3C(=O)[C@@H](c4ccccc4)NC3(C)C)C(=O)N2[C@H]1C(=O)O
Drug Name: HETACILLIN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 389.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.41 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 90.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
COc1cccc(C(=O)CCN[C@@H](C)[C@H](O)c2ccccc2)c1",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 313.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.98 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 58.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
COc1cccc(C(=O)CCN[C@@H](C)[C@H](O)c2ccccc2)c1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 313.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.98 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 58.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
COc1ccc(CNCC(O)COc2ccc3[nH]c(=O)ccc3c2)cc1OC
TOBORINONE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 384.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.07 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 92.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
COc1ccc(CNCC(O)COc2ccc3[nH]c(=O)ccc3c2)cc1OC
TOBORINONE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 384.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.07 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 92.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C(=O)Oc2c(C)c(C)c3c(c2C)CCC(C)(CCCC(C)CCCC(C)CCCC(C)C)O3)C(C)(C)CCC1
Drug Name: TRETINOIN TOCOFERIL",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 713.1 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 14.57 | ‚ö† High (>5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 35.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C(=O)Oc2c(C)c(C)c3c(c2C)CCC(C)(CCCC(C)CCCC(C)CCCC(C)C)O3)C(C)(C)CCC1
Drug Name: TRETINOIN TOCOFERIL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 713.1 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 14.57 | ‚ö† High (>5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 35.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CCCCCCCCCCCCCCCC[N+](C)(C)C1CCCCC1O
CETHEXONIUM",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 368.7 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 6.85 | ‚ö† High (>5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 20.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CCCCCCCCCCCCCCCC[N+](C)(C)C1CCCCC1O
CETHEXONIUM
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 368.7 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 6.85 | ‚ö† High (>5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 20.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
Cc1cc2c(s1)Nc1ccccc1N=C2N1CCN(C)CC1",,"## Molecular Property Analysis: OLANZAPINE

### Structure
```
Cc1cc2c(s1)Nc1ccccc1N=C2N1CCN(C)CC1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 312.4 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 3.44 | 0-5 | ‚úì |
| H-Bond Acceptors | 5.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 30.9 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.810
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- CYP450 substrate likely
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
Cc1cc2c(s1)Nc1ccccc1N=C2N1CCN(C)CC1
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: OLANZAPINE

### Structure
```
Cc1cc2c(s1)Nc1ccccc1N=C2N1CCN(C)CC1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 312.4 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 3.44 | 0-5 | ‚úì |
| H-Bond Acceptors | 5.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 30.9 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.810
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- CYP450 substrate likely
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CC(C)NCC(O)COc1cccc2[nH]ccc12
PINDOLOL",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 248.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.91 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 57.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CC(C)NCC(O)COc1cccc2[nH]ccc12
PINDOLOL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 248.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.91 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 57.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CNCC[C@H](Oc1cccc2ccccc12)c1cccs1.Cl
Drug Name: DULOXETINE HYDROCHLORIDE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 333.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.63 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 21.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CNCC[C@H](Oc1cccc2ccccc12)c1cccs1.Cl
Drug Name: DULOXETINE HYDROCHLORIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 333.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.63 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 21.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CC(=O)[N-]S(=O)(=O)c1ccc(N)cc1.O.[Na+]
Candidate Name: SULFACETAMIDE SODIUM",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 254.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.09 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 89.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CC(=O)[N-]S(=O)(=O)c1ccc(N)cc1.O.[Na+]
Candidate Name: SULFACETAMIDE SODIUM
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 254.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.09 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 89.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CC(C)NC(=O)CN1CCN(Cc2nc3ccccc3n2CCC(=O)c2ccccc2)CC1
Name: NILPRAZOLE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 447.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.95 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 70.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CC(C)NC(=O)CN1CCN(Cc2nc3ccccc3n2CCC(=O)c2ccccc2)CC1
Name: NILPRAZOLE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 447.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.95 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 70.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
C=C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@@]21C
Name: NORVINISTERONE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 300.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.05 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 37.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
C=C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@@]21C
Name: NORVINISTERONE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 300.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.05 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 37.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: Cc1ccc2c(c1)C(N1CCN(C)CC1)=Nc1ccccc1S2
Candidate Name: METIAPINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 323.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.79 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 18.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: Cc1ccc2c(c1)C(N1CCN(C)CC1)=Nc1ccccc1S2
Candidate Name: METIAPINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 323.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.79 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 18.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: NS(=O)(=O)c1ccc(N2C(=O)CC(c3ccccc3)C2=O)c(Cl)c1
Candidate Name: SUCLOFENIDE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 364.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.03 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 97.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: NS(=O)(=O)c1ccc(N2C(=O)CC(c3ccccc3)C2=O)c(Cl)c1
Candidate Name: SUCLOFENIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 364.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.03 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 97.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CC(=O)Oc1cc2c(s1)CCN(C(C(=O)C1CC1)c1ccccc1F)C2
Name: PRASUGREL",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 373.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.89 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 46.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CC(=O)Oc1cc2c(s1)CCN(C(C(=O)C1CC1)c1ccccc1F)C2
Name: PRASUGREL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 373.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.89 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 46.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Which drug candidate has better development potential?
A: CCc1c2c(nc3ccc(OC(=O)N4CCC(N5CCCCC5)CC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)[C@]3(O)CC.Cl.O.O.O (IRINOTECAN HYDROCHLORIDE)
B: Cc1c(C(=O)NN2CCCCC2)c(-c2ccc(Cl)cc2)nn1-c1ccc(Cl)cc1 (Rimonabant (Acomplia))",,"## Comparative Drug Analysis

### Head-to-Head Comparison

| Property | IRINOTECAN HYDROCHLORIDE | Rimonabant (Acomplia) | Better |
|----------|---------|---------|--------|
| Status | approved | withdrawn | üèÜ IRINOTECAN HYDROCHLORIDE |
| Mol. Weight | nan Da | nan Da | üèÜ Rimonabant (Acomplia) |
| LogP | nan | nan | üèÜ Rimonabant (Acomplia) |
| PSA | nan √Ö¬≤ | nan √Ö¬≤ | üèÜ Rimonabant (Acomplia) |

### Assessment

**IRINOTECAN HYDROCHLORIDE** is the clear winner as it has achieved regulatory approval, demonstrating successful clinical development with an acceptable safety/efficacy profile.

**Rimonabant (Acomplia)** has not achieved approval, which may indicate:
- Efficacy challenges in clinical trials
- Safety concerns that limited development
- Strategic decision to discontinue development",comparison,generated,"<|im_start|>user
Which drug candidate has better development potential?
A: CCc1c2c(nc3ccc(OC(=O)N4CCC(N5CCCCC5)CC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)[C@]3(O)CC.Cl.O.O.O (IRINOTECAN HYDROCHLORIDE)
B: Cc1c(C(=O)NN2CCCCC2)c(-c2ccc(Cl)cc2)nn1-c1ccc(Cl)cc1 (Rimonabant (Acomplia))
<|im_end|>
<|im_start|>assistant
## Comparative Drug Analysis

### Head-to-Head Comparison

| Property | IRINOTECAN HYDROCHLORIDE | Rimonabant (Acomplia) | Better |
|----------|---------|---------|--------|
| Status | approved | withdrawn | üèÜ IRINOTECAN HYDROCHLORIDE |
| Mol. Weight | nan Da | nan Da | üèÜ Rimonabant (Acomplia) |
| LogP | nan | nan | üèÜ Rimonabant (Acomplia) |
| PSA | nan √Ö¬≤ | nan √Ö¬≤ | üèÜ Rimonabant (Acomplia) |

### Assessment

**IRINOTECAN HYDROCHLORIDE** is the clear winner as it has achieved regulatory approval, demonstrating successful clinical development with an acceptable safety/efficacy profile.

**Rimonabant (Acomplia)** has not achieved approval, which may indicate:
- Efficacy challenges in clinical trials
- Safety concerns that limited development
- Strategic decision to discontinue development
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
O=C(O)CSC(CCCc1ccccc1)c1ccc(OCc2ccc3ccccc3n2)cc1
Name: AZD-4769",,"## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 457.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 6.70 | ‚ö† High (>5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 59.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
O=C(O)CSC(CCCc1ccccc1)c1ccc(OCc2ccc3ccccc3n2)cc1
Name: AZD-4769
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 457.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 6.70 | ‚ö† High (>5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 59.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CC(C)(C)CC(C)(C)c1ccc(OCCOCCOCCOCCOCCOCCOCCO)cc1",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 514.7 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 3.87 | ‚úì Good (<5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 84.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CC(C)(C)CC(C)(C)c1ccc(OCCOCCOCCOCCOCCOCCOCCO)cc1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 514.7 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 3.87 | ‚úì Good (<5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 84.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CN1CCN(c2cc3c(nn2)Oc2ccccc2N3C)CC1
PIPOFEZINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 297.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.10 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 44.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CN1CCN(c2cc3c(nn2)Oc2ccccc2N3C)CC1
PIPOFEZINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 297.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.10 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 44.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C
Candidate Name: PREDNISOLONE ACETATE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 402.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.13 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 100.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C
Candidate Name: PREDNISOLONE ACETATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 402.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.13 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 100.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O
IDEBENONE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 338.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.46 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 72.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O
IDEBENONE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 338.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.46 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 72.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: O=[Si](O)O[Si](O)(O)O[Si](=O)O
Drug Name: TRISILICATE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 216.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: O=[Si](O)O[Si](O)(O)O[Si](=O)O
Drug Name: TRISILICATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 216.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CSc1ccc2c(c1)C(N1CCN(C)CC1)Cc1ccccc1S2
Drug Name: METITEPINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 356.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.40 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 6.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CSc1ccc2c(c1)C(N1CCN(C)CC1)Cc1ccccc1S2
Drug Name: METITEPINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 356.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.40 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 6.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: Clc1ccc2nsnc2c1NC1=NCCN1
Drug Name: TIZANIDINE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 253.7 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.72 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 62.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: Clc1ccc2nsnc2c1NC1=NCCN1
Drug Name: TIZANIDINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 253.7 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.72 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 62.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C
Name: CHENODIOL",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 392.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.48 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 77.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C
Name: CHENODIOL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 392.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.48 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 77.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(Cl)[C@@H](Cl)C[C@]3(C)[C@]2(C(=O)CCl)O1
Candidate Name: TRICLONIDE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 505.8 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 5.13 | ‚ö† High (>5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 52.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(Cl)[C@@H](Cl)C[C@]3(C)[C@]2(C(=O)CCl)O1
Candidate Name: TRICLONIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 505.8 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 5.13 | ‚ö† High (>5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 52.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CC(=O)SC[C@@H](Cc1ccc2c(c1)OCO2)C(=O)N[C@@H](C)C(=O)OCc1ccccc1
FASIDOTRIL",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 443.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.10 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 90.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CC(=O)SC[C@@H](Cc1ccc2c(c1)OCO2)C(=O)N[C@@H](C)C(=O)OCc1ccccc1
FASIDOTRIL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 443.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.10 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 90.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CC(C)c1noc(N2CCC(COc3ccc(-c4ccc(S(C)(=O)=O)cc4)nc3)CC2)n1
GSK-1292263",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 456.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.95 | ‚úì Good (<5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 98.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CC(C)c1noc(N2CCC(COc3ccc(-c4ccc(S(C)(=O)=O)cc4)nc3)CC2)n1
GSK-1292263
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 456.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.95 | ‚úì Good (<5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 98.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: O=[N+]([O-])OCC(CCl)O[N+](=O)[O-]
Candidate Name: CLONITRATE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 200.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.01 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 104.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: O=[N+]([O-])OCC(CCl)O[N+](=O)[O-]
Candidate Name: CLONITRATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 200.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.01 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 104.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
C[C@@H](N/C(=N\C#N)Nc1ccc(C#N)cc1)C(C)(C)C",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 269.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.83 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 84.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
C[C@@H](N/C(=N\C#N)Nc1ccc(C#N)cc1)C(C)(C)C
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 269.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.83 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 84.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CCOC(=O)C1=CCCC[C@H]1S(=O)(=O)Nc1ccc(F)cc1Cl
Drug Name: RESATORVID",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 361.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.26 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 72.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CCOC(=O)C1=CCCC[C@H]1S(=O)(=O)Nc1ccc(F)cc1Cl
Drug Name: RESATORVID
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 361.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.26 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 72.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
C[C@H]1C[C@@H]2[C@H]([C@@H](O)C[C@@]3(C)[C@H]2CC[C@]3(O)C(=O)CO)[C@@]2(C)C=CC(=O)C=C12
METHYLPREDNISOLONE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 374.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.80 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 94.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
C[C@H]1C[C@@H]2[C@H]([C@@H](O)C[C@@]3(C)[C@H]2CC[C@]3(O)C(=O)CO)[C@@]2(C)C=CC(=O)C=C12
METHYLPREDNISOLONE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 374.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.80 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 94.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: C=CC(=O)N1CC[C@@H](Oc2nc(Nc3ccc(N4CCC(N5CCN(C)CC5)CC4)cc3)c(C(N)=O)nc2CC)C1.CS(=O)(=O)O
Drug Name: NAQUOTINIB MESYLATE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 658.8 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 2.26 | ‚úì Good (<5) |
| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 120.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: C=CC(=O)N1CC[C@@H](Oc2nc(Nc3ccc(N4CCC(N5CCN(C)CC5)CC4)cc3)c(C(N)=O)nc2CC)C1.CS(=O)(=O)O
Drug Name: NAQUOTINIB MESYLATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 658.8 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 2.26 | ‚úì Good (<5) |
| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 120.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CC(=O)C(=O)[O-].[Na+]
Name: PYRUVATE SODIUM",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 110.0 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -0.34 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 54.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CC(=O)C(=O)[O-].[Na+]
Name: PYRUVATE SODIUM
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 110.0 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -0.34 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 54.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
Cc1onc(-c2c(Cl)cccc2Cl)c1C(=O)N[C@@H]1C(=O)N2[C@@H]1SC(C)(C)[C@@H]2C(=O)[O-].O.[Na+]",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 510.3 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 3.20 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 112.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
Cc1onc(-c2c(Cl)cccc2Cl)c1C(=O)N[C@@H]1C(=O)N2[C@@H]1SC(C)(C)[C@@H]2C(=O)[O-].O.[Na+]
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 510.3 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 3.20 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 112.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CC(C)(Cc1ccc(Oc2ncccc2C#N)cc1)NC[C@H](O)COc1ccccc1-c1cccs1
Candidate Name: LUBABEGRON",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 499.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.82 | ‚ö† High (>5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 87.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CC(C)(Cc1ccc(Oc2ncccc2C#N)cc1)NC[C@H](O)COc1ccccc1-c1cccs1
Candidate Name: LUBABEGRON
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 499.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.82 | ‚ö† High (>5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 87.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C(C)C)[C@H]2O)[C@@]2(C)CC(C)=C(O2)[C@H](C)C(=O)[C@]1(C)OC
MITEMCINAL",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 756.0 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 4.53 | ‚úì Good (<5) |
| H-Bond Acceptors | 13.0 | ‚ö† High (>10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 151.7 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C(C)C)[C@H]2O)[C@@]2(C)CC(C)=C(O2)[C@H](C)C(=O)[C@]1(C)OC
MITEMCINAL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 756.0 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 4.53 | ‚úì Good (<5) |
| H-Bond Acceptors | 13.0 | ‚ö† High (>10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 151.7 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CC(=O)NCCCN1CCN(c2cc(Cl)ccc2Cl)CC1
ACAPRAZINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 330.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.64 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 35.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CC(=O)NCCCN1CCN(c2cc(Cl)ccc2Cl)CC1
ACAPRAZINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 330.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.64 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 35.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
NC1=NCC(c2ccccc2)O1
Name: AMINOREX",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 162.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.07 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 47.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
NC1=NCC(c2ccccc2)O1
Name: AMINOREX
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 162.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.07 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 47.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CC(Oc1cccc2ccccc12)/C(N)=N/O",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 230.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.35 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 67.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CC(Oc1cccc2ccccc12)/C(N)=N/O
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 230.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.35 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 67.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CN(CCOc1ccc(NS(C)(=O)=O)cc1)CCc1ccc(NS(C)(=O)=O)cc1
DOFETILIDE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 441.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.98 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 104.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CN(CCOc1ccc(NS(C)(=O)=O)cc1)CCc1ccc(NS(C)(=O)=O)cc1
DOFETILIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 441.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.98 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 104.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CCCCOCC(O)COCCCC",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 204.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.98 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 38.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CCCCOCC(O)COCCCC
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 204.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.98 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 38.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)Cc2ccccc2)C1c1cccc([N+](=O)[O-])c1
Drug Name: NICARDIPINE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 479.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.68 | ‚úì Good (<5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 111.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)Cc2ccccc2)C1c1cccc([N+](=O)[O-])c1
Drug Name: NICARDIPINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 479.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.68 | ‚úì Good (<5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 111.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
COCCCN1CCN(c2ccccc2OC)CC1
DIMETHOLIZINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 264.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.85 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 24.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
COCCCN1CCN(c2ccccc2OC)CC1
DIMETHOLIZINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 264.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.85 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 24.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CC(C)/N=c1\cc2n(-c3ccc(Cl)cc3)c3ccccc3nc-2cc1Nc1ccc(Cl)cc1
Candidate Name: CLOFAZIMINE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 473.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 7.49 | ‚ö† High (>5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 42.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CC(C)/N=c1\cc2n(-c3ccc(Cl)cc3)c3ccccc3nc-2cc1Nc1ccc(Cl)cc1
Candidate Name: CLOFAZIMINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 473.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 7.49 | ‚ö† High (>5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 42.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CC(C)(C)NC[C@H](O)COc1nsnc1N1CCOCC1.O=C(O)/C=C\C(=O)O",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 432.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.50 | ‚úì Good (<5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 79.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CC(C)(C)NC[C@H](O)COc1nsnc1N1CCOCC1.O=C(O)/C=C\C(=O)O
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 432.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.50 | ‚úì Good (<5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 79.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CC(=O)OC1(C(C)CN(C)C)CCCCC1c1ccccc1
Drug Name: NEXERIDINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 303.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.84 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 29.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CC(=O)OC1(C(C)CN(C)C)CCCCC1c1ccccc1
Drug Name: NEXERIDINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 303.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.84 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 29.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CC(C)(C)C(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C
Drug Name: DESOXYCORTICOSTERONE PIVALATE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 414.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.29 | ‚ö† High (>5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 60.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CC(C)(C)C(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C
Drug Name: DESOXYCORTICOSTERONE PIVALATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 414.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.29 | ‚ö† High (>5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 60.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: Nc1ncnc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
Candidate Name: ADENOSINE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 267.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -1.98 | ‚úì Good (<5) |
| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 139.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: Nc1ncnc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
Candidate Name: ADENOSINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 267.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -1.98 | ‚úì Good (<5) |
| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 139.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CC(C)=CCC/C(C)=C/C=C/C(C)=C/C=C/C(C)=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C=C(\C)CCC=C(C)C
Candidate Name: LYCOPENE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 536.9 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 12.94 | ‚ö† High (>5) |
| H-Bond Acceptors | 0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 0.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CC(C)=CCC/C(C)=C/C=C/C(C)=C/C=C/C(C)=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C=C(\C)CCC=C(C)C
Candidate Name: LYCOPENE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 536.9 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 12.94 | ‚ö† High (>5) |
| H-Bond Acceptors | 0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 0.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CN1CC[C@@]2(C)c3cc(OC(=O)N4CCc5ccccc5C4)ccc3N(C)[C@@H]12
Drug Name: QUILOSTIGMINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 377.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.61 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 36.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CN1CC[C@@]2(C)c3cc(OC(=O)N4CCc5ccccc5C4)ccc3N(C)[C@@H]12
Drug Name: QUILOSTIGMINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 377.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.61 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 36.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CN1C(=O)CN2CCc3ccccc3C2c2cc(Cl)ccc21
CLAZOLAM",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 312.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.26 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 23.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CN1C(=O)CN2CCc3ccccc3C2c2cc(Cl)ccc21
CLAZOLAM
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 312.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.26 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 23.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
COc1ncc(F)cc1CNc1ccc(Cc2c[nH]c3ncc(C)cc23)c(F)n1",,"## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 395.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.15 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 75.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
COc1ncc(F)cc1CNc1ccc(Cc2c[nH]c3ncc(C)cc23)c(F)n1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 395.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.15 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 75.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
Nc1ccc(S(=O)(=O)Nc2cnc3c(Cl)cccc3n2)cc1
Name: CHLORSULFAQUINOXALINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 334.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.67 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 98.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
Nc1ccc(S(=O)(=O)Nc2cnc3c(Cl)cccc3n2)cc1
Name: CHLORSULFAQUINOXALINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 334.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.67 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 98.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze the ADMET properties of this compound:
COc1cc2nc(N3CCN(C(=O)C4CCCO4)CC3)nc(N)c2cc1OC",,"## Molecular Property Analysis: TERAZOSIN

### Structure
```
COc1cc2nc(N3CCN(C(=O)C4CCCO4)CC3)nc(N)c2cc1OC
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 387.4 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 1.06 | 0-5 | ‚úì |
| H-Bond Acceptors | 8.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 103.0 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 4.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.830
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Limited CNS penetration expected

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- CYP450 substrate likely
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze the ADMET properties of this compound:
COc1cc2nc(N3CCN(C(=O)C4CCCO4)CC3)nc(N)c2cc1OC
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: TERAZOSIN

### Structure
```
COc1cc2nc(N3CCN(C(=O)C4CCCO4)CC3)nc(N)c2cc1OC
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 387.4 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 1.06 | 0-5 | ‚úì |
| H-Bond Acceptors | 8.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 103.0 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 4.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.830
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Limited CNS penetration expected

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- CYP450 substrate likely
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CCNCC(O)c1cccc(O)c1
Candidate Name: ETILEFRINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 181.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.04 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 52.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CCNCC(O)c1cccc(O)c1
Candidate Name: ETILEFRINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 181.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.04 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 52.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: NC(=O)c1ccc([N+](=O)[O-])cc1Cl
Candidate Name: AKLOMIDE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 200.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.35 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 86.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: NC(=O)c1ccc([N+](=O)[O-])cc1Cl
Candidate Name: AKLOMIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 200.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.35 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 86.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CNC(=O)Oc1ccccc1C(=O)Nc1ccccc1
Drug Name: ANILAMATE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 270.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.66 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 67.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CNC(=O)Oc1ccccc1C(=O)Nc1ccccc1
Drug Name: ANILAMATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 270.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.66 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 67.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: O=C(CCOCCOCCOCCC(=O)Nc1c(I)cc(I)c(C(=O)O)c1I)Nc1c(I)cc(I)c(C(=O)O)c1I
Drug Name: IOTRANIC ACID",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 1243.9 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: O=C(CCOCCOCCOCCC(=O)Nc1c(I)cc(I)c(C(=O)O)c1I)Nc1c(I)cc(I)c(C(=O)O)c1I
Drug Name: IOTRANIC ACID
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 1243.9 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
Cc1ccc(C(C)C)cc1O",,"## Molecular Property Analysis: CARVACROL

### Structure
```
Cc1ccc(C(C)C)cc1O
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 150.2 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 2.82 | 0-5 | ‚úì |
| H-Bond Acceptors | 1.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 20.2 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 1.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.650
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
Cc1ccc(C(C)C)cc1O
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: CARVACROL

### Structure
```
Cc1ccc(C(C)C)cc1O
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 150.2 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 2.82 | 0-5 | ‚úì |
| H-Bond Acceptors | 1.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 20.2 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 1.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.650
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CCOC(Nc1ccc(C(=O)O)cc1)C(=O)c1ccc(-c2ccccc2)cc1",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 375.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.71 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 75.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CCOC(Nc1ccc(C(=O)O)cc1)C(=O)c1ccc(-c2ccccc2)cc1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 375.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.71 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 75.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
O=C1c2ccccc2C(=O)c2c1cn1c2Cc2ccccc2C1
MITOQUIDONE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 299.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.22 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 39.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
O=C1c2ccccc2C(=O)c2c1cn1c2Cc2ccccc2C1
MITOQUIDONE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 299.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.22 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 39.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
COc1ccc(CN2CCN(C(c3ccc(F)cc3)c3ccc(F)cc3)CC2)c(OC)c1OC
LOMERIZINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 468.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.90 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 34.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
COc1ccc(CN2CCN(C(c3ccc(F)cc3)c3ccc(F)cc3)CC2)c(OC)c1OC
LOMERIZINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 468.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.90 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 34.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CC(=O)Oc1cc2c(s1)CCN(C(C(=O)C1CC1)c1ccccc1F)C2.Cl
Candidate Name: PRASUGREL HYDROCHLORIDE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 409.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.89 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 46.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CC(=O)Oc1cc2c(s1)CCN(C(C(=O)C1CC1)c1ccccc1F)C2.Cl
Candidate Name: PRASUGREL HYDROCHLORIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 409.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.89 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 46.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"This drug failed in Phase II/III. Explain why:
Drug: Atabecestat
SMILES: CC(C)(C)NC(=O)C1=CC=C(C=C1)C2=NC3=CC=CC=C3N2",,"## Drug Failure Analysis: Atabecestat

### Summary
**Phase Failed:** Phase II/III
**Year:** 2018.0
**Therapeutic Area:** CNS/Neurology
**Failure Category:** Safety/Efficacy

### Detailed Failure Reason

Liver enzyme elevations and worsening cognition

### Mechanism of Toxicity

nan

### Efficacy Failure Analysis

**Common Reasons for Efficacy Failure:**
1. **Target Selection Issues:** Pre-clinical models may not accurately reflect human disease biology
2. **Patient Population Heterogeneity:** Subgroups may respond differently
3. **Dose Selection:** May not achieve adequate target engagement
4. **Biomarker Disconnect:** Surrogate endpoints may not correlate with clinical outcomes

**Prevention Strategies:**
- Extensive target validation using human genetics data
- Biomarker-driven patient stratification
- PK/PD modeling to optimize dosing
- Adaptive trial designs

### Key Takeaways for Drug Development

1. **Early Safety Screening:** Implement comprehensive in vitro and in vivo safety panels before clinical development
2. **Mechanism Understanding:** Deep mechanistic understanding helps predict and mitigate risks
3. **Patient Monitoring:** Identify high-risk patient populations and implement appropriate monitoring
4. **Structural Optimization:** Use SAR to move away from structural liabilities while maintaining efficacy",failure_analysis,clinical_trial_failures,"<|im_start|>user
This drug failed in Phase II/III. Explain why:
Drug: Atabecestat
SMILES: CC(C)(C)NC(=O)C1=CC=C(C=C1)C2=NC3=CC=CC=C3N2
<|im_end|>
<|im_start|>assistant
## Drug Failure Analysis: Atabecestat

### Summary
**Phase Failed:** Phase II/III
**Year:** 2018.0
**Therapeutic Area:** CNS/Neurology
**Failure Category:** Safety/Efficacy

### Detailed Failure Reason

Liver enzyme elevations and worsening cognition

### Mechanism of Toxicity

nan

### Efficacy Failure Analysis

**Common Reasons for Efficacy Failure:**
1. **Target Selection Issues:** Pre-clinical models may not accurately reflect human disease biology
2. **Patient Population Heterogeneity:** Subgroups may respond differently
3. **Dose Selection:** May not achieve adequate target engagement
4. **Biomarker Disconnect:** Surrogate endpoints may not correlate with clinical outcomes

**Prevention Strategies:**
- Extensive target validation using human genetics data
- Biomarker-driven patient stratification
- PK/PD modeling to optimize dosing
- Adaptive trial designs

### Key Takeaways for Drug Development

1. **Early Safety Screening:** Implement comprehensive in vitro and in vivo safety panels before clinical development
2. **Mechanism Understanding:** Deep mechanistic understanding helps predict and mitigate risks
3. **Patient Monitoring:** Identify high-risk patient populations and implement appropriate monitoring
4. **Structural Optimization:** Use SAR to move away from structural liabilities while maintaining efficacy
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O
Candidate Name: AMODIAQUINE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 355.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.18 | ‚ö† High (>5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 48.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O
Candidate Name: AMODIAQUINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 355.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.18 | ‚ö† High (>5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 48.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Describe the molecular properties and drug-likeness of:
COc1ccc2c(c1)CCC(c1ccccc1)=C2c1ccc(OCCN2CCCC2)cc1",,"## Molecular Property Analysis: NAFOXIDINE

### Structure
```
COc1ccc2c(c1)CCC(c1ccccc1)=C2c1ccc(OCCN2CCCC2)cc1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 425.6 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 6.08 | 0-5 | ‚ö† |
| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 0 | ‚â§5 | ‚úì |
| PSA | 21.7 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 7.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.460
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- May have oral absorption challenges
- Limited CNS penetration expected

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- CYP450 substrate likely
- Potential CYP inhibition risk

**Excretion:**
- Likely hepatic clearance
- Long half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚ö† FAIL
**Veber Rules (Oral Bioavailability):** ‚úì PASS",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Describe the molecular properties and drug-likeness of:
COc1ccc2c(c1)CCC(c1ccccc1)=C2c1ccc(OCCN2CCCC2)cc1
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: NAFOXIDINE

### Structure
```
COc1ccc2c(c1)CCC(c1ccccc1)=C2c1ccc(OCCN2CCCC2)cc1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 425.6 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 6.08 | 0-5 | ‚ö† |
| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 0 | ‚â§5 | ‚úì |
| PSA | 21.7 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 7.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.460
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- May have oral absorption challenges
- Limited CNS penetration expected

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- CYP450 substrate likely
- Potential CYP inhibition risk

**Excretion:**
- Likely hepatic clearance
- Long half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚ö† FAIL
**Veber Rules (Oral Bioavailability):** ‚úì PASS
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CCc1nc2c(N)nc3ccccc3c2n1CCCCNS(C)(=O)=O
Candidate Name: CPG-52852",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 361.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.06 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 102.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CCc1nc2c(N)nc3ccccc3c2n1CCCCNS(C)(=O)=O
Candidate Name: CPG-52852
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 361.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.06 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 102.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CCCCCCCC/C=C\CCCCCCCC(=O)NCc1ccc(O)c(OC)c1
Name: OLVANIL",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 417.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 7.05 | ‚ö† High (>5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 58.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CCCCCCCC/C=C\CCCCCCCC(=O)NCc1ccc(O)c(OC)c1
Name: OLVANIL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 417.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 7.05 | ‚ö† High (>5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 58.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
Cc1nc(NS(=O)(=O)c2ccc(N)cc2)oc1C",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 267.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.67 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 98.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
Cc1nc(NS(=O)(=O)c2ccc(N)cc2)oc1C
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 267.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.67 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 98.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
C/C(=C(\CCOC(=O)c1ccccc1)SS/C(CCOC(=O)c1ccccc1)=C(/C)N(C=O)Cc1cnc(C)nc1N)N(C=O)Cc1cnc(C)nc1N",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 770.9 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 6.00 | ‚ö† High (>5) |
| H-Bond Acceptors | 14.0 | ‚ö† High (>10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 196.8 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 3.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
C/C(=C(\CCOC(=O)c1ccccc1)SS/C(CCOC(=O)c1ccccc1)=C(/C)N(C=O)Cc1cnc(C)nc1N)N(C=O)Cc1cnc(C)nc1N
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 770.9 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 6.00 | ‚ö† High (>5) |
| H-Bond Acceptors | 14.0 | ‚ö† High (>10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 196.8 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 3.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CCCN1CC(c2ccc(S(C)(=O)=O)cc2)=C(c2ccc(C)cc2)C1=O
Drug Name: IMRECOXIB",,"## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 369.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.56 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 54.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CCCN1CC(c2ccc(S(C)(=O)=O)cc2)=C(c2ccc(C)cc2)C1=O
Drug Name: IMRECOXIB
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 369.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.56 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 54.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
Cc1nccn1CCC(C(N)=O)(c1ccccc1)c1ccccc1",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 319.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.05 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 60.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
Cc1nccn1CCC(C(N)=O)(c1ccccc1)c1ccccc1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 319.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.05 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 60.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CC1CCc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23
Drug Name: VEBUFLOXACIN",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 359.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.10 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 65.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CC1CCc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23
Drug Name: VEBUFLOXACIN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 359.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.10 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 65.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CC(=O)[C@]1(O)Cc2c(O)c3c(c(O)c2[C@@H](O[C@H]2C[C@H](N)[C@H](O)[C@H](C)O2)C1)C(=O)c1ccccc1C3=O
IDARUBICIN",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 497.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.02 | ‚úì Good (<5) |
| H-Bond Acceptors | 10.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 176.6 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CC(=O)[C@]1(O)Cc2c(O)c3c(c(O)c2[C@@H](O[C@H]2C[C@H](N)[C@H](O)[C@H](C)O2)C1)C(=O)c1ccccc1C3=O
IDARUBICIN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 497.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.02 | ‚úì Good (<5) |
| H-Bond Acceptors | 10.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 176.6 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CN[C@@H](C)[C@H](O)c1ccccc1.CN[C@@H](C)[C@H](O)c1ccccc1.O=S(=O)(O)O
EPHEDRINE SULFATE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 428.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.33 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 32.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CN[C@@H](C)[C@H](O)c1ccccc1.CN[C@@H](C)[C@H](O)c1ccccc1.O=S(=O)(O)O
EPHEDRINE SULFATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 428.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.33 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 32.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CNC[C@H](O)CC12CCC(c3ccccc31)c1ccccc12
Drug Name: LEVOPROTILINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 293.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.18 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 32.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CNC[C@H](O)CC12CCC(c3ccccc31)c1ccccc12
Drug Name: LEVOPROTILINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 293.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.18 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 32.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CNC(=O)c1ccc(Oc2ccc3c(c2)CCN(C2CCC2)CC3)nc1
GSK189254",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 351.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.19 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 54.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CNC(=O)c1ccc(Oc2ccc3c(c2)CCN(C2CCC2)CC3)nc1
GSK189254
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 351.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.19 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 54.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: O=C1OC(c2ccc(O)cc2)(c2ccc(O)cc2)c2ccccc21
Candidate Name: PHENOLPHTHALEIN",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 318.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.56 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 66.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: O=C1OC(c2ccc(O)cc2)(c2ccc(O)cc2)c2ccccc21
Candidate Name: PHENOLPHTHALEIN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 318.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.56 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 66.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)C3=CC[C@@]21C
Name: ANECORTAVE ACETATE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 386.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.30 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 80.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)C3=CC[C@@]21C
Name: ANECORTAVE ACETATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 386.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.30 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 80.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
NCCCC[C@H](N[C@@H](CCc1ccccc1)C(=O)O)C(=O)N1CCC[C@H]1C(=O)O.O.O",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 441.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.24 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 133.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
NCCCC[C@H](N[C@@H](CCc1ccccc1)C(=O)O)C(=O)N1CCC[C@H]1C(=O)O.O.O
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 441.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.24 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 133.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CN1CCN2c3ncccc3Cc3ccccc3C2C1
MIRTAZAPINE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 265.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.48 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 19.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CN1CCN2c3ncccc3Cc3ccccc3C2C1
MIRTAZAPINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 265.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.48 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 19.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
Cn1cc(C[C@@H](N)C(=O)O)c2ccccc21",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 218.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.13 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 68.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
Cn1cc(C[C@@H](N)C(=O)O)c2ccccc21
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 218.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.13 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 68.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CC(C)(C)CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C
Name: PREDNISOLONE TEBUTATE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 458.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.54 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 100.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CC(C)(C)CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C
Name: PREDNISOLONE TEBUTATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 458.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.54 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 100.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
Drug Name: SU-014813",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 442.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.69 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 106.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
Drug Name: SU-014813
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 442.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.69 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 106.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
Nc1c(NC/C=C\COc2cc(CN3CCCCC3)ccn2)c(=O)c1=O
PIBUTIDINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 356.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.29 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 97.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
Nc1c(NC/C=C\COc2cc(CN3CCCCC3)ccn2)c(=O)c1=O
PIBUTIDINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 356.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.29 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 97.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: Cc1cc(OCCC[N+](C)(C)Cc2ccc(Br)cc2)c(C(C)C)cc1Cl
Candidate Name: HALOPENIUM",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 439.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 6.58 | ‚ö† High (>5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 9.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: Cc1cc(OCCC[N+](C)(C)Cc2ccc(Br)cc2)c(C(C)C)cc1Cl
Candidate Name: HALOPENIUM
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 439.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 6.58 | ‚ö† High (>5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 9.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: COCCCN1CCC(NC(=O)c2cc(Cl)c(N)c3c2OCC3)CC1.O=C(O)CCC(=O)O
Drug Name: PRUCALOPRIDE SUCCINATE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 486.0 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.09 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 76.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: COCCCN1CCC(NC(=O)c2cc(Cl)c(N)c3c2OCC3)CC1.O=C(O)CCC(=O)O
Drug Name: PRUCALOPRIDE SUCCINATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 486.0 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.09 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 76.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: COC(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)Nc1ccc([C@@H]2CC[C@@H](c3ccc(NC(=O)[C@@H]4CCCN4C(=O)[C@@H](NC(=O)OC)C(C)C)cc3)N2c2ccc(C(C)(C)C)cc2)cc1)C(C)C
Candidate Name: OMBITASVIR",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 894.1 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 7.69 | ‚ö† High (>5) |
| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 178.7 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: COC(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)Nc1ccc([C@@H]2CC[C@@H](c3ccc(NC(=O)[C@@H]4CCCN4C(=O)[C@@H](NC(=O)OC)C(C)C)cc3)N2c2ccc(C(C)(C)C)cc2)cc1)C(C)C
Candidate Name: OMBITASVIR
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 894.1 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 7.69 | ‚ö† High (>5) |
| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 178.7 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CN[C@@H]1CCN(c2cc(NCC3CC3)nc(N)n2)C1
Drug Name: ADRIFORANT",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 262.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.68 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 79.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CN[C@@H]1CCN(c2cc(NCC3CC3)nc(N)n2)C1
Drug Name: ADRIFORANT
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 262.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.68 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 79.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
CCOC(=O)c1ccc(N)cc1",,"## Molecular Property Analysis: BENZOCAINE

### Structure
```
CCOC(=O)c1ccc(N)cc1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 165.2 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 1.45 | 0-5 | ‚úì |
| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 52.3 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 2.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.530
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
CCOC(=O)c1ccc(N)cc1
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: BENZOCAINE

### Structure
```
CCOC(=O)c1ccc(N)cc1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 165.2 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 1.45 | 0-5 | ‚úì |
| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 52.3 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 2.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.530
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: OC(COc1cccc2[nH]ccc12)CN1CCC(COc2ccccc2)CC1
Candidate Name: MINDODILOL",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 380.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.70 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 57.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: OC(COc1cccc2[nH]ccc12)CN1CCC(COc2ccccc2)CC1
Candidate Name: MINDODILOL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 380.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.70 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 57.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CCC(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1
EDATREXATE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 467.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.37 | ‚úì Good (<5) |
| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 207.3 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CCC(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1
EDATREXATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 467.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.37 | ‚úì Good (<5) |
| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 207.3 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
COc1cc(O)c2c(c1)C(=O)c1cc3c(c(O)c1C2=O)[C@@H](O[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1OC)[C@H](OC)[C@](C)(O)C3=O",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 574.5 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 0.38 | ‚úì Good (<5) |
| H-Bond Acceptors | 13.0 | ‚ö† High (>10) |
| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 198.5 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
COc1cc(O)c2c(c1)C(=O)c1cc3c(c(O)c1C2=O)[C@@H](O[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1OC)[C@H](OC)[C@](C)(O)C3=O
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 574.5 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 0.38 | ‚úì Good (<5) |
| H-Bond Acceptors | 13.0 | ‚ö† High (>10) |
| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 198.5 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
CCOC(=O)c1ncn2c1CN(C)C(=O)c1cc(F)ccc1-2",,"## Molecular Property Analysis: FLUMAZENIL

### Structure
```
CCOC(=O)c1ncn2c1CN(C)C(=O)c1cc(F)ccc1-2
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 303.3 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 1.77 | 0-5 | ‚úì |
| H-Bond Acceptors | 5.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 0 | ‚â§5 | ‚úì |
| PSA | 64.4 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 2.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.790
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- CYP450 substrate likely
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
CCOC(=O)c1ncn2c1CN(C)C(=O)c1cc(F)ccc1-2
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: FLUMAZENIL

### Structure
```
CCOC(=O)c1ncn2c1CN(C)C(=O)c1cc(F)ccc1-2
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 303.3 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 1.77 | 0-5 | ‚úì |
| H-Bond Acceptors | 5.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 0 | ‚â§5 | ‚úì |
| PSA | 64.4 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 2.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.790
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- CYP450 substrate likely
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CC(C)(C)NCC(O)COc1cccc2c1C(=O)OC2
Drug Name: AFUROLOL",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 279.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.48 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 67.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CC(C)(C)NCC(O)COc1cccc2c1C(=O)OC2
Drug Name: AFUROLOL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 279.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.48 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 67.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CC(C)(C)[C@H](NC(=O)C(F)(F)F)C(=O)N1C[C@H]2[C@@H]([C@H]1C(=O)N[C@H](C#N)C[C@@H]1CCNC1=O)C2(C)C
NIRMATRELVIR",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | nan Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics

### Success Factors

This drug was successfully approved, demonstrating:
1. **Favorable safety profile** through clinical development
2. **Clear efficacy** in target patient population
3. **Acceptable risk-benefit ratio** for intended indication

### Key Success Indicators
- Completed Phase III trials with positive outcomes
- Manageable side effect profile
- Clear differentiation from existing treatments",drug_analysis,processed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CC(C)(C)[C@H](NC(=O)C(F)(F)F)C(=O)N1C[C@H]2[C@@H]([C@H]1C(=O)N[C@H](C#N)C[C@@H]1CCNC1=O)C2(C)C
NIRMATRELVIR
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | nan Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics

### Success Factors

This drug was successfully approved, demonstrating:
1. **Favorable safety profile** through clinical development
2. **Clear efficacy** in target patient population
3. **Acceptable risk-benefit ratio** for intended indication

### Key Success Indicators
- Completed Phase III trials with positive outcomes
- Manageable side effect profile
- Clear differentiation from existing treatments
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
O=C(CBr)N1CC([N+](=O)[O-])([N+](=O)[O-])C1",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 268.0 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -0.53 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 106.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
O=C(CBr)N1CC([N+](=O)[O-])([N+](=O)[O-])C1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 268.0 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -0.53 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 106.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CC(C)OC(=O)CCC/C=C\C[C@@H]1[C@@H](CC[C@@H](O)CCc2ccccc2)[C@H](O)C[C@@H]1O",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 432.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.19 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 87.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CC(C)OC(=O)CCC/C=C\C[C@@H]1[C@@H](CC[C@@H](O)CCc2ccccc2)[C@H](O)C[C@@H]1O
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 432.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.19 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 87.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(CSc3cnns3)CS[C@H]12)c1csc(N)n1
Drug Name: CEFUZONAM",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 513.6 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 0.46 | ‚úì Good (<5) |
| H-Bond Acceptors | 13.0 | ‚ö† High (>10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 173.0 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(CSc3cnns3)CS[C@H]12)c1csc(N)n1
Drug Name: CEFUZONAM
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 513.6 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 0.46 | ‚úì Good (<5) |
| H-Bond Acceptors | 13.0 | ‚ö† High (>10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 173.0 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
CCCCNC(=O)NS(=O)(=O)c1ccc(C)cc1",,"## Molecular Property Analysis: TOLBUTAMIDE

### Structure
```
CCCCNC(=O)NS(=O)(=O)c1ccc(C)cc1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 270.4 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 1.78 | 0-5 | ‚úì |
| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |
| PSA | 75.3 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 5.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.800
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
CCCCNC(=O)NS(=O)(=O)c1ccc(C)cc1
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: TOLBUTAMIDE

### Structure
```
CCCCNC(=O)NS(=O)(=O)c1ccc(C)cc1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 270.4 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 1.78 | 0-5 | ‚úì |
| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |
| PSA | 75.3 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 5.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.800
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity
<|im_end|>"
"Describe the molecular properties and drug-likeness of:
COc1cc2c(cc1OC)-c1c/c(=N\c3c(C)cc(C)cc3C)n(C)c(=O)n1CC2",,"## Molecular Property Analysis: TREQUINSIN

### Structure
```
COc1cc2c(cc1OC)-c1c/c(=N\c3c(C)cc(C)cc3C)n(C)c(=O)n1CC2
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 405.5 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 3.58 | 0-5 | ‚úì |
| H-Bond Acceptors | 6.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 0 | ‚â§5 | ‚úì |
| PSA | 57.8 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.670
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- CYP450 substrate likely
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Long half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Describe the molecular properties and drug-likeness of:
COc1cc2c(cc1OC)-c1c/c(=N\c3c(C)cc(C)cc3C)n(C)c(=O)n1CC2
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: TREQUINSIN

### Structure
```
COc1cc2c(cc1OC)-c1c/c(=N\c3c(C)cc(C)cc3C)n(C)c(=O)n1CC2
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 405.5 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 3.58 | 0-5 | ‚úì |
| H-Bond Acceptors | 6.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 0 | ‚â§5 | ‚úì |
| PSA | 57.8 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.670
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- CYP450 substrate likely
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Long half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: COC(=O)[C@@H]1[C@H]2C[C@H]3c4[nH]c5ccccc5c4CCN3C[C@@H]2CC[C@@H]1O.Cl
Candidate Name: YOHIMBINE HYDROCHLORIDE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 390.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.65 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 65.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: COC(=O)[C@@H]1[C@H]2C[C@H]3c4[nH]c5ccccc5c4CCN3C[C@@H]2CC[C@@H]1O.Cl
Candidate Name: YOHIMBINE HYDROCHLORIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 390.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.65 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 65.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CN[C@@H](C)[C@H](O)c1ccccc1
Drug Name: EPHEDRINE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 165.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.33 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 32.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CN[C@@H](C)[C@H](O)c1ccccc1
Drug Name: EPHEDRINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 165.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.33 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 32.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Describe the molecular properties and drug-likeness of:
CCn1cc(C(=O)O)c(=O)c2cc3c(cc21)OCO3",,"## Molecular Property Analysis: OXOLINIC ACID

### Structure
```
CCn1cc(C(=O)O)c(=O)c2cc3c(cc21)OCO3
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 261.2 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 1.45 | 0-5 | ‚úì |
| H-Bond Acceptors | 5.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 77.8 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 2.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.880
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Describe the molecular properties and drug-likeness of:
CCn1cc(C(=O)O)c(=O)c2cc3c(cc21)OCO3
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: OXOLINIC ACID

### Structure
```
CCn1cc(C(=O)O)c(=O)c2cc3c(cc21)OCO3
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 261.2 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 1.45 | 0-5 | ‚úì |
| H-Bond Acceptors | 5.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 77.8 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 2.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.880
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: O=C1Nc2ccccc2C(c2ccccc2)N1C1CCN(Cc2cccc(OC(F)(F)F)c2)CC1
Candidate Name: AFACIFENACIN",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 481.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 6.19 | ‚ö† High (>5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 44.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: O=C1Nc2ccccc2C(c2ccccc2)N1C1CCN(Cc2cccc(OC(F)(F)F)c2)CC1
Candidate Name: AFACIFENACIN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 481.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 6.19 | ‚ö† High (>5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 44.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
CCCCC1(CCCC)CS(=O)(=O)c2ccc(N(C)C)cc2[C@@H](c2ccc(OCc3ccc(C[N+]45CCN(CC4)CC5)cc3)cc2)[C@H]1O.[Cl-]",,"## Molecular Property Analysis: MARALIXIBAT CHLORIDE

### Structure
```
CCCCC1(CCCC)CS(=O)(=O)c2ccc(N(C)C)cc2[C@@H](c2ccc(OCc3ccc(C[N+]45CCN(CC4)CC5)cc3)cc2)[C@H]1O.[Cl-]
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 710.4 Da | 150-500 Da | ‚ö† |
| LogP (cLogP) | 6.62 | 0-5 | ‚ö† |
| H-Bond Acceptors | 6.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 70.1 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 13.0 | ‚â§10 | ‚ö† |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.210
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- May have oral absorption challenges
- Limited CNS penetration expected

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- CYP450 substrate likely
- Potential CYP inhibition risk

**Excretion:**
- Likely hepatic clearance
- Long half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚ö† FAIL
**Veber Rules (Oral Bioavailability):** ‚ö† FAIL",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
CCCCC1(CCCC)CS(=O)(=O)c2ccc(N(C)C)cc2[C@@H](c2ccc(OCc3ccc(C[N+]45CCN(CC4)CC5)cc3)cc2)[C@H]1O.[Cl-]
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: MARALIXIBAT CHLORIDE

### Structure
```
CCCCC1(CCCC)CS(=O)(=O)c2ccc(N(C)C)cc2[C@@H](c2ccc(OCc3ccc(C[N+]45CCN(CC4)CC5)cc3)cc2)[C@H]1O.[Cl-]
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 710.4 Da | 150-500 Da | ‚ö† |
| LogP (cLogP) | 6.62 | 0-5 | ‚ö† |
| H-Bond Acceptors | 6.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 70.1 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 13.0 | ‚â§10 | ‚ö† |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.210
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- May have oral absorption challenges
- Limited CNS penetration expected

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- CYP450 substrate likely
- Potential CYP inhibition risk

**Excretion:**
- Likely hepatic clearance
- Long half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚ö† FAIL
**Veber Rules (Oral Bioavailability):** ‚ö† FAIL
<|im_end|>"
"Analyze the ADMET properties of this compound:
CCCC(CCC)C(=O)O",,"## Molecular Property Analysis: VALPROIC ACID

### Structure
```
CCCC(CCC)C(=O)O
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 144.2 Da | 150-500 Da | ‚ö† |
| LogP (cLogP) | 2.29 | 0-5 | ‚úì |
| H-Bond Acceptors | 1.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 37.3 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 5.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.640
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze the ADMET properties of this compound:
CCCC(CCC)C(=O)O
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: VALPROIC ACID

### Structure
```
CCCC(CCC)C(=O)O
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 144.2 Da | 150-500 Da | ‚ö† |
| LogP (cLogP) | 2.29 | 0-5 | ‚úì |
| H-Bond Acceptors | 1.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 37.3 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 5.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.640
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
COc1cc2oc(=O)c(C)c(C)c2cc1OCCCN1CCN(c2ccccc2OC)CC1
ENSACULIN",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 452.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.02 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 64.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
COc1cc2oc(=O)c(C)c(C)c2cc1OCCCN1CCN(c2ccccc2OC)CC1
ENSACULIN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 452.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.02 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 64.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
Cl.NCCc1ccc(O)c(O)c1
DOPAMINE HYDROCHLORIDE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 189.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.60 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 66.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
Cl.NCCc1ccc(O)c(O)c1
DOPAMINE HYDROCHLORIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 189.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.60 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 66.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CC(C)Oc1cc(-n2cnc3ccc(N[C@@H](C)c4ncc(F)cn4)nc32)n[nH]1
AZD-7451",,"## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 382.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.03 | ‚úì Good (<5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 106.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CC(C)Oc1cc(-n2cnc3ccc(N[C@@H](C)c4ncc(F)cn4)nc32)n[nH]1
AZD-7451
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 382.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.03 | ‚úì Good (<5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 106.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CC(SC(=S)Nc1ccc(NC(=S)SC(C)c2nc3ccccc3n2C)cc1)c1nc2ccccc2n1C
Drug Name: BISBENDAZOLE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 576.8 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 7.84 | ‚ö† High (>5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 59.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CC(SC(=S)Nc1ccc(NC(=S)SC(C)c2nc3ccccc3n2C)cc1)c1nc2ccccc2n1C
Drug Name: BISBENDAZOLE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 576.8 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 7.84 | ‚ö† High (>5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 59.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: C=CCN1CCCC1CNC(=O)c1cc2nn[nH]c2cc1OC
Drug Name: ALIZAPRIDE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 315.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.35 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 83.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: C=CCN1CCCC1CNC(=O)c1cc2nn[nH]c2cc1OC
Drug Name: ALIZAPRIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 315.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.35 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 83.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CCN(CC)C(=O)C1CN2CCc3cc(OC)c(OC)cc3C2CC1OC(C)=O
Name: BENZQUINAMIDE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 404.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.42 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 68.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CCN(CC)C(=O)C1CN2CCc3cc(OC)c(OC)cc3C2CC1OC(C)=O
Name: BENZQUINAMIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 404.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.42 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 68.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: C[N+]1(C)[C@@H]2CC[C@H]1C[C@@H](OC(=O)C(CO)c1ccccc1)C2.O=[N+]([O-])[O-]
Candidate Name: METHYLATROPINE NITRATE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 366.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.08 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 46.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: C[N+]1(C)[C@@H]2CC[C@H]1C[C@@H](OC(=O)C(CO)c1ccccc1)C2.O=[N+]([O-])[O-]
Candidate Name: METHYLATROPINE NITRATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 366.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.08 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 46.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
COc1cc(-c2ccc(=O)[nH]n2)ccc1OC(F)F",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 268.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.05 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 64.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
COc1cc(-c2ccc(=O)[nH]n2)ccc1OC(F)F
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 268.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.05 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 64.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
c1ccc(CCN2CCC(CCc3c[nH]c4ccccc34)CC2)cc1",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 332.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.06 | ‚ö† High (>5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 19.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
c1ccc(CCN2CCC(CCc3c[nH]c4ccccc34)CC2)cc1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 332.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.06 | ‚ö† High (>5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 19.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
[O-][N+]1=C(c2ccccc2)c2cc(Cl)ccc2N=C(NCC2CC2)C1
Name: CYPRAZEPAM",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 339.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.73 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 50.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
[O-][N+]1=C(c2ccccc2)c2cc(Cl)ccc2N=C(NCC2CC2)C1
Name: CYPRAZEPAM
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 339.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.73 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 50.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CCC[C@@H]1O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)O[C@H](C)OC(=O)OCC)O1
Drug Name: ITROCINONIDE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 568.6 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 4.26 | ‚úì Good (<5) |
| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 117.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CCC[C@@H]1O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)O[C@H](C)OC(=O)OCC)O1
Drug Name: ITROCINONIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 568.6 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 4.26 | ‚úì Good (<5) |
| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 117.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CN(C)C[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1
Drug Name: RUBOXISTAURIN",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 468.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.51 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 68.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CN(C)C[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1
Drug Name: RUBOXISTAURIN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 468.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.51 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 68.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
COc1ccccc1N1CCN(CC(O)COc2ccc(-c3cc(C#N)c(=O)[nH]c3C)cc2)CC1
SATERINONE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 474.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.79 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 101.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
COc1ccccc1N1CCN(CC(O)COc2ccc(-c3cc(C#N)c(=O)[nH]c3C)cc2)CC1
SATERINONE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 474.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.79 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 101.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: Cl.N=C(N)NC(=O)c1nc(Cl)c(N)nc1N.O.O
Drug Name: AMILORIDE HYDROCHLORIDE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 302.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -1.08 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 156.8 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: Cl.N=C(N)NC(=O)c1nc(Cl)c(N)nc1N.O.O
Drug Name: AMILORIDE HYDROCHLORIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 302.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -1.08 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 156.8 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
COc1cc([S+](C)[O-])ccc1-c1nc2cnccc2[nH]1",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 287.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.37 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 73.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
COc1cc([S+](C)[O-])ccc1-c1nc2cnccc2[nH]1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 287.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.37 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 73.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: N#Cc1ccc2c(c1)C1=C(CCN(CC3CCCC3)CC1)c1ccccc1O2
Drug Name: SAVOXEPIN",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 370.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.86 | ‚ö† High (>5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 36.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: N#Cc1ccc2c(c1)C1=C(CCN(CC3CCCC3)CC1)c1ccccc1O2
Drug Name: SAVOXEPIN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 370.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.86 | ‚ö† High (>5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 36.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CC(=O)N[C@H]1[C@H]([C@H](O)[C@H](O)CO)OC(C(=O)O)=C[C@@H]1NC(=N)N
Candidate Name: ZANAMIVIR",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 332.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -3.58 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 8.0 | ‚ö† High (>5) |
| Polar Surface Area | 198.2 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CC(=O)N[C@H]1[C@H]([C@H](O)[C@H](O)CO)OC(C(=O)O)=C[C@@H]1NC(=N)N
Candidate Name: ZANAMIVIR
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 332.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -3.58 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 8.0 | ‚ö† High (>5) |
| Polar Surface Area | 198.2 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: O=C(O)CCCC/C=C(/c1ccccc1)c1cccnc1
Drug Name: ISBOGREL",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 281.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.16 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 50.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: O=C(O)CCCC/C=C(/c1ccccc1)c1cccnc1
Drug Name: ISBOGREL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 281.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.16 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 50.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
Cn1c(=O)c2c(ncn2CCCN2CCC(C(=O)c3ccc(F)cc3)CC2)n(C)c1=O
FLUPROFYLLINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 427.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.56 | ‚úì Good (<5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 82.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
Cn1c(=O)c2c(ncn2CCCN2CCC(C(=O)c3ccc(F)cc3)CC2)n(C)c1=O
FLUPROFYLLINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 427.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.56 | ‚úì Good (<5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 82.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
C#CCN(c1nc(-c2cc(C)c(OC)cc2Cl)c(C)s1)[C@@H](CC1CC1)c1ccc(C)c(F)c1",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 483.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 7.52 | ‚ö† High (>5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 25.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
C#CCN(c1nc(-c2cc(C)c(OC)cc2Cl)c(C)s1)[C@@H](CC1CC1)c1ccc(C)c(F)c1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 483.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 7.52 | ‚ö† High (>5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 25.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
Cc1c(CCN2CCOCC2)c(=O)oc2cc(NC(=O)N3CCOCC3)ccc12
Name: MOROCROMEN",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 401.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.84 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 84.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
Cc1c(CCN2CCOCC2)c(=O)oc2cc(NC(=O)N3CCOCC3)ccc12
Name: MOROCROMEN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 401.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.84 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 84.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: C[N+]1(CCC(C(N)=O)(c2ccccc2)c2ccccc2)CCCCC1.[Br-]
Candidate Name: FENPIVERINIUM BROMIDE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 417.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.48 | ‚úì Good (<5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 43.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: C[N+]1(CCC(C(N)=O)(c2ccccc2)c2ccccc2)CCCCC1.[Br-]
Candidate Name: FENPIVERINIUM BROMIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 417.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.48 | ‚úì Good (<5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 43.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CCc1ccc2c(c1)N(CC(C)CN(C)C)c1ccccc1S2
Drug Name: ETYMEMAZINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 326.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.05 | ‚ö† High (>5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 6.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CCc1ccc2c(c1)N(CC(C)CN(C)C)c1ccccc1S2
Drug Name: ETYMEMAZINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 326.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.05 | ‚ö† High (>5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 6.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: Cc1ccc(O)c2ncccc12
Drug Name: TILIQUINOL",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 159.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.25 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 33.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: Cc1ccc(O)c2ncccc12
Drug Name: TILIQUINOL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 159.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.25 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 33.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
Cc1c(OCC(F)(F)F)ccnc1C[S+]([O-])c1nc2ccccc2[nH]1",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 369.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.52 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 73.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
Cc1c(OCC(F)(F)F)ccnc1C[S+]([O-])c1nc2ccccc2[nH]1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 369.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.52 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 73.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
N[C@@H](C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(Cl)CS[C@H]12)c1ccccc1.O
Name: CEFACLOR",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 385.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.62 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 112.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
N[C@@H](C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(Cl)CS[C@H]12)c1ccccc1.O
Name: CEFACLOR
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 385.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.62 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 112.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: Cc1ccccc1N1CCN(CCCOc2ccccn2)CC1
Candidate Name: TOPRILIDINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 311.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.98 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 28.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: Cc1ccccc1N1CCN(CCCOc2ccccn2)CC1
Candidate Name: TOPRILIDINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 311.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.98 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 28.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
N[C@H](CF)C(=O)O
FLUDALANINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 107.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -0.63 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 63.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
N[C@H](CF)C(=O)O
FLUDALANINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 107.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -0.63 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 63.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: COc1ccccc1OCCNCC(O)COc1cccc2[nH]nnc12
Candidate Name: TRIBENDILOL",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 358.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.37 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 101.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: COc1ccccc1OCCNCC(O)COc1cccc2[nH]nnc12
Candidate Name: TRIBENDILOL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 358.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.37 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 101.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: Oc1ccc(C2CNCCc3c2cc(O)c(O)c3Cl)cc1
Drug Name: FENOLDOPAM",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 305.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.73 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 72.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: Oc1ccc(C2CNCCc3c2cc(O)c(O)c3Cl)cc1
Drug Name: FENOLDOPAM
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 305.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.73 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 72.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
O=C(O[C@H]1CN[C@H](C(=O)O)C1)c1cccs1",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 241.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.72 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 75.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
O=C(O[C@H]1CN[C@H](C(=O)O)C1)c1cccs1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 241.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.72 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 75.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CN[C@@H]1CC[C@@H](c2ccccc2)c2ccccc21
Drug Name: TAMETRALINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 237.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.87 | ‚úì Good (<5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 12.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CN[C@@H]1CC[C@@H](c2ccccc2)c2ccccc21
Drug Name: TAMETRALINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 237.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.87 | ‚úì Good (<5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 12.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
Cc1cc(C)cc(OCC2CNC(=O)O2)c1
METAXALONE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 221.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.79 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 47.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
Cc1cc(C)cc(OCC2CNC(=O)O2)c1
METAXALONE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 221.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.79 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 47.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze the ADMET properties of this compound:
Cc1c(F)c(N2CCNC(C)C2)cc2c1c(=O)c(C(=O)O)cn2C1CC1",,"## Molecular Property Analysis: GREPAFLOXACIN

### Structure
```
Cc1c(F)c(N2CCNC(C)C2)cc2c1c(=O)c(C(=O)O)cn2C1CC1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 359.4 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 2.28 | 0-5 | ‚úì |
| H-Bond Acceptors | 5.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |
| PSA | 74.6 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.880
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- CYP450 substrate likely
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze the ADMET properties of this compound:
Cc1c(F)c(N2CCNC(C)C2)cc2c1c(=O)c(C(=O)O)cn2C1CC1
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: GREPAFLOXACIN

### Structure
```
Cc1c(F)c(N2CCNC(C)C2)cc2c1c(=O)c(C(=O)O)cn2C1CC1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 359.4 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 2.28 | 0-5 | ‚úì |
| H-Bond Acceptors | 5.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |
| PSA | 74.6 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.880
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- CYP450 substrate likely
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
COc1cc(C(=O)Nc2nc(=O)n([C@@H]3O[C@H](C)[C@@H](O)[C@H]3O)cc2F)cc(OC)c1OC
Name: GALOCITABINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 439.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.30 | ‚úì Good (<5) |
| H-Bond Acceptors | 10.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 141.4 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
COc1cc(C(=O)Nc2nc(=O)n([C@@H]3O[C@H](C)[C@@H](O)[C@H]3O)cc2F)cc(OC)c1OC
Name: GALOCITABINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 439.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.30 | ‚úì Good (<5) |
| H-Bond Acceptors | 10.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 141.4 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: [Na+].[O-]Cl
Candidate Name: SODIUM HYPOCHLORITE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 74.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.13 | ‚úì Good (<5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 20.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: [Na+].[O-]Cl
Candidate Name: SODIUM HYPOCHLORITE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 74.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.13 | ‚úì Good (<5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 20.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CC(C)c1cc2[nH]c(=O)n(NS(C)(=O)=O)c(=O)c2cc1-c1ccnn1C
SELURAMPANEL",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 377.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.72 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 118.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CC(C)c1cc2[nH]c(=O)n(NS(C)(=O)=O)c(=O)c2cc1-c1ccnn1C
SELURAMPANEL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 377.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.72 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 118.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CSc1ncc(OCC#CI)cn1
RIMOPROGIN",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 306.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.97 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 35.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CSc1ncc(OCC#CI)cn1
RIMOPROGIN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 306.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.97 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 35.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Describe the molecular properties and drug-likeness of:
Oc1ccc(CC2NCCc3cc(O)c(O)cc32)cc1",,"## Molecular Property Analysis: HIGENAMINE

### Structure
```
Oc1ccc(CC2NCCc3cc(O)c(O)cc32)cc1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 271.3 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 2.23 | 0-5 | ‚úì |
| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 4.0 | ‚â§5 | ‚úì |
| PSA | 72.7 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 2.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.630
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Describe the molecular properties and drug-likeness of:
Oc1ccc(CC2NCCc3cc(O)c(O)cc32)cc1
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: HIGENAMINE

### Structure
```
Oc1ccc(CC2NCCc3cc(O)c(O)cc32)cc1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 271.3 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 2.23 | 0-5 | ‚úì |
| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 4.0 | ‚â§5 | ‚úì |
| PSA | 72.7 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 2.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.630
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CC1=Nc2ccc(Cl)cc2S(=O)(=O)N1
Name: DIAZOXIDE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 230.7 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.68 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 58.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CC1=Nc2ccc(Cl)cc2S(=O)(=O)N1
Name: DIAZOXIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 230.7 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.68 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 58.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CCCSc1ccccc1N1CCN(CCCCn2c(=O)[nH]c3ccccc3c2=O)CC1",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 452.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.79 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 61.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CCCSc1ccccc1N1CCN(CCCCn2c(=O)[nH]c3ccccc3c2=O)CC1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 452.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.79 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 61.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
Nc1ccncc1N
AMIFAMPRIDINE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 109.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.25 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 64.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
Nc1ccncc1N
AMIFAMPRIDINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 109.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.25 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 64.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
c1ccc(C(Cc2noc(CCN3CCCCC3)n2)c2ccccc2)cc1
PRENOXDIAZINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 361.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.47 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 42.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
c1ccc(C(Cc2noc(CCN3CCCCC3)n2)c2ccccc2)cc1
PRENOXDIAZINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 361.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.47 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 42.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
O=c1[nH]c(=O)n([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2F)cc1I
Name: FIALURIDINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 372.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -1.27 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 104.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
O=c1[nH]c(=O)n([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2F)cc1I
Name: FIALURIDINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 372.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -1.27 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 104.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: OCCOCCOc1ccc(/C(=C(/CCCl)c2ccccc2)c2ccccc2)cc1
Candidate Name: FISPEMIFENE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 422.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.66 | ‚ö† High (>5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 38.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: OCCOCCOc1ccc(/C(=C(/CCCl)c2ccccc2)c2ccccc2)cc1
Candidate Name: FISPEMIFENE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 422.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.66 | ‚ö† High (>5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 38.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
O=c1nc2cccccc-2n1Cc1ccccc1
Name: BENHEPAZONE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 236.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.40 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 34.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
O=c1nc2cccccc-2n1Cc1ccccc1
Name: BENHEPAZONE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 236.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.40 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 34.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
Nc1nc2c(ncn2/C=C2/CC2(CO)CO)c(=O)[nH]1
FILOCICLOVIR",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 263.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -1.08 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 130.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
Nc1nc2c(ncn2/C=C2/CC2(CO)CO)c(=O)[nH]1
FILOCICLOVIR
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 263.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -1.08 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 130.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: O=C(c1ccc(CN2CCOCC2)cc1)N1CCN(C2CC2)CC1
Drug Name: BAVISANT",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 329.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.44 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 36.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: O=C(c1ccc(CN2CCOCC2)cc1)N1CCN(C2CC2)CC1
Drug Name: BAVISANT
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 329.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.44 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 36.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
CC(C)NCC(O)COc1cccc2ccccc12",,"## Molecular Property Analysis: PROPRANOLOL

### Structure
```
CC(C)NCC(O)COc1cccc2ccccc12
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 259.4 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 2.58 | 0-5 | ‚úì |
| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |
| PSA | 41.5 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 6.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.840
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
CC(C)NCC(O)COc1cccc2ccccc12
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: PROPRANOLOL

### Structure
```
CC(C)NCC(O)COc1cccc2ccccc12
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 259.4 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 2.58 | 0-5 | ‚úì |
| H-Bond Acceptors | 3.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |
| PSA | 41.5 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 6.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.840
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CCOC(=O)n1ccn(C)c1=S",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 186.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.56 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 36.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CCOC(=O)n1ccn(C)c1=S
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 186.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.56 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 36.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
Nc1nc(C(=O)N[C@H](CO)C(=O)O)c(N)nc1C(=O)N[C@H](CO)C(=O)O",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 372.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -4.01 | ‚úì Good (<5) |
| H-Bond Acceptors | 10.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 8.0 | ‚ö† High (>5) |
| Polar Surface Area | 251.1 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
Nc1nc(C(=O)N[C@H](CO)C(=O)O)c(N)nc1C(=O)N[C@H](CO)C(=O)O
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 372.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -4.01 | ‚úì Good (<5) |
| H-Bond Acceptors | 10.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 8.0 | ‚ö† High (>5) |
| Polar Surface Area | 251.1 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 354.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.20 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 87.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 354.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.20 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 87.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CCCC(=O)O[C@]1(C(=O)COC(C)=O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C
AMEBUCORT",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 488.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.95 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 107.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CCCC(=O)O[C@]1(C(=O)COC(C)=O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C
AMEBUCORT
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 488.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.95 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 107.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CC1(C)OC[C@@H](COC(=O)CCc2ccc(OC[C@@H](O)CNCCNC(=O)N3CCOCC3)cc2)O1
Name: LANDIOLOL",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 509.6 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 0.69 | ‚úì Good (<5) |
| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 127.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CC1(C)OC[C@@H](COC(=O)CCc2ccc(OC[C@@H](O)CNCCNC(=O)N3CCOCC3)cc2)O1
Name: LANDIOLOL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 509.6 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 0.69 | ‚úì Good (<5) |
| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 127.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: Cc1ccc(O)c(-n2nc3ccccc3n2)c1
Candidate Name: DROMETRIZOLE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 225.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.43 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 50.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: Cc1ccc(O)c(-n2nc3ccccc3n2)c1
Candidate Name: DROMETRIZOLE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 225.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.43 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 50.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CC[C@H](CC#N)OC(=O)N[C@@H](C)c1cccc(NC(=O)Nc2ccc(-c3cnco3)c(OC)c2)c1
Drug Name: AVN-944",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 477.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.47 | ‚ö† High (>5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 138.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CC[C@H](CC#N)OC(=O)N[C@@H](C)c1cccc(NC(=O)Nc2ccc(-c3cnco3)c(OC)c2)c1
Drug Name: AVN-944
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 477.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.47 | ‚ö† High (>5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 138.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: O=C(N[C@H]1CN2CCC1CC2)c1cc2ccoc2cn1
Drug Name: PHA-543613",,"## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 271.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.65 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 58.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: O=C(N[C@H]1CN2CCC1CC2)c1cc2ccoc2cn1
Drug Name: PHA-543613
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 271.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.65 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 58.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
O=c1ncn2nc(Sc3ccc(F)cc3F)ccc2c1-c1c(Cl)cccc1Cl
Name: NEFLAMAPIMOD",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 436.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.49 | ‚ö† High (>5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 47.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
O=c1ncn2nc(Sc3ccc(F)cc3F)ccc2c1-c1c(Cl)cccc1Cl
Name: NEFLAMAPIMOD
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 436.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.49 | ‚ö† High (>5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 47.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CC(=O)Oc1ccccc1C(=O)O.NCCCCC(N)C(=O)O
ASPIRIN DL-LYSINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 326.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.31 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 63.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CC(=O)Oc1ccccc1C(=O)O.NCCCCC(N)C(=O)O
ASPIRIN DL-LYSINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 326.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.31 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 63.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CCCCCCCCCCCCC(C#N)(CCCN(C)CCc1ccccc1)c1ccccc1
Candidate Name: RONIPAMIL",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 460.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 8.71 | ‚ö† High (>5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 27.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CCCCCCCCCCCCC(C#N)(CCCN(C)CCc1ccccc1)c1ccccc1
Candidate Name: RONIPAMIL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 460.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 8.71 | ‚ö† High (>5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 27.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: C[C@@H](Cc1ccccc1)N(C)C
Drug Name: DIMETAMFETAMINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 163.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.18 | ‚úì Good (<5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 3.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: C[C@@H](Cc1ccccc1)N(C)C
Drug Name: DIMETAMFETAMINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 163.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.18 | ‚úì Good (<5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 3.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
O=C(O)c1ccccc1O
Name: SALICYLIC ACID",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 138.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.09 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 57.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
O=C(O)c1ccccc1O
Name: SALICYLIC ACID
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 138.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.09 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 57.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
Cc1cc(N)c2ccccc2[n+]1CCCCCCCCCC[n+]1c(C)cc(N)c2ccccc21.[Cl-].[Cl-]",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 527.6 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 6.17 | ‚ö† High (>5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 59.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
Cc1cc(N)c2ccccc2[n+]1CCCCCCCCCC[n+]1c(C)cc(N)c2ccccc21.[Cl-].[Cl-]
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 527.6 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 6.17 | ‚ö† High (>5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 59.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@]2(C)[C@@H]([C@H](C)CC[C@@H](O)C(C)(C)O)CC[C@@H]12
Candidate Name: SECALCIFEROL",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 416.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.70 | ‚ö† High (>5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 60.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@]2(C)[C@@H]([C@H](C)CC[C@@H](O)C(C)(C)O)CC[C@@H]12
Candidate Name: SECALCIFEROL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 416.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.70 | ‚ö† High (>5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 60.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: COc1ccc2[n-]c([S+]([O-])Cc3ncc(C)c(OC)c3C)nc2c1.[Na+]
Candidate Name: OMEPRAZOLE SODIUM",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 367.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.90 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 83.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: COc1ccc2[n-]c([S+]([O-])Cc3ncc(C)c(OC)c3C)nc2c1.[Na+]
Candidate Name: OMEPRAZOLE SODIUM
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 367.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.90 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 83.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
[Cl-].[Rb+]
RUBIDIUM CHLORIDE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 120.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
[Cl-].[Rb+]
RUBIDIUM CHLORIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 120.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CCCC(CCC)(CCC)C(N)=O",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 185.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.86 | ‚úì Good (<5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 43.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CCCC(CCC)(CCC)C(N)=O
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 185.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.86 | ‚úì Good (<5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 43.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CCC(CCCCC1CCC2CC(=O)CC12)OC
Candidate Name: CIOTERONEL",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 252.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.98 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 26.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CCC(CCCCC1CCC2CC(=O)CC12)OC
Candidate Name: CIOTERONEL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 252.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.98 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 26.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: O=C(CO)[C@@H](O)[C@H](O)[C@H](O)CO
Drug Name: FRUCTOSE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 180.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -3.38 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 118.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: O=C(CO)[C@@H](O)[C@H](O)[C@H](O)CO
Drug Name: FRUCTOSE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 180.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -3.38 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 118.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: O=C(O)[C@H](O)[C@@H](O)C(=O)O
Drug Name: TARTARIC ACID",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 150.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -2.12 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 115.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: O=C(O)[C@H](O)[C@@H](O)C(=O)O
Drug Name: TARTARIC ACID
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 150.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -2.12 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 115.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CC(=O)N[C@@H]1[C@@H](COC[C@@H]2O[C@H](C(=O)O)[C@@H](CO)[C@H](O)[C@H]2O)[C@@H](CS(=O)(=O)O)[C@@H](CO)O[C@H]1CO",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 531.5 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | -4.44 | ‚úì Good (<5) |
| H-Bond Acceptors | 12.0 | ‚ö† High (>10) |
| H-Bond Donors | 8.0 | ‚ö† High (>5) |
| Polar Surface Area | 249.6 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 3.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CC(=O)N[C@@H]1[C@@H](COC[C@@H]2O[C@H](C(=O)O)[C@@H](CO)[C@H](O)[C@H]2O)[C@@H](CS(=O)(=O)O)[C@@H](CO)O[C@H]1CO
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 531.5 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | -4.44 | ‚úì Good (<5) |
| H-Bond Acceptors | 12.0 | ‚ö† High (>10) |
| H-Bond Donors | 8.0 | ‚ö† High (>5) |
| Polar Surface Area | 249.6 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 3.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CCCCCCCCCCCCCCCCNc1ccc(C(=O)O)cc1
Candidate Name: CETABEN",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 361.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 7.28 | ‚ö† High (>5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 49.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CCCCCCCCCCCCCCCCNc1ccc(C(=O)O)cc1
Candidate Name: CETABEN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 361.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 7.28 | ‚ö† High (>5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 49.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: O=[N+]([O-])OC[C@H](O[N+](=O)[O-])[C@@H](CO[N+](=O)[O-])O[N+](=O)[O-]
Drug Name: ERYTHRITYL TETRANITRATE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 302.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -1.44 | ‚úì Good (<5) |
| H-Bond Acceptors | 12.0 | ‚ö† High (>10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 209.5 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: O=[N+]([O-])OC[C@H](O[N+](=O)[O-])[C@@H](CO[N+](=O)[O-])O[N+](=O)[O-]
Drug Name: ERYTHRITYL TETRANITRATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 302.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -1.44 | ‚úì Good (<5) |
| H-Bond Acceptors | 12.0 | ‚ö† High (>10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 209.5 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: [15OH2]
Candidate Name: WATER O 15",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 17.0 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -0.82 | ‚úì Good (<5) |
| H-Bond Acceptors | 0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 31.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: [15OH2]
Candidate Name: WATER O 15
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 17.0 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -0.82 | ‚úì Good (<5) |
| H-Bond Acceptors | 0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 31.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: C[C@]12CCC(OC3CCCC3)=CC1=CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O
Candidate Name: PENMESTEROL",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 370.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 6.15 | ‚ö† High (>5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 29.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: C[C@]12CCC(OC3CCCC3)=CC1=CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O
Candidate Name: PENMESTEROL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 370.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 6.15 | ‚ö† High (>5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 29.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CNC(=S)NCO",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 120.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -0.97 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 44.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CNC(=S)NCO
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 120.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -0.97 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 44.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CN1[C@@H]2CC[C@H]1C[C@@H](OC1c3ccccc3C=Cc3ccccc31)C2
Name: DECITROPINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 331.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.90 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 12.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CN1[C@@H]2CC[C@H]1C[C@@H](OC1c3ccccc3C=Cc3ccccc31)C2
Name: DECITROPINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 331.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.90 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 12.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: C[C@]12CC[C@@H]3c4ccc(OC(=O)c5ccccc5)cc4CC[C@H]3[C@@H]1CC[C@@H]2OC(=O)COC(=O)CCCc1ccc(N(CCCl)CCCl)cc1
Drug Name: ATRIMUSTINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 720.7 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 8.52 | ‚ö† High (>5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 82.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: C[C@]12CC[C@@H]3c4ccc(OC(=O)c5ccccc5)cc4CC[C@H]3[C@@H]1CC[C@@H]2OC(=O)COC(=O)CCCc1ccc(N(CCCl)CCCl)cc1
Drug Name: ATRIMUSTINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 720.7 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 8.52 | ‚ö† High (>5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 82.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: NC(=O)CN1CCCC1=O
Drug Name: PIRACETAM",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 142.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -0.91 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 63.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: NC(=O)CN1CCCC1=O
Drug Name: PIRACETAM
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 142.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -0.91 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 63.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CC(C)OC(=O)[C@H](C)N[P@+]([O-])(OC[C@H]1O[C@@](C#N)(c2ccc3c(N)ncnn23)[C@](C)(O)[C@@H]1OC(=O)C(C)C)Oc1ccccc1
Drug Name: GS-6620",,"## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 644.6 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 1.81 | ‚úì Good (<5) |
| H-Bond Acceptors | 15.0 | ‚ö† High (>10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 215.6 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CC(C)OC(=O)[C@H](C)N[P@+]([O-])(OC[C@H]1O[C@@](C#N)(c2ccc3c(N)ncnn23)[C@](C)(O)[C@@H]1OC(=O)C(C)C)Oc1ccccc1
Drug Name: GS-6620
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 644.6 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 1.81 | ‚úì Good (<5) |
| H-Bond Acceptors | 15.0 | ‚ö† High (>10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 215.6 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CCC1(CC)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1
Candidate Name: AMCINAFAL",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 462.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.20 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 93.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CCC1(CC)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1
Candidate Name: AMCINAFAL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 462.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.20 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 93.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: COc1ccc2cc([C@H](C)C(=O)O)ccc2c1
Candidate Name: NAPROXEN",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 230.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.04 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 46.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: COc1ccc2cc([C@H](C)C(=O)O)ccc2c1
Candidate Name: NAPROXEN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 230.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.04 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 46.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
O=C([O-])C[C@H](O)C[C@H](O)/C=C/c1c(C2CC2)nc2ccccc2c1-c1ccc(F)cc1.[Na+]
PITAVASTATIN SODIUM",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | nan Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics

### Success Factors

This drug was successfully approved, demonstrating:
1. **Favorable safety profile** through clinical development
2. **Clear efficacy** in target patient population
3. **Acceptable risk-benefit ratio** for intended indication

### Key Success Indicators
- Completed Phase III trials with positive outcomes
- Manageable side effect profile
- Clear differentiation from existing treatments",drug_analysis,processed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
O=C([O-])C[C@H](O)C[C@H](O)/C=C/c1c(C2CC2)nc2ccccc2c1-c1ccc(F)cc1.[Na+]
PITAVASTATIN SODIUM
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | nan Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics

### Success Factors

This drug was successfully approved, demonstrating:
1. **Favorable safety profile** through clinical development
2. **Clear efficacy** in target patient population
3. **Acceptable risk-benefit ratio** for intended indication

### Key Success Indicators
- Completed Phase III trials with positive outcomes
- Manageable side effect profile
- Clear differentiation from existing treatments
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
[82Rb+].[Cl-]
Name: RUBIDIUM CHLORIDE RB 82",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 117.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
[82Rb+].[Cl-]
Name: RUBIDIUM CHLORIDE RB 82
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 117.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CCCCCCCC/C=C\CCCCCCCC(=O)O",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 282.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 6.11 | ‚ö† High (>5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 37.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CCCCCCCC/C=C\CCCCCCCC(=O)O
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 282.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 6.11 | ‚ö† High (>5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 37.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CCc1cc2c(cc1CC)CC(NC[C@H](O)c1ccc(O)c3[nH]c(=O)ccc13)C2.O=C(O)/C=C\C(=O)O
Name: INDACATEROL MALEATE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 508.6 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 3.15 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 85.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CCc1cc2c(cc1CC)CC(NC[C@H](O)c1ccc(O)c3[nH]c(=O)ccc13)C2.O=C(O)/C=C\C(=O)O
Name: INDACATEROL MALEATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 508.6 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 3.15 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 85.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
Cc1cc2c(cc1CC1=NCCN1)C1CCC2CC1
Name: METRAFAZOLINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 254.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.29 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 24.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
Cc1cc2c(cc1CC1=NCCN1)C1CCC2CC1
Name: METRAFAZOLINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 254.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.29 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 24.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
OC[C@H]1[C@@H](O)[C@H](O)[C@@H](O)CN1CCCCCOCc1ccc(-c2ccccc2)c(F)c1",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 433.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.94 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 93.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
OC[C@H]1[C@@H](O)[C@H](O)[C@@H](O)CN1CCCCCOCc1ccc(-c2ccccc2)c(F)c1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 433.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.94 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 93.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CCOS(=O)(=O)c1cc(C(C)(C)C)cc2cc(C(C)(C)C)ccc12",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 348.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.16 | ‚ö† High (>5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 43.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CCOS(=O)(=O)c1cc(C(C)(C)C)cc2cc(C(C)(C)C)ccc12
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 348.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.16 | ‚ö† High (>5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 43.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: O=C(c1cc2ccccc2o1)N1CCN(Cc2ccccc2)CC1
Candidate Name: BEFURALINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 320.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.39 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 36.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: O=C(c1cc2ccccc2o1)N1CCN(Cc2ccccc2)CC1
Candidate Name: BEFURALINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 320.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.39 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 36.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze the ADMET properties of this compound:
C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1",,"## Molecular Property Analysis: ERLOTINIB

### Structure
```
C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 393.4 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 3.41 | 0-5 | ‚úì |
| H-Bond Acceptors | 7.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 74.7 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 10.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.420
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- CYP450 substrate likely
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze the ADMET properties of this compound:
C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: ERLOTINIB

### Structure
```
C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 393.4 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 3.41 | 0-5 | ‚úì |
| H-Bond Acceptors | 7.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 74.7 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 10.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.420
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- CYP450 substrate likely
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CN(C)CCC(c1ccc(Br)cc1)c1ccccn1
Candidate Name: BROMPHENIRAMINE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 319.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.93 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 16.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CN(C)CCC(c1ccc(Br)cc1)c1ccccn1
Candidate Name: BROMPHENIRAMINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 319.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.93 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 16.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CN/C(=N\S(=O)(=O)c1ccc(Cl)cc1)N1C[C@H](c2ccccc2)C(c2ccc(Cl)cc2)=N1
IBIPINABANT",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 487.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.76 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 74.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CN/C(=N\S(=O)(=O)c1ccc(Cl)cc1)N1C[C@H](c2ccccc2)C(c2ccc(Cl)cc2)=N1
IBIPINABANT
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 487.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.76 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 74.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CCCCCCCCCCCCCCCC(=O)OC1CC(C)=C(/C=C/C(C)=C/C=C/C(C)=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C2=C(C)CC(OC(=O)CCCCCCCCCCCCCCC)CC2(C)C)C(C)(C)C1
Name: XANTOFYL PALMITATE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 1045.7 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CCCCCCCCCCCCCCCC(=O)OC1CC(C)=C(/C=C/C(C)=C/C=C/C(C)=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C2=C(C)CC(OC(=O)CCCCCCCCCCCCCCC)CC2(C)C)C(C)(C)C1
Name: XANTOFYL PALMITATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 1045.7 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CC(C)NC[C@H](O)c1ccc(O)c(O)c1
Drug Name: LEVISOPRENALINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 211.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.13 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 72.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CC(C)NC[C@H](O)c1ccc(O)c(O)c1
Drug Name: LEVISOPRENALINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 211.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.13 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 72.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CCCCCNCC(N)=O
Drug Name: MILACEMIDE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 144.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.25 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 55.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CCCCCNCC(N)=O
Drug Name: MILACEMIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 144.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.25 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 55.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CCSc1ccc2c(c1)N(CCCN1CCN(C)CC1)c1ccccc1S2.O=C(O)/C=C\C(=O)O.O=C(O)/C=C\C(=O)O
Name: THIETHYLPERAZINE MALEATE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | nan Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics

### Success Factors

This drug was successfully approved, demonstrating:
1. **Favorable safety profile** through clinical development
2. **Clear efficacy** in target patient population
3. **Acceptable risk-benefit ratio** for intended indication

### Key Success Indicators
- Completed Phase III trials with positive outcomes
- Manageable side effect profile
- Clear differentiation from existing treatments",drug_analysis,processed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CCSc1ccc2c(c1)N(CCCN1CCN(C)CC1)c1ccccc1S2.O=C(O)/C=C\C(=O)O.O=C(O)/C=C\C(=O)O
Name: THIETHYLPERAZINE MALEATE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | nan Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics

### Success Factors

This drug was successfully approved, demonstrating:
1. **Favorable safety profile** through clinical development
2. **Clear efficacy** in target patient population
3. **Acceptable risk-benefit ratio** for intended indication

### Key Success Indicators
- Completed Phase III trials with positive outcomes
- Manageable side effect profile
- Clear differentiation from existing treatments
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O[C@@H]5O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 576.9 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 5.85 | ‚ö† High (>5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 99.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O[C@@H]5O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 576.9 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 5.85 | ‚ö† High (>5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 4.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 99.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
O=C1c2ccccc2S(=O)(=O)N1CCCN1CCN(c2ncccn2)CC1",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 387.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.83 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 86.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
O=C1c2ccccc2S(=O)(=O)N1CCCN1CCN(c2ncccn2)CC1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 387.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.83 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 86.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
O=C1c2ccccc2C(=O)C1c1ccc(F)cc1
Name: FLUINDIONE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 240.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.99 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 34.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
O=C1c2ccccc2C(=O)C1c1ccc(F)cc1
Name: FLUINDIONE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 240.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.99 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 34.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Describe the molecular properties and drug-likeness of:
CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=CCS[C@H]12)c1csc(N)n1",,"## Molecular Property Analysis: CEFTIZOXIME

### Structure
```
CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=CCS[C@H]12)c1csc(N)n1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 383.4 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | -0.56 | 0-5 | ‚ö† |
| H-Bond Acceptors | 9.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 3.0 | ‚â§5 | ‚úì |
| PSA | 147.2 √Ö¬≤ | <140 √Ö¬≤ | ‚ö† |
| Rotatable Bonds | 5.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.350
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- May have oral absorption challenges
- Limited CNS penetration expected

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Low (hydrophilic)

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- May undergo renal clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚ö† FAIL

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Describe the molecular properties and drug-likeness of:
CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=CCS[C@H]12)c1csc(N)n1
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: CEFTIZOXIME

### Structure
```
CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=CCS[C@H]12)c1csc(N)n1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 383.4 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | -0.56 | 0-5 | ‚ö† |
| H-Bond Acceptors | 9.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 3.0 | ‚â§5 | ‚úì |
| PSA | 147.2 √Ö¬≤ | <140 √Ö¬≤ | ‚ö† |
| Rotatable Bonds | 5.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.350
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- May have oral absorption challenges
- Limited CNS penetration expected

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Low (hydrophilic)

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- May undergo renal clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚ö† FAIL

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
Cc1nc2c(N3CCNCC3)cccc2n1S(=O)(=O)c1ccccc1
PF-05212377",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 356.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.99 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 67.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
Cc1nc2c(N3CCNCC3)cccc2n1S(=O)(=O)c1ccccc1
PF-05212377
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 356.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.99 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 67.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CCCCOCCOC(=O)c1cccnc1
Candidate Name: NICOBOXIL",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 223.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.06 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 48.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CCCCOCCOC(=O)c1cccnc1
Candidate Name: NICOBOXIL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 223.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.06 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 48.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: O=C(Cn1cnnn1)N[C@@H]1C(=O)N2C(C(=O)O)=C(CSc3nncs3)CS[C@H]12
Drug Name: CEFTEZOLE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 440.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -0.94 | ‚úì Good (<5) |
| H-Bond Acceptors | 12.0 | ‚ö† High (>10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 156.1 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: O=C(Cn1cnnn1)N[C@@H]1C(=O)N2C(C(=O)O)=C(CSc3nncs3)CS[C@H]12
Drug Name: CEFTEZOLE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 440.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -0.94 | ‚úì Good (<5) |
| H-Bond Acceptors | 12.0 | ‚ö† High (>10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 156.1 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CC(=O)N(C)c1c(I)c(C(=O)O)c(I)c(N(CC(O)COCCCCOCC(O)CN(C(C)=O)c2c(I)c(C(=O)O)c(I)c(N(C)C(C)=O)c2I)C(C)=O)c1I
IOZOMIC ACID",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 1458.1 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CC(=O)N(C)c1c(I)c(C(=O)O)c(I)c(N(CC(O)COCCCCOCC(O)CN(C(C)=O)c2c(I)c(C(=O)O)c(I)c(N(C)C(C)=O)c2I)C(C)=O)c1I
IOZOMIC ACID
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 1458.1 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
COC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@H](N)C3=CCC=CC3)[C@H]2SC1",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 365.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -0.07 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 122.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
COC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@H](N)C3=CCC=CC3)[C@H]2SC1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 365.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -0.07 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 122.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CCCCC/C=C\C/C=C\CCCCCCCC(=O)NC(Cc1ccc(C)cc1)c1ccccc1
Drug Name: MOCTAMIDE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 473.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 9.21 | ‚ö† High (>5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 29.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CCCCC/C=C\C/C=C\CCCCCCCC(=O)NC(Cc1ccc(C)cc1)c1ccccc1
Drug Name: MOCTAMIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 473.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 9.21 | ‚ö† High (>5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 29.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: NC(=O)c1ccc2c(c1O)[C@]13CCN(CC4CC4)[C@H](C2)[C@]1(O)CCC(=O)C3
Candidate Name: SAMIDORPHAN",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 370.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.25 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 103.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: NC(=O)c1ccc2c(c1O)[C@]13CCN(CC4CC4)[C@H](C2)[C@]1(O)CCC(=O)C3
Candidate Name: SAMIDORPHAN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 370.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.25 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 103.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
Cc1cc(-c2ccccc2[C@@H](C)OC[C@H](O)CNC(C)(C)Cc2ccc(Cl)c(F)c2)ccc1C(=O)O.Cc1cc(-c2ccccc2[C@@H](C)OC[C@H](O)CNC(C)(C)Cc2ccc(Cl)c(F)c2)ccc1C(=O)O.O.O=S(=O)(O)O",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 1144.2 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 6.20 | ‚ö† High (>5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 78.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
Cc1cc(-c2ccccc2[C@@H](C)OC[C@H](O)CNC(C)(C)Cc2ccc(Cl)c(F)c2)ccc1C(=O)O.Cc1cc(-c2ccccc2[C@@H](C)OC[C@H](O)CNC(C)(C)Cc2ccc(Cl)c(F)c2)ccc1C(=O)O.O.O=S(=O)(O)O
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 1144.2 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 6.20 | ‚ö† High (>5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 78.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Analyze the ADMET properties of this compound:
CCCCCCOc1nsnc1C1=CCCN(C)C1",,"## Molecular Property Analysis: XANOMELINE

### Structure
```
CCCCCCOc1nsnc1C1=CCCN(C)C1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 281.4 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 3.22 | 0-5 | ‚úì |
| H-Bond Acceptors | 5.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 0 | ‚â§5 | ‚úì |
| PSA | 38.2 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 7.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.720
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze the ADMET properties of this compound:
CCCCCCOc1nsnc1C1=CCCN(C)C1
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: XANOMELINE

### Structure
```
CCCCCCOc1nsnc1C1=CCCN(C)C1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 281.4 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 3.22 | 0-5 | ‚úì |
| H-Bond Acceptors | 5.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 0 | ‚â§5 | ‚úì |
| PSA | 38.2 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 7.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.720
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
Cc1ccccc1-c1cc(N2CC[N+](C)(COP(=O)([O-])O)CC2)ncc1N(C)C(=O)C(C)(C)c1cc(C(F)(F)F)cc(C(F)(F)F)c1
FOSNETUPITANT",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | nan Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics

### Success Factors

This drug was successfully approved, demonstrating:
1. **Favorable safety profile** through clinical development
2. **Clear efficacy** in target patient population
3. **Acceptable risk-benefit ratio** for intended indication

### Key Success Indicators
- Completed Phase III trials with positive outcomes
- Manageable side effect profile
- Clear differentiation from existing treatments",drug_analysis,processed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
Cc1ccccc1-c1cc(N2CC[N+](C)(COP(=O)([O-])O)CC2)ncc1N(C)C(=O)C(C)(C)c1cc(C(F)(F)F)cc(C(F)(F)F)c1
FOSNETUPITANT
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | nan Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics

### Success Factors

This drug was successfully approved, demonstrating:
1. **Favorable safety profile** through clinical development
2. **Clear efficacy** in target patient population
3. **Acceptable risk-benefit ratio** for intended indication

### Key Success Indicators
- Completed Phase III trials with positive outcomes
- Manageable side effect profile
- Clear differentiation from existing treatments
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CCC(=O)C(c1ccccc1)(c1ccccc1)C(C)CN(C)C
ISOMETHADONE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 309.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.15 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 20.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CCC(=O)C(c1ccccc1)(c1ccccc1)C(C)CN(C)C
ISOMETHADONE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 309.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.15 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 20.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
Cc1n[nH]c(C)c1CCCOc1cc(C(=O)O)ccc1F",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | nan Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics

### Success Factors

This drug was successfully approved, demonstrating:
1. **Favorable safety profile** through clinical development
2. **Clear efficacy** in target patient population
3. **Acceptable risk-benefit ratio** for intended indication

### Key Success Indicators
- Completed Phase III trials with positive outcomes
- Manageable side effect profile
- Clear differentiation from existing treatments",drug_analysis,processed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
Cc1n[nH]c(C)c1CCCOc1cc(C(=O)O)ccc1F
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | nan Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics

### Success Factors

This drug was successfully approved, demonstrating:
1. **Favorable safety profile** through clinical development
2. **Clear efficacy** in target patient population
3. **Acceptable risk-benefit ratio** for intended indication

### Key Success Indicators
- Completed Phase III trials with positive outcomes
- Manageable side effect profile
- Clear differentiation from existing treatments
<|im_end|>"
"Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
C[C@](N)(Cc1ccc(O)c(O)c1)C(=O)O",,"## Molecular Property Analysis: METHYLDOPA

### Structure
```
C[C@](N)(Cc1ccc(O)c(O)c1)C(=O)O
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 211.2 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 0.44 | 0-5 | ‚úì |
| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 4.0 | ‚â§5 | ‚úì |
| PSA | 103.8 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.540
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Limited CNS penetration expected

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Low (hydrophilic)

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- May undergo renal clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the Lipinski's Rule of 5 compliance and pharmacokinetic potential:
C[C@](N)(Cc1ccc(O)c(O)c1)C(=O)O
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: METHYLDOPA

### Structure
```
C[C@](N)(Cc1ccc(O)c(O)c1)C(=O)O
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 211.2 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 0.44 | 0-5 | ‚úì |
| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 4.0 | ‚â§5 | ‚úì |
| PSA | 103.8 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.540
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Limited CNS penetration expected

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Low (hydrophilic)

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- May undergo renal clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: COCC[n+]1c2c(n(Cc3cnccn3)c1C)C(=O)c1ccccc1C2=O
Drug Name: SEPANTRONIUM",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 363.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.34 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 78.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: COCC[n+]1c2c(n(Cc3cnccn3)c1C)C(=O)c1ccccc1C2=O
Drug Name: SEPANTRONIUM
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 363.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.34 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 78.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Describe the molecular properties and drug-likeness of:
Cc1ccc(-c2ncc(Cl)cc2-c2ccc(S(C)(=O)=O)cc2)cn1",,"## Molecular Property Analysis: ETORICOXIB

### Structure
```
Cc1ccc(-c2ncc(Cl)cc2-c2ccc(S(C)(=O)=O)cc2)cn1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 358.9 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 4.18 | 0-5 | ‚úì |
| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 0 | ‚â§5 | ‚úì |
| PSA | 59.9 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.700
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- CYP450 substrate likely
- Potential CYP inhibition risk

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Describe the molecular properties and drug-likeness of:
Cc1ccc(-c2ncc(Cl)cc2-c2ccc(S(C)(=O)=O)cc2)cn1
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: ETORICOXIB

### Structure
```
Cc1ccc(-c2ncc(Cl)cc2-c2ccc(S(C)(=O)=O)cc2)cn1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 358.9 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 4.18 | 0-5 | ‚úì |
| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 0 | ‚â§5 | ‚úì |
| PSA | 59.9 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.700
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- CYP450 substrate likely
- Potential CYP inhibition risk

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
NC(=O)C1CN(CCCCC(c2ccc(F)cc2)c2ccc(F)cc2)CCN1CC(=O)Nc1c(Cl)cc(N)cc1Cl",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 604.5 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 5.27 | ‚ö† High (>5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 104.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
NC(=O)C1CN(CCCCC(c2ccc(F)cc2)c2ccc(F)cc2)CCN1CC(=O)Nc1c(Cl)cc(N)cc1Cl
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 604.5 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 5.27 | ‚ö† High (>5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 104.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Analyze the ADMET properties of this compound:
Cc1ncc([N+](=O)[O-])n1CCO",,"## Molecular Property Analysis: METRONIDAZOLE

### Structure
```
Cc1ncc([N+](=O)[O-])n1CCO
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 171.2 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 0.09 | 0-5 | ‚úì |
| H-Bond Acceptors | 5.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 81.2 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.520
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Limited CNS penetration expected

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Low (hydrophilic)

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- May undergo renal clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze the ADMET properties of this compound:
Cc1ncc([N+](=O)[O-])n1CCO
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: METRONIDAZOLE

### Structure
```
Cc1ncc([N+](=O)[O-])n1CCO
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 171.2 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 0.09 | 0-5 | ‚úì |
| H-Bond Acceptors | 5.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 81.2 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.520
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Limited CNS penetration expected

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Low (hydrophilic)

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- May undergo renal clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
C[C@]12CC[C@H]([N+]3(C)CCCC3)CC1=CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CCC[N+]2(C)C
Name: CANDOCURONIUM",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 386.7 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.39 | ‚ö† High (>5) |
| H-Bond Acceptors | 0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 0.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
C[C@]12CC[C@H]([N+]3(C)CCCC3)CC1=CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CCC[N+]2(C)C
Name: CANDOCURONIUM
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 386.7 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.39 | ‚ö† High (>5) |
| H-Bond Acceptors | 0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 0.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
NS(=O)(=O)c1cc(-c2nnn[nH]2)c(NCc2cccs2)cc1Cl
Name: AZOSEMIDE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 370.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.84 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 126.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
NS(=O)(=O)c1cc(-c2nnn[nH]2)c(NCc2cccs2)cc1Cl
Name: AZOSEMIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 370.9 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.84 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 126.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CN1CCC(N(Cc2ccccc2)c2ccccc2)CC1
Name: BAMIPINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 280.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.79 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 6.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CN1CCC(N(Cc2ccccc2)c2ccccc2)CC1
Name: BAMIPINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 280.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.79 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 6.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CC(C)(C)c1ccc(C(=O)CCCN2CCC(OC(c3ccccc3)c3ccccc3)CC2)cc1
Drug Name: EBASTINE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 469.7 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 7.22 | ‚ö† High (>5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 29.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CC(C)(C)c1ccc(C(=O)CCCN2CCC(OC(c3ccccc3)c3ccccc3)CC2)cc1
Drug Name: EBASTINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 469.7 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 7.22 | ‚ö† High (>5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 29.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CCCN(CCC)S(=O)(=O)c1ccc(C(=O)O)cc1
Name: PROBENECID",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 285.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.20 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 74.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CCCN(CCC)S(=O)(=O)c1ccc(C(=O)O)cc1
Name: PROBENECID
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 285.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.20 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 74.7 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: Oc1c(Br)cc(Br)cc1CN[C@H]1CC[C@H](O)CC1
Drug Name: DEMBREXINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 379.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.31 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 52.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: Oc1c(Br)cc(Br)cc1CN[C@H]1CC[C@H](O)CC1
Drug Name: DEMBREXINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 379.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.31 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 52.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: Cc1ncc(CO)c(C=O)c1O
Drug Name: PYRIDOXAL",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 167.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.40 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 70.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: Cc1ncc(CO)c(C=O)c1O
Drug Name: PYRIDOXAL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 167.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.40 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 70.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
[K]",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 39.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
[K]
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 39.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: CCN[C@H](C)Cc1cccc(C(F)(F)F)c1
Drug Name: LEVOFENFLURAMINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 231.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.25 | ‚úì Good (<5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 12.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: CCN[C@H](C)Cc1cccc(C(F)(F)F)c1
Drug Name: LEVOFENFLURAMINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 231.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.25 | ‚úì Good (<5) |
| H-Bond Acceptors | 1.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 12.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c(/C=N/N5CCN(C)CC5)c(O)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C
Name: RIFAMPIN",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 823.0 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 4.34 | ‚úì Good (<5) |
| H-Bond Acceptors | 15.0 | ‚ö† High (>10) |
| H-Bond Donors | 6.0 | ‚ö† High (>5) |
| Polar Surface Area | 220.2 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 3.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c(/C=N/N5CCN(C)CC5)c(O)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C
Name: RIFAMPIN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 823.0 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 4.34 | ‚úì Good (<5) |
| H-Bond Acceptors | 15.0 | ‚ö† High (>10) |
| H-Bond Donors | 6.0 | ‚ö† High (>5) |
| Polar Surface Area | 220.2 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 3.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CC[N+](CC)(CC)CC
Candidate Name: TETRYLAMMONIUM",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 130.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.88 | ‚úì Good (<5) |
| H-Bond Acceptors | 0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 0.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CC[N+](CC)(CC)CC
Candidate Name: TETRYLAMMONIUM
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 130.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 1.88 | ‚úì Good (<5) |
| H-Bond Acceptors | 0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 0.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CSc1ccc(C(=O)/C=C/c2cc(C)c(OC(C)(C)C(=O)O)c(C)c2)cc1
ELAFIBRANOR",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 384.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.16 | ‚ö† High (>5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 63.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CSc1ccc(C(=O)/C=C/c2cc(C)c(OC(C)(C)C(=O)O)c(C)c2)cc1
ELAFIBRANOR
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 384.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 5.16 | ‚ö† High (>5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 63.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
NS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 546.2 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 2.53 | ‚úì Good (<5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 142.2 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
NS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 546.2 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 2.53 | ‚úì Good (<5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 142.2 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CCN[C@H]1CN(CCCOC)S(=O)(=O)c2sc(S(N)(=O)=O)cc21",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 383.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.09 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 118.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CCN[C@H]1CN(CCCOC)S(=O)(=O)c2sc(S(N)(=O)=O)cc21
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 383.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.09 | ‚úì Good (<5) |
| H-Bond Acceptors | 7.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 118.8 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CC(C)=CCC/C(C)=C/CC/C(C)=C/CCC1(C)CCc2cc(O)ccc2O1
Name: TOCOTRIENOL",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 382.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 7.68 | ‚ö† High (>5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 29.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CC(C)=CCC/C(C)=C/CC/C(C)=C/CCC1(C)CCc2cc(O)ccc2O1
Name: TOCOTRIENOL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 382.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 7.68 | ‚ö† High (>5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 29.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CC#C[C@]1(O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C
Name: DIMETHISTERONE ANHYDROUS",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 340.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.52 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 37.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CC#C[C@]1(O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C
Name: DIMETHISTERONE ANHYDROUS
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 340.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.52 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 37.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CC(C(=O)O)c1ccc(N2CC=CC2)c(Cl)c1
Name: PIRPROFEN",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 251.7 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.90 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 40.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CC(C(=O)O)c1ccc(N2CC=CC2)c(Cl)c1
Name: PIRPROFEN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 251.7 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.90 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 40.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: C=CC[C@H]1C(=O)C(C)(C)[C@@H](O)CC(=O)O[C@H](c2ccc3sc(C)nc3c2)C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@@H]1O
Drug Name: SAGOPILONE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 543.7 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 5.46 | ‚ö† High (>5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 109.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: C=CC[C@H]1C(=O)C(C)(C)[C@@H](O)CC(=O)O[C@H](c2ccc3sc(C)nc3c2)C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@@H]1O
Drug Name: SAGOPILONE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 543.7 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 5.46 | ‚ö† High (>5) |
| H-Bond Acceptors | 8.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 109.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(/C(CO)=N/NC(=O)CCCCCN1C(=O)C=CC1=O)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1
Candidate Name: ALDOXORUBICIN",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 750.8 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 0.39 | ‚úì Good (<5) |
| H-Bond Acceptors | 15.0 | ‚ö† High (>10) |
| H-Bond Donors | 7.0 | ‚ö† High (>5) |
| Polar Surface Area | 267.8 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 3.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(/C(CO)=N/NC(=O)CCCCCN1C(=O)C=CC1=O)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1
Candidate Name: ALDOXORUBICIN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 750.8 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 0.39 | ‚úì Good (<5) |
| H-Bond Acceptors | 15.0 | ‚ö† High (>10) |
| H-Bond Donors | 7.0 | ‚ö† High (>5) |
| Polar Surface Area | 267.8 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 3.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Analyze the ADMET properties of this compound:
CNC(C)C(O)c1ccc(O)c(O)c1",,"## Molecular Property Analysis: DIOXIFEDRINE

### Structure
```
CNC(C)C(O)c1ccc(O)c(O)c1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 197.2 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 0.74 | 0-5 | ‚úì |
| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 4.0 | ‚â§5 | ‚úì |
| PSA | 72.7 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.540
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Limited CNS penetration expected

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Low (hydrophilic)

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- May undergo renal clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze the ADMET properties of this compound:
CNC(C)C(O)c1ccc(O)c(O)c1
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: DIOXIFEDRINE

### Structure
```
CNC(C)C(O)c1ccc(O)c(O)c1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 197.2 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 0.74 | 0-5 | ‚úì |
| H-Bond Acceptors | 4.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 4.0 | ‚â§5 | ‚úì |
| PSA | 72.7 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.540
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Limited CNS penetration expected

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Low (hydrophilic)

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- May undergo renal clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: N#CC(c1ccc(Cl)cc1)c1ccc(-n2ncc(=O)[nH]c2=O)cc1Cl
Drug Name: CLAZURIL",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 373.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.88 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 91.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: N#CC(c1ccc(Cl)cc1)c1ccc(-n2ncc(=O)[nH]c2=O)cc1Cl
Drug Name: CLAZURIL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 373.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.88 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 91.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: Cc1nnc(C(=O)NC(C)(C)c2nc(C(=O)NCc3ccc(F)cc3)c([O-])c(=O)n2C)o1.[K+]
Drug Name: RALTEGRAVIR POTASSIUM",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 482.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.91 | ‚úì Good (<5) |
| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 152.2 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: Cc1nnc(C(=O)NC(C)(C)c2nc(C(=O)NCc3ccc(F)cc3)c([O-])c(=O)n2C)o1.[K+]
Drug Name: RALTEGRAVIR POTASSIUM
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 482.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.91 | ‚úì Good (<5) |
| H-Bond Acceptors | 9.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 152.2 √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CNC(=O)c1c(I)c(NC(C)=O)c(I)c(C(=O)O)c1I.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO
IOTHALAMATE MEGLUMINE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 809.1 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 2.52 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 95.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CNC(=O)c1c(I)c(NC(C)=O)c(I)c(C(=O)O)c1I.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO
IOTHALAMATE MEGLUMINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 809.1 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 2.52 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 95.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
O=C1c2c(O)cccc2Cc2cccc(O)c21
ANTHRALIN",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 226.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.23 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 57.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
O=C1c2c(O)cccc2Cc2cccc(O)c21
ANTHRALIN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 226.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.23 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 57.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CN(C)CCCSc1c2ccccc2nn1Cc1ccccc1
DAZIDAMINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 325.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.13 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 21.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CN(C)CCCSc1c2ccccc2nn1Cc1ccccc1
DAZIDAMINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 325.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.13 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 21.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CC(=O)Nc1cc([As](=O)(O)O)ccc1O
ACETARSONE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 275.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CC(=O)Nc1cc([As](=O)(O)O)ccc1O
ACETARSONE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 275.1 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12
OSI-930",,"## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 443.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 6.06 | ‚ö† High (>5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 63.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12
OSI-930
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 443.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 6.06 | ‚ö† High (>5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 63.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CC1(C)OC(c2ccc(S(N)(=O)=O)cc2)=C(c2cccc(F)c2)C1=O
Candidate Name: POLMACOXIB",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 361.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.72 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 86.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CC1(C)OC(c2ccc(S(N)(=O)=O)cc2)=C(c2cccc(F)c2)C1=O
Candidate Name: POLMACOXIB
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 361.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.72 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 86.5 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CO[P@](=O)(c1cc(C)cc(/C=C/C#N)c1)c1c(C(N)=O)[nH]c2ccc(Cl)cc12
Name: FOSDEVIRINE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 413.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.64 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 109.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CO[P@](=O)(c1cc(C)cc(/C=C/C#N)c1)c1c(C(N)=O)[nH]c2ccc(Cl)cc12
Name: FOSDEVIRINE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 413.8 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.64 | ‚úì Good (<5) |
| H-Bond Acceptors | 4.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 109.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Describe the molecular properties and drug-likeness of:
CC[C@H]1OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@@H](CC=O)C[C@@H](C)C(=O)/C=C/[C@]2(C)O[C@H]2[C@@H]1C",,"## Molecular Property Analysis: ROSARAMICIN

### Structure
```
CC[C@H]1OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@@H](CC=O)C[C@@H](C)C(=O)/C=C/[C@]2(C)O[C@H]2[C@@H]1C
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 581.8 Da | 150-500 Da | ‚ö† |
| LogP (cLogP) | 2.67 | 0-5 | ‚úì |
| H-Bond Acceptors | 10.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |
| PSA | 135.1 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 6.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.270
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Limited CNS penetration expected

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- CYP450 substrate likely
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚ö† FAIL
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Describe the molecular properties and drug-likeness of:
CC[C@H]1OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@@H](CC=O)C[C@@H](C)C(=O)/C=C/[C@]2(C)O[C@H]2[C@@H]1C
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: ROSARAMICIN

### Structure
```
CC[C@H]1OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@@H](CC=O)C[C@@H](C)C(=O)/C=C/[C@]2(C)O[C@H]2[C@@H]1C
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 581.8 Da | 150-500 Da | ‚ö† |
| LogP (cLogP) | 2.67 | 0-5 | ‚úì |
| H-Bond Acceptors | 10.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 2.0 | ‚â§5 | ‚úì |
| PSA | 135.1 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 6.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.270
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Limited CNS penetration expected

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Moderate

**Metabolism:**
- CYP450 substrate likely
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚ö† FAIL
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CC(C)(C)NC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C
Candidate Name: FINASTERIDE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 372.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.81 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 58.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CC(C)(C)NC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C
Candidate Name: FINASTERIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 372.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.81 | ‚úì Good (<5) |
| H-Bond Acceptors | 2.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 58.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: O=C(CCCN1CCC(C(=O)c2ccc(F)cc2)CC1)c1ccc(F)cc1
Drug Name: LENPERONE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 371.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.52 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 37.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: O=C(CCCN1CCC(C(=O)c2ccc(F)cc2)CC1)c1ccc(F)cc1
Drug Name: LENPERONE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 371.4 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.52 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 37.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: C[N+](C)(C)CCO.C[N+](C)(C)CCO.O=C([O-])c1ccccc1O.O=C([O-])c1ccccc1O.O=S(=O)([O-])[O-].[Mg+2]
Drug Name: SALCOLEX",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 602.9 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: C[N+](C)(C)CCO.C[N+](C)(C)CCO.O=C([O-])c1ccccc1O.O=C([O-])c1ccccc1O.O=S(=O)([O-])[O-].[Mg+2]
Drug Name: SALCOLEX
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 602.9 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | nan | ‚ö† High (>5) |
| H-Bond Acceptors | nan | ‚ö† High (>10) |
| H-Bond Donors | nan | ‚ö† High (>5) |
| Polar Surface Area | nan √Ö¬≤ | ‚ö† High (>140) |
| Rule of 5 Violations | nan | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Analyze the ADMET properties of this compound:
CCNC1(c2ccccc2)CCCCC1",,"## Molecular Property Analysis: ETICYCLIDINE

### Structure
```
CCNC1(c2ccccc2)CCCCC1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 203.3 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 3.46 | 0-5 | ‚úì |
| H-Bond Acceptors | 1.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 12.0 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.790
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze the ADMET properties of this compound:
CCNC1(c2ccccc2)CCCCC1
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: ETICYCLIDINE

### Structure
```
CCNC1(c2ccccc2)CCCCC1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 203.3 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 3.46 | 0-5 | ‚úì |
| H-Bond Acceptors | 1.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 1.0 | ‚â§5 | ‚úì |
| PSA | 12.0 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 3.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.790
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS
<|im_end|>"
"Describe the molecular properties and drug-likeness of:
COc1ccc2c(c1)CN(C)CC2c1ccc(Cl)c(Cl)c1",,"## Molecular Property Analysis: DICLOFENSINE

### Structure
```
COc1ccc2c(c1)CN(C)CC2c1ccc(Cl)c(Cl)c1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 322.2 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 4.58 | 0-5 | ‚úì |
| H-Bond Acceptors | 2.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 0 | ‚â§5 | ‚úì |
| PSA | 12.5 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 2.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.800
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- CYP450 substrate likely
- Potential CYP inhibition risk

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Describe the molecular properties and drug-likeness of:
COc1ccc2c(c1)CN(C)CC2c1ccc(Cl)c(Cl)c1
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: DICLOFENSINE

### Structure
```
COc1ccc2c(c1)CN(C)CC2c1ccc(Cl)c(Cl)c1
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 322.2 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | 4.58 | 0-5 | ‚úì |
| H-Bond Acceptors | 2.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 0 | ‚â§5 | ‚úì |
| PSA | 12.5 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 2.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.800
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Likely CNS penetrant

**Distribution:**
- High plasma protein binding likely
- Estimated Vd: High (lipophilic)

**Metabolism:**
- CYP450 substrate likely
- Potential CYP inhibition risk

**Excretion:**
- Likely hepatic clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CCc1nc2c(C)cc(-c3cn4c(n3)CCCC4)cc2n1Cc1ccc(-c2ccccc2C(=O)O)cc1
Name: POMISARTAN",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 490.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 6.52 | ‚ö† High (>5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 72.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CCc1nc2c(C)cc(-c3cn4c(n3)CCCC4)cc2n1Cc1ccc(-c2ccccc2C(=O)O)cc1
Name: POMISARTAN
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 490.6 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 6.52 | ‚ö† High (>5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 72.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
C[N+](C)(CCCCCC[N+](C)(C)C1c2ccccc2-c2ccccc21)C1c2ccccc2-c2ccccc21.[Br-].[Br-]
HEXAFLUORENIUM BROMIDE",,"## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 662.5 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 8.24 | ‚ö† High (>5) |
| H-Bond Acceptors | 0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 0.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
C[N+](C)(CCCCCC[N+](C)(C)C1c2ccccc2-c2ccccc21)C1c2ccccc2-c2ccccc21.[Br-].[Br-]
HEXAFLUORENIUM BROMIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚úÖ APPROVED
**Confidence Level:** High

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 662.5 Da | ‚ö† High (>500) |
| LogP (Lipophilicity) | 8.24 | ‚ö† High (>5) |
| H-Bond Acceptors | 0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 0.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 2.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **poor drug-like properties**:
- Multiple violations of Lipinski's Rule of 5
- May have bioavailability challenges
- Consider structural modifications to improve pharmacokinetics
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: c1ccc2ccccc2c1
Candidate Name: NAPHTHALENE",,"## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 128.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.84 | ‚úì Good (<5) |
| H-Bond Acceptors | 0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 0.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: c1ccc2ccccc2c1
Candidate Name: NAPHTHALENE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: ‚ö†Ô∏è UNLIKELY TO SUCCEED
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 128.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.84 | ‚úì Good (<5) |
| H-Bond Acceptors | 0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 0.0 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Provide a comprehensive drug development assessment for:
Molecular Structure: CCCCC1(CCOC(N)=O)C(=O)NC(=O)NC1=O
Candidate Name: CARBUBARB",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 271.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.01 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 127.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Provide a comprehensive drug development assessment for:
Molecular Structure: CCCCC1(CCOC(N)=O)C(=O)NC(=O)NC1=O
Candidate Name: CARBUBARB
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 271.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 0.01 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 3.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 127.6 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Analyze this drug candidate and predict its approval likelihood:
SMILES: OC[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@H]1O
Drug Name: LEVOGLUCOSE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 180.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -3.22 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 110.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Analyze this drug candidate and predict its approval likelihood:
SMILES: OC[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@H]1O
Drug Name: LEVOGLUCOSE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 180.2 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | -3.22 | ‚úì Good (<5) |
| H-Bond Acceptors | 6.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 5.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 110.4 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Describe the molecular properties and drug-likeness of:
OC[C@H]1O[C@@H](n2cnc3c2N=CNC[C@H]3O)[C@H](O)[C@@H]1O",,"## Molecular Property Analysis: COFORMYCIN

### Structure
```
OC[C@H]1O[C@@H](n2cnc3c2N=CNC[C@H]3O)[C@H](O)[C@@H]1O
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 284.3 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | -2.21 | 0-5 | ‚ö† |
| H-Bond Acceptors | 9.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 5.0 | ‚â§5 | ‚úì |
| PSA | 132.4 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 2.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.420
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Limited CNS penetration expected

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Low (hydrophilic)

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- May undergo renal clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity",property_analysis,chembl_compounds_detailed,"<|im_start|>user
Describe the molecular properties and drug-likeness of:
OC[C@H]1O[C@@H](n2cnc3c2N=CNC[C@H]3O)[C@H](O)[C@@H]1O
<|im_end|>
<|im_start|>assistant
## Molecular Property Analysis: COFORMYCIN

### Structure
```
OC[C@H]1O[C@@H](n2cnc3c2N=CNC[C@H]3O)[C@H](O)[C@@H]1O
```

### Physicochemical Properties

| Property | Value | Optimal Range | Status |
|----------|-------|---------------|--------|
| Molecular Weight | 284.3 Da | 150-500 Da | ‚úì |
| LogP (cLogP) | -2.21 | 0-5 | ‚ö† |
| H-Bond Acceptors | 9.0 | ‚â§10 | ‚úì |
| H-Bond Donors | 5.0 | ‚â§5 | ‚úì |
| PSA | 132.4 √Ö¬≤ | <140 √Ö¬≤ | ‚úì |
| Rotatable Bonds | 2.0 | ‚â§10 | ‚úì |

### Drug-Likeness Score
**QED (Quantitative Estimate of Drug-likeness):** 0.420
- Score ranges from 0 (least drug-like) to 1 (most drug-like)
- QED >0.5 is generally considered favorable

### ADMET Predictions

**Absorption:**
- Good oral absorption expected
- Limited CNS penetration expected

**Distribution:**
- Moderate plasma protein binding expected
- Estimated Vd: Low (hydrophilic)

**Metabolism:**
- May undergo phase II metabolism primarily
- Low CYP inhibition expected

**Excretion:**
- May undergo renal clearance
- Moderate half-life expected

### Rule-Based Assessments

**Lipinski's Rule of 5:** ‚úì PASS
**Veber Rules (Oral Bioavailability):** ‚úì PASS

### Natural Product Flag
This compound is derived from or inspired by natural products, which often have:
- Complex stereochemistry
- Unique mechanisms of action
- Potentially better target selectivity
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CC1(CN2CCC(n3c(=O)[nH]c4ccccc43)CC2)OCc2ccccc2-n2cccc21
Name: ZALDARIDE",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 428.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.20 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 55.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CC1(CN2CCC(n3c(=O)[nH]c4ccccc43)CC2)OCc2ccccc2-n2cccc21
Name: ZALDARIDE
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 428.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 4.20 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 1.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 55.2 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"Evaluate the safety and efficacy potential of the following molecule:
CC(C)c1cc(C(C)C)c(-c2csc(N(CCN(C)C)Cc3cccnc3)n2)c(C(C)C)c1
Name: FOROPAFANT",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 464.7 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 7.14 | ‚ö† High (>5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 32.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Evaluate the safety and efficacy potential of the following molecule:
CC(C)c1cc(C(C)C)c(-c2csc(N(CCN(C)C)Cc3cccnc3)n2)c(C(C)C)c1
Name: FOROPAFANT
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 464.7 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 7.14 | ‚ö† High (>5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 32.3 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 1.0 | ‚ö† Non-compliant |

### Drug-Likeness Assessment

The compound shows **acceptable drug-like properties** with minor concerns:
- Minor deviation from Lipinski's Rule of 5
- May require formulation optimization for oral delivery
<|im_end|>"
"Predict whether this drug candidate will succeed in clinical trials:
CCCN(c1ccncc1)n1ccc2ccccc21",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 251.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.72 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 21.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
Predict whether this drug candidate will succeed in clinical trials:
CCCN(c1ccncc1)n1ccc2ccccc21
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 251.3 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 3.72 | ‚úì Good (<5) |
| H-Bond Acceptors | 3.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 21.1 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
"As a pharmaceutical researcher, analyze this compound:
CCCC[C@H](N[C@@H](C)C(=O)N1[C@H](C(=O)OCC)C[C@@H]2CCCC[C@@H]21)C(=O)O
ORBUTOPRIL",,"## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 382.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.33 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 95.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability",drug_analysis,chembl_compounds_detailed,"<|im_start|>user
As a pharmaceutical researcher, analyze this compound:
CCCC[C@H](N[C@@H](C)C(=O)N1[C@H](C(=O)OCC)C[C@@H]2CCCC[C@@H]21)C(=O)O
ORBUTOPRIL
<|im_end|>
<|im_start|>assistant
## Drug Analysis Report

### Prediction: üî¨ IN DEVELOPMENT
**Confidence Level:** Medium

### Molecular Properties Analysis

| Property | Value | Assessment |
|----------|-------|------------|
| Molecular Weight | 382.5 Da | ‚úì Good (<500) |
| LogP (Lipophilicity) | 2.33 | ‚úì Good (<5) |
| H-Bond Acceptors | 5.0 | ‚úì Good (‚â§10) |
| H-Bond Donors | 2.0 | ‚úì Good (‚â§5) |
| Polar Surface Area | 95.9 √Ö¬≤ | ‚úì Good (‚â§140) |
| Rule of 5 Violations | 0 | ‚úì Compliant |

### Drug-Likeness Assessment

The compound shows **excellent drug-like properties**:
- Fully compliant with Lipinski's Rule of 5
- Good balance of hydrophilicity/lipophilicity for membrane permeation
- Suitable molecular weight for oral bioavailability
<|im_end|>"
